0001575705-16-000130.txt : 20160516 0001575705-16-000130.hdr.sgml : 20160516 20160516170354 ACCESSION NUMBER: 0001575705-16-000130 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 82 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160516 DATE AS OF CHANGE: 20160516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: First Choice Healthcare Solutions, Inc. CENTRAL INDEX KEY: 0001416876 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 900687379 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53012 FILM NUMBER: 161654931 BUSINESS ADDRESS: STREET 1: 709 S. HARBOR CITY BLVD. STREET 2: SUITE 250 CITY: MELBOURNE STATE: FL ZIP: 32901 BUSINESS PHONE: (321) 725-0090 MAIL ADDRESS: STREET 1: 709 S. HARBOR CITY BLVD. STREET 2: SUITE 250 CITY: MELBOURNE STATE: FL ZIP: 32901 FORMER COMPANY: FORMER CONFORMED NAME: Medical Billing Assistance, Inc. DATE OF NAME CHANGE: 20110107 FORMER COMPANY: FORMER CONFORMED NAME: Medical Billing Assistance Inc DATE OF NAME CHANGE: 20071030 10-Q 1 fchs_1q16.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: March 31, 2016

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission File Number: 000-53012

FIRST CHOICE HEALTHCARE SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

Delaware		90-0687379
(State or other jurisdiction of incorporation)		(IRS Employer Identification No.)

709 S. Harbor City Boulevard, Suite 250, Melbourne, Florida 32901

(Address of principal executive offices)

(321) 725-0090

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months, and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files. Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer	☐		Accelerated filer	☐
Non-accelerated filer	☐		Smaller reporting company	☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 12, 2016, there were 23,908,983 shares outstanding of the registrant’s Common Stock.

PART I.	FINANCIAL INFORMATION		3

	ITEM 1	Financial Statements	3

		Condensed consolidated balance sheets as of March 31, 2016 (unaudited) and December 31, 2015	3

		Condensed consolidated statements of operations for the three months ended March 31, 2016 and 2015 (unaudited)	4

		Condensed consolidated statement of stockholders’ equity for the three months ended March 31, 2016 (unaudited)	5

		Condensed consolidated statements of cash flows for the three months ended March 31, 2016 and 2015 (unaudited)	6

		Notes to condensed consolidated financial statements (unaudited)	7

	ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	26

	ITEM 3.	Quantitative and Qualitative Disclosures about Market Risk	31

	ITEM 4.	Controls and Procedures	31

PART II.	OTHER INFORMATION		32

	ITEM 1.	Legal Proceedings	32
	ITEM 1A.	Risk Factors	32
	ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	32
	ITEM 3.	Defaults Upon Senior Securities	32
	ITEM 4.	Mine Safety Disclosures	32
	ITEM 5.	Other Information	32
	ITEM 6.	Exhibits	32

	SIGNATURES		33

PART I

ITEM 1. FINANCIAL STATEMENTS

FIRST CHOICE HEALTHCARE SOLUTIONS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31,			December 31,
	2016			2015
	(unaudited)
ASSETS
Current assets
Cash (amounts related to VIE of $1,624,203 and $1,556,303)	$	10,051,999		$	1,594,998
Cash-restricted		—			359,414
Accounts receivable, net (amounts related to VIE of $4,806,623 and $4,544,308)		7,448,429			6,623,894
Employee loans (amounts related to VIE of $882,226 and $636,293)		918,226			672,293
Prepaid and other current assets (amounts related to VIE of $151,931 and $183,465)		225,150			316,773
Capitalized financing costs, current portion (amounts related to VIE of $329 and $1,317)		329			39,533
Total current assets		18,644,133			9,606,905

Property, plant and equipment, net of accumulated depreciation of $989,481 and $3,075,648 (amounts related to VIE of $724,859 and $773,808)		2,689,335			8,613,502

Other assets
Goodwill (amount relating to VIE of $899,465)		899,465			899,465
Deferred costs, net of amortization of $295,757 and $215,096		2,930,670			3,011,331
Patient list, net of accumulated amortization of $80,000 and $75,000		220,000			225,000
Patents, net of accumulated amortization of $42,975 and $38,200		243,525			248,300
Investments (amounts related to VIE of $22,005 and $16,914)		22,005			16,914
Deferred Tax Asset		181,029			—
Deposits		17,003			2,571
Total other assets		4,513,697			4,403,581

Total assets	$	25,847,165		$	22,623,988

LIABILITIES AND EQUITY
Current liabilities
Accounts payable and accrued expenses (amounts related to VIE of $2,321,972 and $2,319,056)	$	4,078,887		$	3,937,244
Accounts payable, related party (amount related to VIE of $251,588)		251,588			251,588
Stock based payable		1,280,200			1,198,900
Advances, related party		133,796			43,082
AMT Tax Payable		181,029			—
Settlement payable		450,000			600,000
Line of credit, short term (amount related to VIE of $439,524 and $416,888)		2,939,524			2,566,888
Note payable, related party, current portion (amount related to VIE of $437,372 and $428,645)		437,372			428,645
Notes payable, current portion (amount related to VIE of $7,235 and $10,341)		507,209			7,652,941
Unearned revenue		42,704			42,704
Deferred rent, short term portion (amount related to VIE of $118,810)		118,810			118,810
Total current liabilities		10,421,119			16,840,802

Long term debt:
Deposits held		67,432			67,432
Notes payable, long term portion		406,830			535,822
Deferred rent, long term portion (amount related to VIE of $2,200,603 and $2,141,199)		2,200,603			2,141,199
Total long term debt		2,674,865			2,744,453

Total liabilities		13,095,984			19,585,255

Equity
Preferred stock, $0.01 par value; 1,000,000 shares authorized, Nil issued and outstanding		—			—
Common stock, $0.001 par value; 100,000,000 shares authorized, 22,967,626 and 22,867,626 shares issued and outstanding as of March 31, 2016 and December 31, 2015, respectively		22,968			22,868
Common stock subscription		175,000			175,000
Additional paid in capital		21,288,692			21,196,792
Accumulated deficit		(9,707,976	)		(19,274,917	)
Total stockholders’ equity attributable to First Choice Healthcare Solutions, Inc.		11,778,684			2,119,743
Non-controlling interest		972,497			918,990
Total equity		12,751,181			3,038,733

Total liabilities and equity	$	25,847,165		$	22,623,988

See the accompanying notes to these unaudited condensed consolidated financial statements

FIRST CHOICE HEALTHCARE SOLUTIONS, INC

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

	Three months ended March 31,
	2016			2015
Revenues:
Patient Service Revenue	$	6,877,665		$	2,285,288
Provision for bad debts		(262,524	)		(45,224	)
Net patient service revenue less provision for bad debts		6,615,141			2,240,064
Rental Revenue		626,612			265,103
Total Revenue		7,241,753			2,505,167

Operating expenses:
Salaries and benefits		2,780,569			946,120
Other operating expenses		1,187,274			451,485
General and administrative		2,405,877			553,284
Depreciation and amortization		298,950			140,509
Total operating expenses		6,672,670			2,091,398

Net income from operations		569,083			413,769

Other income (expense):
Gain on sale of property and improvements		9,188,968			—
Miscellaneous income (expense)		58,857			750
Amortization financing costs		(15,325	)		(20,686	)
Interest expense, net		(181,135	)		(363,144	)
Total other expense		9,051,365			(383,080	)

Net income before provision for income taxes		9,620,448			30,689

Income taxes (benefit)		—			—

Net income		9,620,448			30,689

Non-controlling interest (note 15)		(53,507	)		—

NET INCOME ATTRIBUTABLE TO FIRST CHOICE HEALTHCARE SOLUTIONS, INC.	$	9,566,941		$	30,689

Net income per common share, basic	$	0.42		$	0.00

Net income per common share, diluted	$	0.36		$	0.00

Weighted average number of common shares outstanding, basic		22,886,307			18,062,046

Weighted average number of common shares outstanding, diluted		26,219,641			22,090,565

See the accompanying notes to these unaudited condensed consolidated financial statements

FIRST CHOICE HEALTHCARE SOLUTIONS, INC.

STATEMENT OF STOCKHOLDERS’ EQUITY

THREE MONTHS ENDED MARCH 31, 2016

(unaudited)

	Common stock				Additional Paid in		Common Stock		Accumulated			Non-controlling
	Shares		Amount		Capital		Subscriptions		Deficit			Interest		Total
Balance, December 31, 2015		22,867,626	$	22,868	$	21,196,792	$	175,000	$	(19,274,917	)	$	918,990	$	3,038,733
Common stock issued in connection with loan extension		100,000		100		91,900		—		—			—		92,000
Net income		—		—		—		—		9,566,941			53,507		9,620,448
Balance, March 31, 2016		22,967,626	$	22,968	$	21,288,692	$	175,000	$	(9,707,976	)	$	972,497	$	12,751,181

FIRST CHOICE HEALTHCARE SOLUTIONS, INC

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

	Three months ended March 31,
	2016			2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income	$	9,620,448		$	30,689
Adjustments to reconcile net loss to cash provided by operating activities:
Depreciation and amortization		298,950			140,509
Amortization of financing costs		15,325			20,686
Bad debt expense		262,524			45,224
Gain on sale of property		(9,188,968	)		—
Common stock issued in connection with loan extension		92,000			99,000
Stock based compensation		81,300			48,250
Changes in operating assets and liabilities:
Accounts receivable		(1,087,059	)		(492,641	)
Prepaid expenses and other		91,623			26,075
Restricted funds		359,414			(66,478	)
Employee loans		(245,933	)		—
Accounts payable and accrued expenses		122,628			(38,121	)
Settlement payable		(150,000	)		—
Deposits		(14,432	)		—
Deferred rent		59,404			—
Unearned income		—			12,876
Net cash provided by (used in) operating activities		317,224			(173,931	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of property		15,068,497
Purchase of equipment		(126,073	)		(8,284	)
Net cash provided by (used in) investing activities		14,942,424			(8,284	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from advances		90,714			74,000
Proceeds from lines of credit		372,636			140,000
Net payments on notes payable		(7,265,997	)		(198,078	)
Net cash (used in) provided by financing activities		(6,802,647	)		15,922

Net increase (decrease) in cash and cash equivalents		8,457,001			(166,293	)
Cash and cash equivalents, beginning of period		1,594,998			279,087

Cash and cash equivalents, end of period	$	10,051,999		$	112,794

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the period for interest	$	181,135		$	264,144
Cash paid during the period for taxes	$	—		$	—

Supplemental Disclosure on non-cash investing and financing activities:
Common stock issued in settlement of accrued expenses	$	—		$	15,000

See the accompanying notes to these unaudited condensed consolidated financial statements

NOTE 1 —BASIS OF PRESENTATION

A summary of the significant accounting policies applied in the presentation of the accompanying unaudited condensed consolidated financial statements follows:

General

The (a) condensed consolidated balance sheet as of December 31, 2015, which has been derived from the audited financial statements of First Choice Healthcare Solutions, Inc. (“FCHS” and including, where appropriate, its consolidated subsidiaries and entities in which we have a controlling financial interest, the “Company”), and (b) the unaudited condensed consolidated interim financial statements as of March 31, 2016 of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. To determine if we hold a controlling financial interest in an entity, we first evaluate if we are required to apply the variable interest entity (“VIE”) model to the entity, otherwise the entity is evaluated under the voting interest model.

Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2016 are not necessarily indicative of results that may be expected for the year ending December 31, 2015. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2016 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on April 14, 2016.

Basis of Presentation

Effective April 4, 2012, Medical Billing Assistance, Inc., a Colorado corporation (“Medical Billing”), merged with and into the Company. The effect of the merger was that Medical Billing reincorporated from Colorado to Delaware (the “Reincorporation”). The Company is deemed to be the successor issuer of Medical Billing under Rule 12g-3 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

As a result of the Reincorporation, the Company changed its name to First Choice Healthcare Solutions, Inc. and its shares underwent an effective four-for-one reverse split. Other than the foregoing, the Reincorporation did not result in any change in the business, management, fiscal year, accounting, and location of the principal executive offices, assets or liabilities of the Company.

On April 2, 2012, the Company, through its wholly owned subsidiary FCID Medical, Inc., completed its acquisition of First Choice Medical Group of Brevard, LLC (“First Choice – Brevard”), pursuant to the Membership Interest Purchase Closing Agreement (the “Purchase Agreement”). The Company has been managing the practice of First Choice – Brevard since November 1, 2011, pursuant to a Management Services Agreement.

Brevard Orthopaedic Spine & Pain Clinic, Inc.

Effective May 1, 2015, the Company, through its recently formed wholly owned subsidiary, TBC Holdings of Melbourne, Inc., entered into an Operation and Control Agreement (the Agreement”) with Brevard Orthopaedic Spine & Pain Clinic, Inc. (“The B.A.C.K. Center”), whereby the Company will have sole and exclusive management and control of The B.A.C.K. Center, including, but not limited to, administrative, financial, facility and business operations, including the requirement to absorb losses or right to receive economic benefits. The initial term of the Agreement expires on December 31, 2016 with an option by the Company to extend the term until December 31, 2023.

The Agreement allows the Company to hold the current or potential rights that give it the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance, combined with a variable interest that gives the Company the right to receive potentially significant benefits or the obligation to absorb potentially significant losses. The Company has a controlling financial interest in the VIE. Rights held by others to remove the party with power over the VIE are not considered unless one party can exercise those rights unilaterally. When changes occur to the structure of the entity, the Company will reconsider whether it is subject to the VIE model. The Company continuously evaluates whether it has a controlling financial interest in the VIE.

Crane Creek Surgery Center

Effective October 1, 2015, the Company, through its recently formed wholly owned subsidiary, CCSC Holdings, Inc., acquired a 40% interest in Crane Creek Surgery Center (“Crane Creek”) in exchange for an investment of $560,000 comprised of $140,000 cash and a promissory note for $420,000 which bears 8% interest per annum, matures April 15, 2016 and is personally guaranteed by the Company’s Chief Executive Officer. In connection with the investment, the Company is entitled 51% voting rights for all decisions that most significantly affect the economic performance of Crane Creek. The 40% equity interest acquired entitles the Company to 40% of the profit or loss of Crank Creek. This note was paid in full on April 15, 2016.

The unaudited condensed consolidated financial statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries FCID Holdings, Inc., MTMC of Melbourne, Inc., Marina Towers, LLC, FCID Medical Inc., TBC Holdings of Melbourne, Inc., First Choice – Brevard, Surgical Partners of Melbourne, Inc. and CCSC Holdings, Inc., along with two VIE, The B.A.C.K. Center and Crane Creek. All significant intercompany balances and transactions, including those involving the VIE, have been eliminated in consolidation.

NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES

Use of estimates

The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, and stock-based compensation. Actual results may differ from these estimates.

Revenue recognition

The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, “Revenue Recognition” (“ASC 605-10”), which requires that four basic criteria be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.

ASC 605-10 incorporates Accounting Standards Codification subtopic 605-25, “Multiple-Element Arrangements” (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. The effect of implementing ASC 605-25 on the Company’s financial position and results of operations was not significant.

The Company recognizes in accordance with Accounting Standards Codification subtopic 954-310, “Health Care Entities” (“ASC 954-310”), significant patient service revenue at the time the services are rendered, even though it does not assess the patient’s ability to pay. Therefore, The Company’s interim and annual periods reports disclose both, its policy for assessing and disclosing the timing and amount of uncollectable patient service revenue recognized as doubtful. Qualitative and quantitative information about significant changes in the allowance for doubtful accounts related to patient accounts receivable are disclosed in the Company’s reports. These estimates are based upon the past history and identified trends for each of our payers.

Patient service revenue

The Company recognizes patient service revenue associated with services provided to patients who have third-party payer coverage on the basis of contractual rates for the services provided. For uninsured or self-pay patients that do not qualify for charity care, the Company recognizes revenue on the basis of its standard rates for services provided (or on the basis of discounted rates, if negotiated or provided by policy). On the basis of historical experience, a portion of the Company’s patient service revenue may be potentially uncollectible due to patients who are unable or unwilling to pay for the services provided or the portion of their bill for which they are responsible. Thus, the Company records a provision for bad debts related to potentially uncollectible patient service revenue in the period the services are provided.

Rental revenue

FCID Holdings had one real estate holding, Marina Towers, a Class A 78,000 square foot, six-story building located on the Indian River in Melbourne, Florida. The address is 709 South Harbor City Boulevard, Melbourne, Florida 32901. In addition to housing our corporate headquarters and First Choice Medical Group, the building, which averages 95% annual occupancy, also leases commercial office space to tenants. Our corporate headquarters currently utilize 2,521 square feet on the fifth floor of Marina Towers; and First Choice Medical Group, including its MRI center and Physical Therapy center, currently occupies 26,838 square feet on the ground, first and second floors. Until March 2016, Marina Towers was owned by Marina Towers, LLC, a subsidiary owned by FCID Holdings (99%) and MTMC of Melbourne, Inc. (1%), both wholly owned subsidiaries of the Company.

On March 31, 2016, we completed the sale of Marina Towers to Global Medical REIT Inc. for a purchase price of $15.45 million. In addition, our wholly owned subsidiary, Marina Towers, LLC, leased back the entire facility via a 10-year absolute triple-net master lease agreement that will expire in 2026 and be renewable for two five-year periods on the same terms and conditions as the primary lease term with the exception of rent, which will be adjusted to the prevailing market rent at renewal and will escalate in successive years during the extended lease period.

Until Marina Towers’ sale on March 31, 2016, the Company recognized rental revenue associated with the period of time the facility is leased at the contractual lease rates (or on the basis of discounted rates, if negotiated).

In addition, beginning May 1, 2015, TBC Holdings of Melbourne, Inc., through The B.A.C.K. Center, subleases approximately 34,480 square feet of commercial office space to third party tenants.

Cash

Cash consists of cash held in bank demand deposits. The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. As of March 31, 2016, the Company had $10,051,999 cash, of which $1,624,203 held by VIE. As of December 31, 2015, the Company had $1,594,998 cash, of which $1,556,303 held by VIE.

Concentrations of credit risk

The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Occasionally, the Company’s cash and cash equivalents in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.

Accounts receivables

Accounts receivables are carried at their estimated collectible amounts net of doubtful accounts. The Company analyzes its past history and identifies trends for each major payer sources of revenue to estimate the appropriate allowance for doubtful accounts and provision for bad debts. Management regularly reviews data about these major payer sources of revenue in evaluating the sufficiency of the allowance for doubtful accounts.

	●	Rental receivables. Accounts receivables from rental activities are periodically evaluated for collectability in determining the appropriate allowance for doubtful account provision for bad debts and provision of bad debts.

	●	Patient receivables. Accounts receivables from services provided to patients who have third-party coverage, the Company analyzes contractually due amounts and provides a provision for bad debts, if necessary. The Company records a provision for bad debts in the period of service on the basis of past experience or when indications are the patients are unable or unwilling to pay the portion of their bill for which they are responsible. The difference between the standard rates (or the discounted rates if negotiated) and the amounts actually collected after all reasonable collection efforts have been exhausted, is charged off against the allowance for doubtful accounts.

As of March 31, 2016 and December 31, 2015, the Company’s provision for bad debts was $2,917,884 and $2,498,398, respectively.

Segment information

Accounting Standards Codification subtopic “Segment Reporting” 280-10 (“ASC 280-10”) establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders. ASC 280-10 also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein represents all of the material financial information related to the Company’s principal operating segments (see Note 17 – Segment Information).

Patents

Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are not amortized, but are tested for impairment annually. The Company’s intangible assets with finite lives are patent costs, which are amortized over their economic or legal life, whichever is shorter. These patent costs were acquired on September 7, 2013 by the issuance of 636,666 shares of the Company’s common stock to a related party. The shares of common stock were valued at $286,500, which was estimated to be approximately the fair value of the patent acquired and did not materially differ from the fair value of the common stock. The amortization for the three months ended March 31, 2016 and 2015 was $4,775 and $4,775, respectively. Accumulated amortization of patent costs was $42,975 and $38,200 at March 31, 2016 and December 31, 2015, respectively.

Patient list

Patient list is comprised of acquired patients in connection with the acquisition of First Choice - Brevard and is amortized ratably over the estimated useful life of 15 years. The amortization expenses for the three months ended March 31, 2016 and 2015 was $5,000 and $5,000, respectively. Accumulated amortization of patient list costs was $80,000 and $75,000 at March 31, 2016 and December 31, 2015, respectively.

Net income per share

The Company computes basic net income per share by dividing net income per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted income per share for the three months ended March 31, 2016 and 2015 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.

Potentially dilutive securities excluded from the computation of basic and diluted net income per share are as follows:

	March 31, 2016		March 31, 2015
Warrants to purchase common stock		4,324,630		4,195,000
Options to purchase common stock		3,000,000		—
Totals		7,324,630		4,195,000

Stock-based compensation

The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the consolidated statements of operations, as if such amounts were paid in cash.

Deferred costs

On May 1, 2015, in connection with the Operation and Control Agreement with Brevard Orthopaedic Spine & Pain Clinic, Inc. (“The B.A.C.K. Center”), the Company reserved 3,000,000 options to purchase the Company’s common stock at $1.35 per share, expiring on December 31, 2023 and vesting contingent on The B.A.C.K. Center employees executing employment agreements with TBC Holding and the acquisition of the variable interest entity. The determined fair value of $3,226,427, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 134.09% and Risk free rate: 2.12%, is amortized ratably to operations over an estimated 8.67-year life. The amortization for the three months ended March 31, 2016 was $80,661. Accumulated amortization of the deferred costs was $295,757 at March 31, 2016.

Investments

The Company has adopted Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures (“ASC 323-10), which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company owned a 0.6660% interest in a non-consolidated affiliate, Doctor’s Surgical Partnership, LTD. In accordance with the equity method of accounting, investments in non-consolidated affiliates are carried at cost and adjusted for the Company’s proportionate share of their undistributed earnings or losses.

Income Taxes

The Company accounts for income taxes pursuant to Accounting Standards Codified 740 (“ASC 740”). Under ASC 740 deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Fair value

Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:

	●	Level 1 - Quoted prices in active markets for identical assets or liabilities.

	●	Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

	●	Level 3 - Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

The carrying value of the Company’s cash, accounts receivable, accounts payable, short-term borrowings (including lines of credit and notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity.

As of March 31, 2016 and December 31, 2015, the Company did not have any items that would be classified as level 1, 2 or 3 disclosures.

Recent accounting pronouncements

There are other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

Subsequent events

The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed.

NOTE 3 – LIQUIDITY

The Company incurred various non-recurring expenses in 2015 in connection with the planned development of its Healthcare Services Business. Management believes the continuing trend of positive growth before interest, taxes, depreciation and amortization in 2016 will support improved liquidity. In 2015, the Company converted to equity a total of $2,892,314 in outstanding debt, advances and accrued interest. Currently, the Company has four main sources of liquidity, its line of credit with CT Capital, LP; patient service revenue received from FCID Medical, Inc., TBC Holdings of Melbourne, Inc. and CCSC Holdings, Inc.; and rental revenue received from its real estate interests, FCID Holdings, Inc. and TBC Holdings of Melbourne, Inc.

On June 13, 2013, the Company’s subsidiary, First Choice – Brevard entered into a loan and security agreement with CT Capital, Ltd., d/b/a CT Capital, LP, a Florida limited liability partnership for an accounts receivable line of credit in the maximum aggregate amount of $1,500,000. Under the line of credit with CT Capital, the Company reduced the annual interest rate from 12% per annum to 6% per annum in exchange for the issuance to CT Capital of 100,000 restricted shares of the Company’s common stock. On June 9, 2015, First Choice – Brevard entered into a modification agreement amending the loan and security agreement, increasing the maximum aggregate amount available from $1,500,000 to $2,000,000 and on December 14, 2015, increasing the maximum aggregate available from $2,000,000 to $2,500,000 and extending the maturity date to July 30, 2017 in exchange for 100,000 restricted shares of the Company’s common stock. The $500,000 increase may be repaid at any time, and is not subject to the conversion provision set forth in the loan agreement. All other terms and conditions of the loan agreement remain in full force and effect. As of March 31, 2016, the Company had used $2,500,000 of the amount available under the line of credit. (See Note 6 – Lines of Credit)

FCID Holdings had one real estate holding, Marina Towers, a Class A 78,000 square foot, six-story building located on the Indian River in Melbourne, Florida. The address is 709 South Harbor City Boulevard, Melbourne, Florida 32901. In addition to housing our corporate headquarters and First Choice Medical Group, the building, which averages 95% annual occupancy, also leases commercial office space to tenants. Our corporate headquarters currently utilizes 2,521 square feet on the fifth floor of Marina Towers; and First Choice Medical Group, including its MRI center and Physical Therapy center, currently occupies 26,838 square feet on the ground, first and second floors. Until March 2016, Marina Towers was owned by Marina Towers, LLC, a subsidiary owned by FCID Holdings (99%) and MTMC of Melbourne, Inc. (1%), both wholly owned subsidiaries of the Company.

In addition, beginning May 1, 2015, TBC Holdings of Melbourne, Inc., through The B.A.C.K. Center, subleases 31,835 square feet of commercial office space to third party tenants as of March 31, 2016.

The Company believes that the current positive cash balance, along with continued execution of its business development plan and the sale and leaseback of Marina Towers, will allow the Company to further improve its working capital and currently anticipates that it will have sufficient capital resources to meet projected cash flow requirements through the date that is one year and one day from the filing of this report.

However, in order to execute the Company’s business development plan, which there can be no assurance it will do, the Company may need to raise additional funds through public or private equity offerings, debt financings, corporate collaborations or other means and potentially reduce operating expenditures. If the Company is unable to secure additional capital, it may be required to curtail its business development initiatives and take additional measures to reduce costs in order to conserve its cash.

NOTE 4 — PROPERTY, PLANT, AND EQUIPMENT

Property, plant and equipment at March 31, 2016 and December 31, 2015 are as follows:

	March 31, 2016			December 31, 2015
Land	$	—		$	1,000,000
Building		—			3,055,168
Building improvements		182,246			4,211,749
Computer equipment		348,180			340,065
Medical equipment		2,888,249			2,822,027
Office equipment		260,141			260,141
		3,678,816			11,689,150
Less: accumulated depreciation		(989,481	)		(3,075,648	)
	$	2,689,335		$	8,613,502

During the three months ended March 31, 2016 and 2015, depreciation expense charged to operations was $208,514 and $130,734, respectively.

Sale/Leaseback

On March 31, 2016, the Company sold Marina Towers, a 78,000 square-foot medical office building for a purchase price of $15.45 million to Global Medical REIT Inc. The acquisition includes the site and building, an easement on the adjacent property to the north for surface parking, all tenant leases, and above and below ground garages (the “Property”).

The entire facility was leased back to Marina Towers, LLC, a wholly owned subsidiary of the Company, via a 10-year absolute triple-net master lease agreement that expires in 2026. The Company has two successive options to renew the lease for five-year periods on the same terms and conditions as the primary non-revocable lease term with the exception of rent, which will be adjusted to the prevailing fair market rent at renewal and will escalate in successive years during the extended lease period. The Company does not have any residual interest nor the option to repurchase the facility at the end of the lease term.

The lease is classified as an operating lease and as such recorded a gain on sale of property of $9,188,968 during the three months ended March 31, 2016.

The following is a schedule of future minimum lease payments for the non-cancelable operating lease for each of the next five years ending December 31 and thereafter:

Nine months ended December 31, 2016	$	828,506
Year ended December 31, 2017		1,104,675
Year ended December 31, 2018		1,104,675
Year ended December 31, 2019		1,121,246
Year ended December 31, 2020		1,143,670
Year ended December 31, 2021 and thereafter		6,387,969
	$	11,690,741

For the three months ended March 31, 2016, the Company collected $268,513 in net rental revenue from third party tenants of Marina Towers.

NOTE 5 — ADVANCES

At March 31, 2016 and December 31, 2015, the Company received an aggregate of $133,796 and $43,082, respectively, as cash advances from non-related parties. The advances are due upon demand with an interest rate of 12% per annum.

NOTE 6 — LINES OF CREDIT

Line of credit, CT Capital

On June 13, 2013, the Company’s subsidiary, First Choice – Brevard entered into a loan and security agreement (the “Loan Agreement”) with CT Capital, Ltd., d/b/a CT Capital, LP, a Florida limited liability partnership (the “Lender”). Under the Loan Agreement, the Lender committed to make an accounts receivable line of credit in the maximum aggregate amount of $1,500,000 to First Choice - Brevard with an interest rate of 12% per annum (the “Loan”). The maturity date of the Loan is December 31, 2016. Interest is due and payable monthly. Upon default, the interest may be adjusted to the highest rate permissible by law. The Loan is secured by the accounts receivable and assets of the Company’s subsidiary, First Choice – Brevard, which constitute the collateral for the repayment of the Loan. The Loan Agreement also includes covenants, representations, warranties, indemnities and events of default that are customary for facilities of this type. The advance rate is defined as: 80% of all receivables to be 120 days or less at the net collection rate of approximately 27% of total billings, excluding patient billings and collections. Additionally, allowable accounts receivable will also include 50% of all accounts receivable protected by legal letters of protection. At any time up until December 31, 2016, the Lender may convert all or any portion of the outstanding principal amount or interest on the Loan into common stock of the Company at a conversion price of $0.75 per share. The Company did not record an embedded beneficial conversion feature in the note since the fair value of the common stock did not exceed the conversion rate at the date of commitment.

On November 8, 2013, in consideration for the issuance of 100,000 restricted shares of the Company’s common stock, the Lender agreed to modify its Loan. Under the Loan Agreement, as amended, the annual rate of interest of the Loan was reduced from 12% per annum to 6% per annum and will remain at 6% until November 1, 2015. All other terms under the Loan Agreement remain the same.

On June 9, 2015, First Choice – Brevard and the Lender entered into a Modification Agreement (“Modification”) further amending the Loan Agreement dated June 13, 2013, thereby increasing the Company’s accounts receivable line of credit from $1,500,000 to $2,000,000. All of the other terms and conditions of the Loan Agreement, as amended, remain in full force and effect.

On December 14, 2015, First Choice-Brevard entered into a Modification Agreement (“Modification”) amending the Loan and Security Agreement dated June 13, 2013. The Modification Agreement increased the Company’s accounts receivable line of credit from $2,000,000 to $2,500,000 and extended the maturity date of the Loan Agreement to June 30, 2017 (“Maturity Date”). In addition, the Company agreed to maintain an outstanding balance of not less than $1,000,000 until the Maturity Date (“Minimum Borrowing”) and provide sixty (60) days prior written notice to prepay up to $1,000,000 of the outstanding indebtedness in excess of the Minimum Borrowing. All of the other terms and conditions of the Loan Agreement remain in full force and effect.

In consideration of the $500,000 increase in the accounts receivable line of credit, the Company issued the Lender 100,000 shares of its common stock, valued at $92,000. The $500,000 increase may be repaid by the Company at any time, and is not subject to the conversion provisions set forth in the Loan Agreement. The shares were accrued for as of December 31, 2015 and issued in the current quarter.

The obligations of the Company under the Loan Agreement, as amended, are guaranteed by certain affiliates of the Company, including a personal guarantee issued by the Company’s Chief Executive Officer.

As of March 31, 2016 and December 31, 2015, the outstanding balance was $2,500,000 and $2,150,000, respectively.

Line of credit, Florida Business Bank

On June 27, 2012, The B.A.C.K. Center entered into a Promissory Note (the “Loan Agreement”) with Florida Business Bank, a Florida banking corporation (the “Lender”). Under the Loan Agreement, the Lender committed to make an accounts receivable line of credit in the maximum aggregate amount of $1,000,000, with an interest rate of Prime floating plus 1.0%, as published in The Wall Street Journal, with a floor of 4.50% per annum (the “Loan”).

The Loan was modified on April 9, 2013, allowing a temporary increase to $1,383,000 and allowing for a one-time draw of up to $995,000 to be distributed to the shareholders for the purposes of financing the capitalization of TBC Equipment Leasing, LLC. The one-time draw was repaid within 45 days and the availability under the Loan returned to $1,000,000. The modification allows for an interest rate of one month Libor floating plus 2.75%, as published in The Wall Street Journal, with a floor of 2.96% per annum.

Interest shall be due and payable monthly and principal is due on demand. The outstanding principal balance plus all accrued but unpaid interest shall be due on demand (the “Maturity Date”). Upon default, the interest may be adjusted to the highest rate permissible by law.

The Loan is secured by all assets of The B.A.C.K. Center now owned or hereafter acquired. The assets constitute the collateral for the repayment of the Loan.

The Loan Agreement also includes covenants, representations, warranties, indemnities and events of default that are customary for facilities of this type. The advance rate is defined as: 60% of eligible accounts receivables. Eligible receivables include all Medicare and Medicaid receivables less than 90 days old multiplied by a factor of 0.25, plus all other receivables less than 90 days old multiplied by a factor of 0.50. As of March 31, 2016, The B.A.C.K. Center had not violated the loan covenants.

The obligations of The B.A.C.K Center under the Loan Agreement are guaranteed by the shareholders of The B.A.C.K. Center. The Loan Agreement is also guaranteed in the amount of $950,000 by related parties of The B.A.C.K. Center. As of March 31, 2016 and December 31, 2015, the outstanding balance on the Loan was $439,524 and $416,888, respectively.

NOTE 7 — SETTLEMENT PAYABLE

On November 2, 2015, the Company and MedTRX Collection Services, Inc. signed a settlement and mutual release agreement, whereby the parties have agreed to settle all disputes and the pending arbitration actions and release each other from all claims, counterclaims, liabilities and obligations, except for obligations stipulated in the settlement or as otherwise reserved.

In connection with the settlement, on November 6, 2015, the Company issued two non-interest bearing promissory notes in aggregate of $650,000, due the earlier of a) April 2, 2016, b) the date real estate (as identified) is sold, financed or transferred or c) date the stock payment (as described above) is redeemed. As of March 31, 2016 and December 31, 2015, the balance due on outstanding settlement promissory notes was $450,000 and $600,000, respectively. However, the Company paid the notes in full on April 1, 2016.

NOTE 8 — NOTE PAYABLE, RELATED PARTY

Effective October 1, 2016, the Company acquired a 40% interest in Crane Creek Surgery Center (“Crane Creek”) in exchange for an investment of $560,000 comprised of $140,000 cash and a promissory note for $420,000 which bears 8% interest per annum, matures April 15, 2016 and is personally guaranteed by the Company’s Chief Executive Officer. The promissory note was issued to certain equity owners of The B.A.C.K. Center, an entity consolidated with the Company under VIE accounting. The outstanding principal and interest at March 31, 2015 and December 31, 2015 was $437,372 and $428,645, respectively. This note was paid in full on April 15, 2016.

NOTE 9— NOTES PAYABLE

Notes payable as of March 31, 2016 and December 31, 2015 are comprised of the following:

	March 31, 2016			December 31, 2015
Mortgage Payable	$	—		$	7,153,262
Note Payable, GE Capital (MRI)		746,390			844,098
Note Payable, GE Capital (X-ray)		85,457			97,232
Note Payable, GE Arm		61,080			67,455
Capital Lease Equipment		21,112			26,716
		914,039			8,188,763
Less current portion		(507,209	)		(7,652,941	)
	$	406,830		$	535,822

Mortgage payable

On August 12, 2011, the Company refinanced its existing mortgage note payable providing additional working capital funds. The aggregate amount of the note of $7,550,000 with 6.10% interest per annum with monthly payments of $45,753 beginning in October 2011 based on a 30-year amortization schedule with all remaining principal and interest due in full on September 16, 2016. The note is secured by land and the building along with first priority assignment of leases and rents. In connection with the sale/leaseback transaction (See Note 4), the Company paid off the outstanding balance as of March 31, 2016.

Note payable — equipment financing

On May 21, 2012, the Company entered into a note payable with GE Healthcare Financial Services (“GE Capital”) in the amount of approximately $2.4 million for equipment financing.

On September 27, 2012, the Company accepted the delivery of MRI equipment under the equipment finance lease. As such, the component price accepted of $1,771,390 is due over 60 months and the associated monthly payment is $0 for the first three months and $38,152 per month for the remaining 57 months including interest at 7.9375% per annum. On March 8, 2013, the Company amended the equipment finance lease to interest only payments of $11,779 for the first three months and $38,152 per month for the remaining monthly payments.

On August 22, 2012, the Company accepted the delivery of X-ray equipment under the equipment finance lease. As such, the component price accepted of $212,389 is due over 60 months and the associated monthly payment is $0 for the first three months and $4,300 per month for the remaining 57 months including interest at 7.9375% per annum. On March 8, 2013, the Company amended the equipment finance lease to interest only payments of $1,384 for the first three months and $4,575 per month for the remaining monthly payments.

On February 25, 2013, the Company accepted the delivery of C-arm equipment under the equipment finance lease. As such, the component price accepted of $124,797 is due over 63 months and the associated monthly payment is $0 for the first three months and $2,388 for the remaining 60 months, including interest at 7.39% per annum.

Capital leases — equipment

On June 11, 2013, the Company entered into a lease agreement to acquire equipment with 48 monthly payments of $956 payable through June 1, 2017 with an effective interest rate of 14.002% per annum. The Company may elect to acquire the leased equipment at a nominal amount at the end of the lease.

On October 25, 2011, The B.A.C.K. Center entered into a lease agreement to acquire equipment with 60 monthly payments of $1,036 payable through October 26, 2016, with no stated interest rate. The B.A.C.K. Center may elect to acquire the leased equipment at a nominal amount at the end of the lease.

Aggregate principal maturities of long-term debt as of March 31, 2016:

	Amount
Nine months ended December 31, 2016	$	378,217
Year ended December 31, 2017		519,226
Year ended December 31, 2018		16,596
Total	$	914,039

NOTE 10 — RELATED PARTY TRANSACTIONS

Effective October 1, 2015, the Company acquired a 40% interest in Crane Creek Surgery Center (“Crane Creek”) in exchange for an investment of $560,000 comprised of $140,000 cash and a promissory note for $420,000 which bears 8% interest per annum, matures April 15, 2016 and is personally guaranteed by the Company’s Chief Executive Officer. The promissory note was issued to certain equity owners of The B.A.C.K. Center, an entity consolidated with the Company under VIE accounting. This note was paid in full on April 15, 2016.

As of March 31, 2016, the Company received an aggregate of $133,796 as cash advances from related parties. The advances are due upon demand with an interest rate of 12% per annum. On April 6, 2016, the Company paid the advances in full. (See Note 20 – Subsequent Events.)

NOTE 11 — CAPITAL STOCK

During the three months ended March 31, 2016, the Company issued an aggregate of 100,000 shares of its common stock in connection with an increase in credit line, valued at $92,000. (see Note 6 – Lines of Credit.)

Stock-based payable

The Company was obligated to issue its common stock to officers and consultants for past and future services as of March 31, 2016. The estimated liability as of March 31, 2016 of $1,280,200 ($0.78 per share) was determined based on services rendered. The shares were issued in reliance upon the exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”).

NOTE 12 — STOCK OPTIONS AND WARRANTS

Warrants

The following table summarizes the warrants outstanding and the related exercise prices for the underlying shares of the Company’s common stock as of March 31, 2016:

Warrants Outstanding							Warrants Exercisable
Price		Outstanding		Expiration Date	Weighted Price		Exercisable		Weighted Price

$	1.35		2,449,630	November 2018 ~ November 2020	$	1.35		2,449,630	$	1.35
$	3.60		1,875,000	December 23, 2018	$	3.60		1,875,000	$	3.60
			4,324,630		$	2.32		4,324,630	$	2.32

The warrant to purchase up to 2,449,630 shares of the Company’s common stock may be exercised on a cashless basis. The warrant to purchase up to 1,875,000 shares of the Company’s common stock may not be exercised on a cashless basis.

Transactions involving stock warrants issued are summarized as follows:

	Number of Shares		Weighted Average Price Per Share
Outstanding at December 31, 2015:		4,324,630	$	2.32
Granted		—		—
Exercised		—		—
Expired		—		—
Outstanding at March 31, 2016		4,324,630	$	2.32

Options

The following table presents information related to stock options at March 31, 2016:

Options Outstanding
Exercise Price		Number of Options		Weighted Average Remaining Life in Years		Exercisable Number of Options
$	1.35		3,000,000		7.75		—

Transactions involving stock options issued are summarized as follows:

	Number of Shares		Weighted Average Price Per Share
Outstanding at December 31, 2015:		3,000,000	$	1.35
Granted		—		—
Exercised		—		—
Expired		—		—
Outstanding at March 31, 2016		3,000,000	$	1.35

NOTE 15 — VARIABLE INTEREST ENTITY

Brevard Orthopaedic Spine & Pain Clinic, Inc.

Effective May 1, 2015, the Company, through its recently formed wholly owned subsidiary, TBC Holdings of Melbourne, Inc., entered into an Operation and Control Agreement (the Agreement”) with Brevard Orthopaedic Spine & Pain Clinic, Inc. (“The B.A.C.K. Center”), whereby the Company will have sole and exclusive management and control of The B.A.C.K. Center, including, but not limited to, administrative, financial, facility and business operations including the requirement to absorb losses or right to receive economic benefits The initial term of the Agreement expires on December 31, 2016, with an option by the Company to extend the term until December 31, 2023. The Company issued 3,000,000 options to purchase the Company’s common stock, vesting contingent on The B.A.C.K. Center employees signing employment contracts with First Choice – Brevard.

The Company has determined that The B.A.C.K. Center is a Variable Interest Entity (“VIE”) in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 810, “Consolidation”. In evaluating whether the Company has the power to direct the activities of a VIE that most significantly impact its economic performance, the Company considers the purpose for which the VIE was created, the importance of each of the activities in which it is engaged and the Company’s decision-making role, if any, in those activities that significantly determine the entity’s economic performance as compared to other economic interest holders.

This evaluation requires consideration of all facts and circumstances relevant to decision-making that affects the entity’s future performance and the exercise of professional judgment in deciding which decision-making rights are most important.

In determining whether the Company has the right to receive benefits or the obligation to absorb losses that could potentially be significant to the VIE, the Company evaluates all of its economic interests in the entity, regardless of form (debt, equity, management and servicing fees, and other contractual arrangements). This evaluation considers all relevant factors of the entity’s structure, including: the entity’s capital structure, contractual rights to earnings (losses), subordination of our interests relative to those of other investors, contingent payments, as well as other contractual arrangements that have potential to be economically significant. The evaluation of each of these factors in reaching a conclusion about the potential significance of the Company’s economic interests is a matter that requires the exercise of professional judgment. The assets of The B.A.C.K. Center can only be used to settle obligations of the VIE, additionally, creditors of The B.A.C.K. Center do not have recourse against the general credit of the primary beneficiary.

The table below summarizes the assets and liabilities associated with The B.A.C.K. Center as of March 31, 2016 and as of December 31, 2015:

	March 31, 2016			December 31, 2015
Current assets:
Cash	$	1,120,942		$	996,986
Accounts receivable		3,915,553			3,727,419
Other current assets		1,034,157			819,757
Total current assets		6,070,652			5,544,162
Property and equipment, net		57,579			60,978
Other assets		22,334			18,231
Total assets	$	6,150,565		$	5,623,371

Current liabilities:
Accounts payable and accrued liabilities	$	1,997,207		$	1,877,690
Due to First Choice Healthcare Solutions, Inc.		2,058,624			1,729,882
Other current liabilities		446,759			427,229
Total current liabilities		4,502,590			4,034,801
Long term debt		1,786,661			1,727,256
Total liabilities		6,289,251			5,762,057
Non-controlling interest		(138,686	)		(138,686	)
Total liabilities and deficit	$	6,150,565		$	5,623,371

Total revenues from The B.A.C.K. Center were $3,449,722 for the three months ended March 31, 2016. Related expenses consisted primarily of salaries and benefits of $1,457,911, general and administrative expenses of $1,654,107, depreciation of $5,515 and interest and financing costs of $3,447. (See Note 17 – Segment Reporting)

Crane Creek Surgery Center

The Company has determined that Crane Creek is a Variable Interest Entity (“VIE”) in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 810, “Consolidation”. In evaluating whether the Company has the power to direct the activities of a VIE that most significantly impact its economic performance, the Company considers the purpose for which the VIE was created, the importance of each of the activities in which it is engaged and the Company’s decision-making role, if any, in those activities that significantly determine the entity’s economic performance as compared to other economic interest holders.

The assets of Crane Creek can only be used to settle obligations of the VIE, additionally, creditors of the Crane Creek do not have recourse against the general credit of the primary beneficiary.

The table below summarizes the assets and liabilities associated with the Crane Creek as of March 31, 2016 and December 31, 2015:

	March 31, 2016		December 31, 2015
Current assets:
Cash	$	503,262	$	559,318
Accounts receivable		891,070		816,889
Total current assets		1,394,332		1,376,207
Property and equipment, net		667,280		712,830
Goodwill		899,465		899,465
Total assets	$	2,961,077	$	2,988,502

Current liabilities:
Accounts payable and accrued liabilities	$	324,764	$	441,368
Other current liabilities		251,588		251,588
Total current liabilities		576,352		692,956
Deferred rent		532,754		532,752
Total liabilities		1,109,106		1,225,708

Equity-First Choice Healthcare Solutions, Inc		740,788		705,118
Non-controlling interest		1,111,183		1,057,676
Total liabilities and deficit	$	2,961,077	$	2,988,502

Total revenues from the Crane Creek were $1,271,308 for the three months ended March 31, 2016. Related expenses consisted primarily of salaries and benefits of $293,337, practice supplies and operating of $709,646, general and administrative expenses of $109,275, depreciation of $71,256 and miscellaneous income of $1,382. (See Note 17 – Segment Reporting)

NOTE 16 — NON-CONTROLLING INTEREST

Effective May 1, 2015, the Company, through its recently formed wholly owned subsidiary, TBC Holdings of Melbourne, Inc. entered into an Operation and Control Agreement (the Agreement”) with Brevard Orthopaedic Spine & Pain Clinic, Inc. (“The B.A.C.K. Center”), whereby the Company will have sole and exclusive management and control of The B.A.C.K. Center, including, but not limited to, administrative, financial, facility and business operations, including the requirement to absorb losses or right to receive economic benefits. The initial term of the Agreement expires on December 31, 2016 with an option by the Company to extend the term until December 31, 2023.

A reconciliation of the non-controlling income attributable to the Company:

Net loss attributable to non-controlling interest for the three months ended March 31, 2016:

Net income	$	328,741
Average Non-controlling interest percentage of profit/losses		-0-	%
Net income attributable to the non-controlling interest	$	-0-

The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2016:

Balance, December 31, 2015	$	(138,686	)
Transfer (to) from the non-controlling interest as a result of change in ownership		—
Net income attributable to the non-controlling interest		—
Balance, March 31, 2016	$	(138,686	)

A reconciliation of the non-controlling income attributable to the Company:

Net income attributable to non-controlling interest for the three months ended March 31, 2016:

Net income	$	89,177
Average Non-controlling interest percentage of profit/losses		60	%
Net income/loss attributable to the non-controlling interest	$	53,507

The following table summarizes the changes in non-controlling interest from October 1, 2015 to December 31, 2015:

Balance, December 31, 2015	$	1,057,676
Transfer (to) from the non-controlling interest as a result of change in ownership		—
Net income attributable to the non-controlling interest		53,507
Balance, March 31, 2016	$	1,111,183

NOTE 17 — SEGMENT REPORTING

The Company reports segment information based on the “management” approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of the Company’s reportable segments. The Company has four reportable segments: Marina Towers, LLC, FCID Medical, Inc., CCSC Holdings, Inc. and The B.A.C.K Center.

The Marina Towers, LLC segment derives revenue from the operating leases of its owned building; FCID Medical and the CCSC Holdings segments derives revenue for medical services provided to patients; and The B.A.C.K Center derives revenue for subleasing space within its building and medical services provided to patients.

Information concerning the operations of the Company’s reportable segments is as follows:

Summary Statement of Operations for the three months ended March 31, 2016:

	Marina			FCID			Brevard			The Crane						Intercompany
	Towers			Medical			Orthopaedic			Center			Corporate			Eliminations			Total
Revenue:
Net Patient Service Revenue	$	—		$	2,308,935		$	3,034,898		$	1,271,308		$	—		$	—		$	6,615,141
Rental revenue		428,246			—			358,099						—			(159,733	)		626,612
Total Revenue		428,246			2,308,935			3,392,997			1,271,308			—			(159,733	)		7,241,753

Operating expenses:
Salaries & benefits		3,000			829,220			1,457,911			293,337			197,101			—			2,780,569
Other operating expenses		105,954			531,407						709,646			—			(159,733	)		1,187,274
General and administrative		23,907			361,803			1,581,793			109,275			329,099			—			2,405,877
Depreciation and amortization		69,951			66,792			5,515			71,256			85,436			—			298,950
Total operating expenses		202,812			1,789,222			3,045,219			1,183,514			611,636			(159,733	)		6,672,670

Net income (loss) from operations:		225,434			519,713			347,778			87,794			(611,636	)		—			569,083

Interest expense		(110,156	)		(56,818	)		(2,459	)		(8,726	)		(2,976	)		—			(181,135	)
Amortization of financing costs		(14,337	)		—			(988	)		—			—			—			(15,325	)
Gain on sale of property		9,188,968			—			—			—			—			—			9,188,968
Other income (expense)		750			—			56,725			1,382			—			—			58,857

Net income (loss) before income taxes:		9,290,659			462,895			401,056			80,450			(614,612	)		—			9,620,448

Income taxes		—			—									—			—			—

Net income (loss)		9,290,659			462,895			401,056			80,450			(614,612	)		—			9,620,448

Non-controlling interest		—			—			—			(53,507	)		—			—			(53,507	)

Net income (loss) attributable to First Choice Healthcare Solutions	$	9,290,659		$	462,895		$	401,056		$	26,943		$	(614,612	)	$	—		$	9,566,941

Summary Statement of Operations for the three months ended March 31, 2015:

	Marina			FCID						Intercompany
	Towers			Medical			Corporate			Eliminations			Total
Revenue:
Net Patient Service Revenue	$	—		$	2,240,064		$	—		$	—		$	2,240,064
Rental revenue		375,321			—			—			(110,218	)		265,103
Total Revenue		375,321			2,240,064			—			(110,218	)		2,505,167

Operating expenses:
Salaries & benefits		3,000			836,987			106,133			—			946,120
Other operating expenses		103,331			458,372			—			(110,218	)		451,485
General and administrative		22,642			291,159			239,483			—			553,284
Depreciation and amortization		69,219			66,515			4,775			—			140,509
Total operating expenses		198,192			1,653,033			350,391			(110,218	)		2,091,398

Net income (loss) from operations:		177,129			587,031			(350,391	)		—			413,769

Interest expense		(110,496	)		(51,784	)		(200,864	)		—			(363,144	)
Amortization of financing costs		(14,337	)		(6,349	)		—			—			(20,686	)
Other income (expense)		750			—			—			—			750

Net Income (loss):		53,046			528,898			(551,255	)		—			30,689

Income taxes		—			—			—			—			—

Net income (loss)	$	53,046		$	528,898		$	(551,255	)	$	—		$	30,689

Selected financial data:

	Marina		FCID		Brevard		The Crane
	Towers		Medical		Orthopaedic		Center		Corporate		Total
Assets:
At March 31, 2016:	$	8,642,412	$	4,872,351	$	6,176,738	$	2,961,076	$	3,194,588	$	25,847,165
At December 31, 2015:	$	6,309,955	$	4,391,192	$	5,623,370	$	3,013,011	$	3,286,460	$	22,623,988

Assets acquired
Three months ended March 31, 2016	$	49,824	$	49,893	$	2,116	$	24,240	$	—	$	126,073
Three months ended March 31, 2015	$	6,628	$	1,656	$	—	$	—	$	—	$	8,284

NOTE 18 - COMMITMENTS AND CONTINGENCIES

Litigation – Health First Management

The B.A.C.K. Center has a claim filed in Brevard County, Florida Circuit Court against Health First Management, Inc. due to a contract dispute. A counterclaim was filed against the Company. The case has been litigated for a substantial amount of time and a trial is anticipated to take place within the next 12 months. The Company has vigorously defended against the counterclaim. The Company has accrued a possible loss contingency of approximately $118,000 during the year ended December 31, 2015.

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

Operating leases

The B.A.C.K. Center leases office space under various non-cancelable operating leases that expire at various dates through June 2026. Terms of the lease agreements provide for rental payments ranging from approximately $4,200 to $200,000 per month. Certain leases include charges for sales and real estate taxes and a proration of common area maintenance expenses. Under generally accepted accounting principles (GAAP), all rental payments, including fixed rent increases, are recognized on a straight-line basis over the life of the lease. The GAAP rent expense and the actual lease payments are reflected as deferred rent on the accompanying balance sheet. From the date of the Operation and Control Agreement through December 31, 2015, lease expense amounted to $2,360,986.

The following is a schedule of future minimum lease payments for all non-cancelable operating leases for each of the next five years ending December 31 and thereafter:

Nine months ended December 31, 2016		2,620,910
Year ended December 31, 2017		3,444,197
Year ended December 31, 2018		3,444,209
Year ended December 31, 2019		3,444,221
	$	12,953,537

Sale/Leaseback

Effective March 31, 2016, the Company leased Marina Towers under a sale/leaseback transaction (See Note 4), via a 10-year absolute triple-net master lease agreement that expires in 2026. The Company has two successive options to renew the lease for five-year periods on the same terms and conditions as the primary non-revocable lease term with the exception of rent, which will be adjusted to the prevailing fair market rent at renewal and will escalate in successive years during the extended lease period. The Company does not have any residual interest nor the option to repurchase the facility at the end of the lease term.

The following is a schedule of future minimum lease payments for the non-cancelable operating lease for each of the next five years ending December 31 and thereafter:

Nine months ended December 31, 2016	$	828,506
Year ended December 31, 2017		1,104,675
Year ended December 31, 2018		1,104,675
Year ended December 31, 2019		1,121,246
Year ended December 31, 2020		1,143,670
Year ended December 31, 2021 and thereafter		6,387,969
	$	11,690,741

For the three months ended March 31, 2016, the Company collected $268,513 in net rental revenue from third party tenants of Marina Towers.

Guarantees

The B.A.C.K. Center’s shareholders and a related party have guaranteed the full and prompt payment of the base rent, the additional rent and any all other sums and charges payable by a tenant, its successors and assigns under the lease, and the full performance and observance of all the covenants, terms, conditions and agreements for one of the above mentioned operating leases.

NOTE 19 – INCOME TAXES

In the first quarter of 2016, effective March 31, 2016, we sold and leased back Marina Towers under a sale/leaseback transaction (See “Gain on Sale of Property and Improvements”). In connection with the sale, the Company reported a gain on sale of the property of $9,188,968 (GAAP Basis) for the three months ended March 31, 2016. There was a Tax Basis gain of approximate $9,051,430. The difference between the GAPP Basis and Tax Basis gain was mainly attributable to depreciation. The gain was offset by Net Operation Losses the Company has generated in prior periods, so no income tax was recorded, but an estimated Alternative Minimum Tax liability of $181,089 was recorded. Offsetting the Alternative Minimum tax recorded is a Deferred Tax Asset of the same amount related to the Alternative Minimum Tax Liability (Alternative Minimum Tax Credit Carryforward). Management believes the Company will utilize the Alternative Minimum Tax Carryforward in future periods, as of the March 31, 2016 reporting period.

The Company’s effective tax rate in the first quarter of 2016 is approximately 38.6% See Note 20, Income Taxes, in the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2015 for additional information.

NOTE 20 – SUBSEQUENT EVENTS

On April 1, 2016, the Company paid the following notes in full. In connection with the MedTRX Collection Services, Inc. settlement, on November 6, 2015, the Company issued two non-interest bearing promissory notes in aggregate of $650,000, due the earlier of a) April 2, 2016, b) the date real estate (as identified) is sold, financed or transferred or c) date the stock payment (as described above) is redeemed. As of March 31, 2016, the balance due on outstanding settlement promissory notes was $450,000.

On April 6, 2016, the Company paid the following advances in full. As of March 31, 2016, the Company received an aggregate of $133,796 as cash advances from related parties. The advances are due upon demand with an interest rate of 12% per annum.

On April 15, 2016, the Company paid the following note in full. The promissory note was issued to certain equity owners of The B.A.C.K. Center, an entity consolidated with the Company under VIE accounting. Effective October 1, 2015, the Company acquired a 40% interest in Crane Creek Surgery Center (“Crane Creek”) in exchange for an investment of $560,000 comprised of $140,000 cash and a promissory note for $420,000 which bears 8% interest per annum, matures April 15, 2016 and is personally guaranteed by the Company’s Chief Executive Officer.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This quarterly report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934 (“Exchange Act”). Forward-looking statements reflect the current view about future events. When used in this quarterly report on Form 10-Q, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this quarterly report on Form 10-Q relating to our business strategy, our future operating results, and our liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, the execution of our strategy to grow our business by hiring additional physicians to create Medical Centers of Excellence that fit our defined criteria; evolving healthcare laws and regulations; changes in the rates or methods of third-party reimbursements for medical services; accelerated pace of consolidation in the hospital industry; changes in our medical technology as it relates to our services and procedures; any failures in our information technology systems to protect the privacy and security of protected information and other similar cyber security risks; our ability to raise capital to fund continuing operations; and other factors relating to our industry, our operations and results of operations and any new Medical Centers of Excellence that we may open. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Overview

First Choice Healthcare Solutions, Inc. (“FCHS,” “the Company,” “we,” “our” or “us”) is implementing the second phase of a defined growth strategy aimed at building a network of localized, integrated healthcare delivery platforms comprised of non-physician-owned medical centers of excellence, which concentrate on treating patients in the following specialties: Orthopaedics, Spine Surgery, Neurology, Interventional Pain Management and related diagnostic and ancillary services in key expansion markets throughout the Southeastern U.S.

Successful implementation of our first phase allowed us to confirm that by integrating the synergistic mix of Orthopaedic, Spine Surgery, Neurology and Interventional Pain specialties with related diagnostic and ancillary services and state-of-the-art equipment and technologies across legacy brick-and-mortar boundaries, we are able to effectively:

	●	provide patients with direct and convenient access to musculoskeletal and rehabilitative care via our best-in-class team of surgeons, physicians and care specialists, and wide array of ancillary and diagnostic services, which includes, but is not limited to, magnetic resonance imaging (“MRI”), X-ray (“X-ray”), durable medical equipment (“DME”) and rehabilitative care, including physical therapy (“PT”) and occupational therapy (“OT”).

	●	empower physicians to collaborate as a unified care team, optimizing care coordination and improving outcomes;

	●	advance the quality and cost effectiveness of our patients’ healthcare, thereby achieving faster recoveries at materially reduced costs; and

	●	achieve strong, sustainable financial performance that serves to create long-term value for our stockholders.

Our goal is to build a network of non-physician-owned and operated Medical Centers of Excellence in diverse locations, primarily throughout the southeastern region of the United States. By centralizing current and future Centers’ business management functions, including call center operations, scheduling, billing, compliance, accounting, marketing, advertising, legal, information technology and record-keeping, at our corporate headquarters, we will maintain efficiencies and scales of economies. We believe our structure will enable our staff physicians to focus on the practice of medicine and the delivery of quality care to the patients we serve, as opposed to having their time and attention focused on business administration responsibilities. We currently have 116 employees, including physicians and physician assistants.

Our Healthcare Services Business

We currently own and operate First Choice Medical Group of Brevard, LLC (“First Choice – Brevard”), our multi-specialty Medical Center of Excellence. Located in Melbourne, Florida, First Choice – Brevard specializes in the delivery of musculoskeletal medicine, via our strategically aligned sub-specialties in orthopaedics, neurology and interventional pain medicine, coupled with on-site diagnostic and ancillary services, including MRI, X-ray, DME, PT and OT with multiple quality-focused goals centered on enriching our patients’ care experiences.

On May 1, 2015, through our wholly-owned subsidiary, TBC Holdings of Melbourne, Inc., we entered into an Operation and Control Agreement (the “Agreement”) with Brevard Orthopaedic Spine & Pain Clinic, Inc. (“The B.A.C.K. Center”), a premier spine, orthopaedic and pain practice in Brevard County, Florida. The B.A.C.K. Center operates two medical offices located in Melbourne and Merritt Island, Florida.

On October 1, 2015, through our newly formed wholly-owned subsidiary, CCSC Holdings, Inc., we acquired a 40% interest in Melbourne, Florida-based Crane Creek Surgery Center (“Crane Creek”). Established in 2009, Crane Creek is an AAAHC accredited facility dedicated to delivering excellent, ambulatory surgical care in a convenient, comfortable outpatient environment. The modern 18,000+ square foot facility is located in Melbourne, Florida within the Crane Creek Medical Center building, which is also home to Osler Medical and The B.A.C.K. Center. Crane Creek’s facility houses four state-of-the-art operating rooms and a procedure room; with capacity and capability to host 4,000-5,000 orthopaedic, spine, interventional pain and general surgical procedures each year. The other owners of Crane Creek are CCSC TBC Group, LLC (“TBC Group”), owned by Richard Hynes, M.D., FASC and Devin Datta, M.D.; and Blue Chip Surgical Center Partners, which develops and manages 17 world class ambulatory surgery centers across the United States. Drs. Hynes and Datta are both affiliated with The B.A.C.K. Center. Together, CCSC Holdings and TBC Group own 75% interest in Crane Creek. In accordance with the Crane Creek Restated and Amended Operating Agreement, CCSC Holdings will exercise sufficient control over the business of Crane Creek that will allow First Choice to treat it as a variable interest entity, effective October 1, 2015. As a result, First Choice will include the financial results of Crane Creek in its consolidated financial statements in accordance with generally accepted accounting principles as if it were a wholly-owned subsidiary. Dr. Hynes has been appointed as Crane Creek’s Medical Board president and as Medical Director.

Our Real Estate Business

FCID Holdings, Inc. (“FCID Holdings”) is our wholly owned subsidiary, which operates our real estate interests. FCID Holdings had one real estate holding, Marina Towers, LLC, a 78,000 square foot, Class A, six-story building located on the Indian River in Melbourne, Florida. In addition to housing our corporate headquarters and FCMG, the building, which averages 95% annual occupancy, also leases approximately 48,698 square feet of commercial office space to third party tenants. In addition, beginning May 1, 2015, TBC Holdings of Melbourne, Inc., through The B.A.C.K. Center, subleases approximately 34,480 square feet of commercial office space to third party tenants.

New Accounting Pronouncements

There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

Results of Operations for the Three Months Ended March 31, 2016 and 2015

Revenues

Total revenues increased 189% to $7,241,753 for the three months ended March 31, 2016 as compared to revenues of $2,505,167 for the same period in the prior year. The increase is primarily attributed to the addition on May 1, 2015 of Brevard Orthopaedic Spine & Pain Clinic, Inc. (“The B.A.C.K. Center”) and on October 1, 2015 of Crane Creek Surgical Center (“Crane Creek), which contributed revenues of $3,392,997 and $1,271,308, respectively, for the quarter comprised of additional patient services revenue of $4,306,206 and rental revenue of $358,099. Patient services revenue generated by First Choice Medical Group (“FCMG”) increased by $68,871, or 3%, after factoring provision for doubtful accounts. Rental revenue increased by $361,509, totaling $626,612 and $265,103 for the three months ended March 31, 2016 and 2015, respectively, primarily due to the addition of rental revenue from The B.A.C.K. Center.

The provision for doubtful accounts during the first quarter of 2016 totaled $626,612. We adopted the provisions of ASU 2011-07 in 2014, which requires that healthcare entities change the presentation of the statement of operations by reclassifying the provision for doubtful accounts from an operating expense to a deduction from patient service revenues. All periods presented have been reclassified in accordance with ASU 2011-07.

Operating Expenses

Operating expenses include the following:

	Three Months Ended March 31, 2016		Three Months Ended March 31, 2015
Salaries and Benefits	$	2,780,569	$	946,120
Other operating expenses		1,187,274		451,485
General and administrative		2,405,877		553,284
Depreciation and amortization		298,950		140,509
Total operating expenses	$	6,672,670	$	2,091,398

The major components of operating expenses include practice salaries and benefits, practice supplies and other operating costs, depreciation and general and administrative expenses, which included legal, accounting and professional fees associated with being a public entity.

Salaries and benefits increased 194% to $2,780,569 for the three months ended March 31, 2016, compared to $946,120 for the three months ended March 31, 2015. The increase was primarily due to the addition on May 1, 2015 of The B.A.C.K. Center and October 1, 2015 of Crane Creek, which represented an additional $1,751,248 in the reporting period. The existing segments netted an increase of $83,201 as compared to 2015. Other operating expenses increased 163% to $1,187,274 from $451,485 due to the increase in patient service volume from 2015 to 2016 with the added facilities.

General and administrative expenses for the three months ended March 31, 2016 increased 335% to $2,405,877, up from $553,284. The increase was largely attributable adding The B.A.C.K. Center and Crane Creek, adding $1,691,067 in costs. We believe that each additional sale or service and corresponding gross profit of such sale or service has minimal incremental offsetting operating expenses. Thus, additional sales could contribute to profit at a higher rate of return on sales as a result of not needing to expand operating expenses at the same pace as sales.

Depreciation and amortization increased 112% from $140,509 for the three months ended March 31, 2016 to $298,950 for the three months ended March 31, 2015. The increase is primarily from our two additional operating segments.

Net Income from Operations

The income from operations for the three months ended March 31, 2016 increased 38% to $569,083, which compared to income from operations of $413,769 for the same period in the prior year. Notwithstanding non-cash expenses totaling $658,099 for the three months ended March 31, 2016, which included stock-based compensation, depreciation and amortization, income from operations totaled $1,227,182. This compared to income from operations of $668,438 after factoring $254,669 in non-cash stock-based compensation, depreciation and amortization recorded for the three months ended March 31, 2015.

Gain on Sale of Property and Improvements

Effective March 31, 2016, we sold and leased back Marina Towers under a sale/leaseback transaction via a 10-year absolute triple-net master lease agreement that expires in 2026. The Company has two successive options to renew the lease for five-year periods on the same terms and conditions as the primary non-revocable lease term with the exception of rent, which will be adjusted to the prevailing fair market rent at renewal and will escalate in successive years during the extended lease period. In connection with the sale, we reported a gain on sale of property of $9,188,968 for the three months ended March 31, 2016.

Interest Expense

Interest expense decreased 50% to $181,135 for the three months ended March 31, 2016, which compared to $363,144 for the three months ended March 31, 2015. The decrease primarily is due to payoff conversions of our convertible notes payable with Hillair in 2015 as compared to the same period last year, net with increase from The B.A.C.K. Center in 2015 of $2,459.

Net Income

As a result of all the above, we reported net income of $9,566,941 for the three months ended March 31, 2016, representing a significant improvement over net income of $30,689 reported for the same three-month period in the prior year.

Segment Results

The following are the revenues, operating expenses and net loss by segment for the three months ended March 31, 2016 and 2015, respectively. The significant fluctuations in the line items are described above.

For the Three Months Ended March 31, 2016:

	Marina		FCID		Brevard		The Crane					Intercompany
	Towers		Medical		Orthopaedic		Center		Corporate			Eliminations			Total
Revenue:
Net Patient Service Revenue	$	—	$	2,308,935	$	3,034,898	$	1,271,308	$	—		$	—		$	6,615,141
Rental revenue		428,246		—		358,099				—			(159,733	)		626,612
Total Revenue		428,246		2,308,935		3,392,997		1,271,308		—			(159,733	)		7,241,753
Total operating expenses		202,812		1,789,222		3,045,219		1,183,514		611,636			(159,733	)		6,672,670

Net income (loss) from operations:		225,434		519,713		347,778		87,794		(611,636	)		—			569,083

For the Three Months Ended March 31, 2015:

	Marina		FCID					Intercompany
	Towers		Medical		Corporate			Eliminations			Total
Revenue:
Net Patient Service Revenue	$	—	$	2,240,064	$	—		$	—		$	2,240,064
Rental revenue		375,321		—		—			(110,218	)		265,103
Total Revenue		375,321		2,240,064		—			(110,218	)		2,505,167
Total operating expenses		198,192		1,653,033		350,391			(110,218	)		2,091,398

Net income (loss) from operations:		177,129		587,031		(350,391	)		—			413,769

Liquidity and Capital Resources

As of March 31, 2016, we had cash of $10,051,999 and accounts receivables totaling $7,448,429. This compared to cash of $1,594,998, restricted cash of $359,414 and accounts receivable of $6,623,894 as of the end of 2015.

The Marina Towers building is 95% occupied. We believe that ongoing operations of Marina Towers, LLC, the current positive cash balance, along with continued execution of Marina Tower’s business development plan, will allow us to further improve our working capital; and that we will have sufficient capital resources to meet projected cash flow requirements through the date that is one year plus a day from the filing date of this report. However, there can be no assurance that we will be successful in fully executing our business development plan.

Net cash provided by our operating activities for the three months ended March 31, 2016 totaled $317,224, which compared to net cash used in our operations for the three months ended March 31, 2015 of $173,931. The increase in cash provided was due primarily to net income of $9,620,448 for the current period as compared to net income of $30,689 for the three months ended March 31, 2015. This was offset by stock-based compensation of $81,300, payment of the non-cash loan extension of $92,000, bad debt expense of $262,524 and depreciation and amortization of 314,275, net with gain on sale of property of $9,188,968 for the three months ended March 31, 2016 as compared to $353,669 for the same period last year. In addition, our operating assets increased by $881,955 and $533,044 for the three months ended March 31, 2016 and 2015, respectively; and our operating liabilities increased in 2016 by $17,600 as compared to decreasing by $25,245 for the three months ended March 31, 2015.

Net cash flows provided by investing activities was $14,942,424 for the three months ended March 31, 2016, compared to $8,284 used in investing activities for the three months ended March 31, 2015. In 2016, we received $15,068,497 net proceeds from the sale of Marina Towers. Purchases of equipment were $126,073 and $8,284 for the three months ended March 31, 2016 and 2015, respectively, due to less cash spent on the purchase of equipment in 2015 compared to the current year.

Cash flows used in financing activities was $6,802,647 for three months ended March 31, 2016, compared to net cash provided by financing activities of $15,922 for the three months ended March 31, 2015. The cash flows provided by (used in) financing activities were the result of:

	Three Months ended March 31, 2016			Three Months ended March 31, 2015
Proceeds from advances	$	90,714		$	74,000
Proceeds from lines of credit		372,636	)		140,000
Net payments on notes payable		(7,265,997	)		(198,078	)
Net cash provided by (used in) financing activities	$	(6,802,647	)	$	15,922

On March 31, 2016, in connection with the sale/leaseback transaction of Marina Towers, we paid off the outstanding mortgage balance due of $7,223,771.

Currently, we are actively engaged in identifying and pursuing discussions with prospective acquisitions and/or implementation of operation and management agreements that qualify as variable interest entities in accordance with generally accepted accounting practices in key target markets — with those being largely in the southeastern U.S. Over the next 12 months, we expect to incur significant capital costs to further develop and expand our medical operations. We plan to add another medical center of excellence and purchase additional diagnostic equipment for our operations. We expect to need additional capital of approximately $4-6 million to fund the development and expansion of our operations over the next 12 months. However, there can be no assurance that we will be able to negotiate acceptable terms for, or find suitable candidates for, such acquisition.

There can be no assurance that our cash flow will increase in the near future from anticipated new business activities, or that revenues generated from our existing operations will be sufficient to allow us to continue to pursue new customer programs or profitable ventures.

Off Balance Sheet Arrangements

We currently have no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Critical Accounting Policies and Estimates

Our unaudited condensed consolidated financial statements have been prepared by management in accordance with U.S. GAAP.

Recently Issued Accounting Pronouncements

There were various updated recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.

Management does not believe that any other recently issued but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

Inflation

The effect of inflation on our revenue and operating results was not significant.

Climate Change

We believe that neither climate change, nor government regulations related to climate change, have had, or are expected to have, any material effect on our operations.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

As a smaller reporting company, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information required by this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Pursuant to Rule 13a-15(b) under the Exchange Act, we carried out an evaluation, with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal controls over financial reporting (as such term is defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended March 31, 2016, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II

Item 1. Legal Proceedings

Item 1A. Risk Factors

There have been no material changes to the Risk Factors reported in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2015.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3. Defaults upon Senior Securities

There has been no default in the payment of principal, interest, sinking or purchase fund installment, or any other material default, with respect to any indebtedness of our Company.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

31.1		Certification by the Principal Executive Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).*
31.2		Certification by the Principal Accounting Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).*
32.1		Certification by the Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
32.2		Certification by the Principal Accounting Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

* Filed herewith.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report on Form 10-Q to be signed on its behalf by the undersigned thereunto duly authorized.

	FIRST CHOICE HEALTHCARE SOLUTIONS, INC.

Dated: May 16, 2016	By:	/s/ Christian C. Romandetti
		Christian C. Romandetti
		Chief Executive Officer (Principal Executive Officer)

Dated: May 16, 2016	By:	/s/ Donald A. Bittar
		Donald A. Bittar
		Interim Chief Financial Officer (Principal Accounting Officer)

EX-31.1 2 ex31_1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

I, Christian C. Romandetti, certify that:

1)	I have reviewed this Quarterly Report on Form 10-Q of First Choice Healthcare Solutions, Inc. (the “registrant”);

2)	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report;

3)	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this report;

4)	The small business issuer’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5)	I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	By:	/s/ Christian c. romandetti
		Christian C. Romandetti
		Chief Executive Officer

		May 16, 2016

EX-31.2 3 ex31_2.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

I, Donald A. Bittar, certify that:

1)	I have reviewed this Quarterly Report on Form 10-Q of First Choice Healthcare Solutions, Inc. (the “registrant”);

2)	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report;

3)	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4)	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5)	I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer’s auditors and the audit committee of the small business issuer’s board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	By:	/s/ DONALD A. BITTAR
		Donald A. Bittar
		Interim Chief Financial Officer

		May 16, 2016

EX-32.1 4 ex32_1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of First Choice Healthcare Solutions, Inc. (the “Company”), as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Christian C. Romandetti, the Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in such Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	By:	/s/ CHRISTIAN C. ROMANDETTI
		Christian C. Romandetti
		Chief Executive Officer

Dated: May 16, 2016

EX-32.2 5 ex32_2.htm EXHIBIT 32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of First Choice Healthcare Solutions, Inc. (the “Company”), as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Donald A. Bittar, the Interim Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 16, 2016	By:	/s/ DONALD A. BITTAR
		Donald A. Bittar
		Interim Chief Financial Officer

EX-101.INS 6 fchs-20160331.xml XBRL INSTANCE FILE 0001416876 2015-12-31 0001416876 2015-01-01 2015-03-31 0001416876 us-gaap:PatentsMember 2015-12-31 0001416876 fchs:PatientListsMember 2015-12-31 0001416876 us-gaap:CommonStockMember 2015-12-31 0001416876 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001416876 us-gaap:RetainedEarningsMember 2015-12-31 0001416876 us-gaap:NoncontrollingInterestMember 2015-12-31 0001416876 2016-01-01 2016-03-31 0001416876 2016-03-31 0001416876 us-gaap:CommonStockMember 2016-03-31 0001416876 us-gaap:AdditionalPaidInCapitalMember 2016-03-31 0001416876 us-gaap:RetainedEarningsMember 2016-03-31 0001416876 us-gaap:NoncontrollingInterestMember 2016-03-31 0001416876 us-gaap:LandMember 2015-12-31 0001416876 us-gaap:BuildingMember 2015-12-31 0001416876 us-gaap:BuildingImprovementsMember 2015-12-31 0001416876 us-gaap:ComputerEquipmentMember 2015-12-31 0001416876 fchs:MedicalEquipmentMember 2015-12-31 0001416876 us-gaap:OfficeEquipmentMember 2015-12-31 0001416876 us-gaap:MortgagesMember 2015-12-31 0001416876 fchs:NotePayableGeCapitalMriMember 2015-12-31 0001416876 fchs:NotePayableGeCapitalXraysMember 2015-12-31 0001416876 fchs:NotePayableGeArmMember 2015-12-31 0001416876 fchs:CapitalLeaseEquipmentMember 2015-12-31 0001416876 fchs:MarinaTowersMember 2016-03-31 0001416876 fchs:FcidMedicalMember 2016-03-31 0001416876 fchs:BrevardOrthopaedicMember 2015-12-31 0001416876 us-gaap:CorporateMember 2015-12-31 0001416876 fchs:CtCapitalLtdMember 2015-12-31 0001416876 fchs:CommonStockSubscriptionsMember 2015-12-31 0001416876 fchs:BrevardOrthopaedicSpinePainClinicIncMember 2015-05-02 2015-05-31 0001416876 fchs:BrevardOrthopaedicSpinePainClinicIncMember 2015-05-31 0001416876 fchs:TbcHoldingsOfMelbourneIncMember 2015-05-31 0001416876 fchs:PatientListsMember 2016-03-31 0001416876 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2016-01-01 2016-03-31 0001416876 us-gaap:OfficeEquipmentMember 2016-03-31 0001416876 us-gaap:ComputerEquipmentMember 2016-03-31 0001416876 us-gaap:BuildingImprovementsMember 2016-03-31 0001416876 us-gaap:BuildingMember 2016-03-31 0001416876 us-gaap:LandMember 2016-03-31 0001416876 fchs:MedicalEquipmentMember 2016-03-31 0001416876 fchs:CtCapitalLtdMember 2013-06-01 2013-06-13 0001416876 fchs:CtCapitalLtdMember 2013-06-13 0001416876 fchs:CapitalLeaseEquipmentMember 2016-03-31 0001416876 fchs:NotePayableGeArmMember 2016-03-31 0001416876 fchs:NotePayableGeCapitalXraysMember 2016-03-31 0001416876 fchs:NotePayableGeCapitalMriMember 2016-03-31 0001416876 us-gaap:MortgagesMember 2016-03-31 0001416876 fchs:NonEmployeesMember fchs:WarrantTwoMember 2016-01-01 2016-03-31 0001416876 fchs:NonEmployeesMember fchs:WarrantTwoMember 2016-03-31 0001416876 fchs:NonEmployeesMember us-gaap:WarrantMember 2016-03-31 0001416876 fchs:NonEmployeesMember fchs:WarrantOneMember 2016-03-31 0001416876 fchs:NonEmployeesMember us-gaap:WarrantMember 2016-01-01 2016-03-31 0001416876 us-gaap:WarrantsNotSettleableInCashMember 2016-03-31 0001416876 fchs:WarrantsSettleableInCashMember 2016-03-31 0001416876 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2015-12-31 0001416876 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2015-05-01 0001416876 fchs:DonaldBittarMember 2013-08-30 2013-09-07 0001416876 us-gaap:PatentsMember fchs:DonaldBittarMember 2013-09-01 2013-09-07 0001416876 fchs:CtCapitalLtdMember 2013-11-01 2013-11-08 0001416876 2013-06-01 2013-06-13 0001416876 fchs:LineOfCreditFloridaBusinessBankMember 2012-06-01 2012-06-27 0001416876 fchs:TbcEquipmentLeasingLlcMember 2013-04-01 2013-04-09 0001416876 us-gaap:AccountsReceivableMember fchs:LineOfCreditFloridaBusinessBankMember 2012-06-01 2012-06-27 0001416876 us-gaap:AccountsReceivableMember us-gaap:MinimumMember 2015-06-09 0001416876 us-gaap:AccountsReceivableMember us-gaap:MaximumMember 2015-06-09 0001416876 fchs:CtCapitalLtdMember 2013-11-08 0001416876 2013-06-13 0001416876 us-gaap:AccountsReceivableMember fchs:LineOfCreditFloridaBusinessBankMember 2012-06-27 0001416876 fchs:CtCapitalLtdMember 2016-03-31 0001416876 fchs:MarinaTowersMember 2016-01-01 2016-03-31 0001416876 fchs:TheCraneCenterMember 2015-12-31 0001416876 us-gaap:MinimumMember 2015-01-01 2015-12-31 0001416876 us-gaap:MaximumMember 2015-01-01 2015-12-31 0001416876 fchs:CraneCreekSurgeryCenterMember 2016-03-31 0001416876 fchs:CraneCreekSurgeryCenterMember 2016-01-01 2016-03-31 0001416876 fchs:WarrantsToPurchaseCommonStockMember 2015-01-01 2015-03-31 0001416876 fchs:OptionsToPurchaseCommonStockMember 2015-01-01 2015-03-31 0001416876 fchs:WarrantsToPurchaseCommonStockMember 2016-01-01 2016-03-31 0001416876 fchs:OptionsToPurchaseCommonStockMember 2016-01-01 2016-03-31 0001416876 fchs:PatientListsMember 2016-01-01 2016-03-31 0001416876 us-gaap:PatentsMember 2016-01-01 2016-03-31 0001416876 fchs:PatientListsMember 2015-01-01 2015-03-31 0001416876 us-gaap:PatentsMember 2015-01-01 2015-03-31 0001416876 fchs:BrevardOrthopaedicSpinePainClinicIncMember 2016-01-01 2016-03-31 0001416876 fchs:DoctorsSurgicalPartnershipLtdMember 2016-03-31 0001416876 us-gaap:MaximumMember 2015-06-09 0001416876 us-gaap:MinimumMember 2015-06-09 0001416876 2015-06-01 2015-06-09 0001416876 us-gaap:MaximumMember 2015-12-14 0001416876 us-gaap:MinimumMember 2015-12-14 0001416876 2015-12-01 2015-12-14 0001416876 fchs:LineOfCreditFloridaBusinessBankMember 2015-01-01 2015-12-31 0001416876 fchs:LineOfCreditFloridaBusinessBankMember 2016-03-31 0001416876 2015-12-14 0001416876 fchs:MedTrxCollectionServicesMember fchs:TwoNonInterestBearingPromissoryNotesMember 2015-11-06 0001416876 fchs:EquipmentCapitalLeaseMember 2013-06-01 2013-06-11 0001416876 us-gaap:MortgagesMember 2011-08-01 2011-08-12 0001416876 us-gaap:MortgagesMember 2011-08-12 0001416876 fchs:XRayEquipmentMember 2012-08-01 2012-08-22 0001416876 fchs:MriEquipmentMember 2012-09-01 2012-09-27 0001416876 fchs:EquipmentCapitalLeaseMember 2013-06-11 0001416876 fchs:MriEquipmentMember 2013-03-08 0001416876 fchs:XRayEquipmentMember 2013-03-08 0001416876 fchs:CarmEquipmentMember 2013-02-25 0001416876 fchs:MriEquipmentMember 2012-09-27 0001416876 fchs:XRayEquipmentMember 2012-08-22 0001416876 fchs:GeHealthcareFinancialServicesMember 2012-05-21 0001416876 fchs:EquipmentCapitalLeaseMember 2011-10-25 0001416876 fchs:EquipmentCapitalLeaseMember 2011-10-01 2011-10-25 0001416876 fchs:VariableInterestEntityMember 2015-12-31 0001416876 fchs:CtCapitalLtdMember 2015-01-01 2015-12-31 0001416876 fchs:NonEmployeesMember fchs:WarrantOneMember us-gaap:MaximumMember 2016-01-01 2016-03-31 0001416876 fchs:FutureServicesMember us-gaap:CommonStockMember 2016-01-01 2016-03-31 0001416876 fchs:FutureServicesMember us-gaap:CommonStockMember 2016-03-31 0001416876 2016-05-12 0001416876 fchs:FirstAndSecondFloorOfMarinaTowersMember 2016-03-31 0001416876 fchs:MtmcMelbourneIncMember 2016-03-31 0001416876 fchs:LineOfCreditFloridaBusinessBankMember 2016-01-01 2016-03-31 0001416876 fchs:CraneCreekSurgeryCenterMember 2015-01-01 2015-12-31 0001416876 us-gaap:PatentsMember 2016-03-31 0001416876 fchs:VariableInterestEntityMember 2016-03-31 0001416876 us-gaap:CommonStockMember 2016-01-01 2016-03-31 0001416876 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-03-31 0001416876 fchs:CommonStockSubscriptionsMember 2016-01-01 2016-03-31 0001416876 fchs:CommonStockSubscriptionsMember 2016-03-31 0001416876 us-gaap:RetainedEarningsMember 2016-01-01 2016-03-31 0001416876 us-gaap:NoncontrollingInterestMember 2016-01-01 2016-03-31 0001416876 2014-12-31 0001416876 2015-03-31 0001416876 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2016-03-31 0001416876 fchs:CraneCreekSurgeryCenterMember 2015-12-31 0001416876 fchs:FcidMedicalMember 2016-01-01 2016-03-31 0001416876 fchs:BrevardOrthopaedicMember 2016-01-01 2016-03-31 0001416876 fchs:TheCraneCenterMember 2016-01-01 2016-03-31 0001416876 us-gaap:CorporateMember 2016-01-01 2016-03-31 0001416876 us-gaap:IntersegmentEliminationMember 2016-01-01 2016-03-31 0001416876 fchs:MarinaTowersMember 2015-01-01 2015-03-31 0001416876 fchs:FcidMedicalMember 2015-01-01 2015-03-31 0001416876 fchs:BrevardOrthopaedicMember 2015-01-01 2015-03-31 0001416876 fchs:TheCraneCenterMember 2015-01-01 2015-03-31 0001416876 us-gaap:CorporateMember 2015-01-01 2015-03-31 0001416876 us-gaap:IntersegmentEliminationMember 2015-01-01 2015-03-31 0001416876 fchs:BrevardOrthopaedicMember 2016-03-31 0001416876 fchs:TheCraneCenterMember 2016-03-31 0001416876 us-gaap:CorporateMember 2016-03-31 0001416876 fchs:MarinaTowersMember 2015-12-31 0001416876 fchs:FcidMedicalMember 2015-12-31 0001416876 2015-01-01 2015-12-31 0001416876 us-gaap:SubsequentEventMember fchs:MedtrxMember fchs:TwoPromissoryNotesMember 2016-04-02 0001416876 us-gaap:SubsequentEventMember fchs:BackCenterMember 2016-04-15 0001416876 fchs:MarinaTowersMember 2016-03-01 2016-03-31 0001416876 fchs:FifthFloorOfMarinaTowersMember 2016-03-31 0001416876 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2015-05-02 2015-12-31 0001416876 fchs:NonEmployeesMember fchs:WarrantOneMember us-gaap:MinimumMember 2016-01-01 2016-03-31 0001416876 us-gaap:LineOfCreditMember us-gaap:CommonStockMember 2016-01-01 2016-03-31 0001416876 us-gaap:SubsequentEventMember fchs:MedtrxMember fchs:TwoPromissoryNotesMember 2016-03-30 2016-04-02 0001416876 us-gaap:SubsequentEventMember fchs:BackCenterMember 2016-04-03 2016-04-15 0001416876 fchs:NonEmployeesMember us-gaap:WarrantMember 2015-12-31 0001416876 fchs:MedtrxMember fchs:TwoPromissoryNotesMember 2016-03-31 0001416876 fchs:CraneCreekSurgeryCenterMember 2015-10-02 2015-10-31 0001416876 fchs:CraneCreekSurgeryCenter1Member 2015-10-01 0001416876 2015-06-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:sqft

1594998

10051999

996986

503262

1556303

1624203

279087

112794

1120942

559318

6623894

7448429

3727419

891070

3915553

816889

9606905

18644133

5544162

1394332

6070652

1376207

8613502

2689335

60978

667280

57579

712830

22623988

25847165

8642412

4872351

5623370

3286460

5623371

3013011

2961077

25847165

6150565

2988502

6176738

2961076

3194588

6309955

4391192

3937244

4078887

1877690

324764

2319056

2321972

1997207

441368

118810

16840802

10421119

4034801

576352

4502590

692956

2141199

2200603

532754

2141199

2200603

532752

19585255

13095984

5762057

1109106

6289251

1225708

22868

22968

740788

705118

918990

972497

-138686

1111183

-138686

1057676

3038733

22868

21196792

-19274917

918990

12751181

22968

21288692

-9707976

972497

175000

22623988

25847165

5623371

2961077

6150565

2988502

30689

9566941

328741

9290659

89177

9566941

53507

462895

401056

26943

-614612

53046

528898

-551255

1280200

2236907

2892314

3226427

30689

9620448

9290659

462895

401056

80450

-614612

53046

528898

-551255

30689

9620448

9290659

462895

401056

80450

-614612

-363144

-181135

3447

-110156

-56818

-2459

-8726

-2976

-110496

-51784

-200864

20686

15325

14337

295757

988

14337

6349

750

58857

750

56725

1382

750

413769

569083

225434

519713

347778

87794

-611636

177129

587031

-350391

2091398

6672670

202812

1789222

3045219

1183514

611636

-159733

198192

1653033

350391

-110218

553284

2405877

1654107

23907

109275

361803

1581793

109275

329099

22642

291159

239483

451485

1187274

105954

531407

709646

-159733

103331

458372

-110218

946120

2780569

1457911

3000

293337

829220

1457911

293337

197101

3000

836987

106133

2505167

7241753

3449722

428246

1271308

2308935

3392997

1271308

-159733

375321

2240064

-110218

265103

626612

286500

428246

358099

-159733

375321

-110218

2240064

6615141

2308935

3034898

1271308

2240064

3075648

989481

773808

724859

0.01

1000000

0.001

0.78

100000000

22867626

22967626

22867626

22967626

48250

81300

11689150

3678816

1000000

3055168

4211749

340065

2822027

260141

348180

182246

2888249

215096 295757

140509

298950

69951

66792

5515

71256

85436

69219

66515

4775

22867626

22967626

100000

92000

100

91900

899465

251588

-53507

53507

-53507

7550000

2400000

0.12

0.0739

0.079375

3.60 1.35

3000000

1875000

4324630

2449630

4324630

2018-12-23

2020-11-08

2018-11-08

1.35

3.60

2.32

1.35

2.32

-0

1875000

4324630

2449630

3.60

2.32

1.35

0.00

129630

3000000

2449630

1875000

819757

1034157

18231

22334

1729882

2058624

450000

427229

251588

446759

251588

914039

1727256

1786661

75000

38200

75000

80000

42975

316773

225150

183465

151931

428645

437372

428645

437372

12953537

11690741

140000 140000

650000

8188763

914039

7153262

844098

97232

67455

26716

21112

61080

85457

746390

560000 560000

420000

0.08

2016-04-01

2016-04-15

2017-07-30

2017-06-01

2016-09-16

2016-04-02

2016-04-15

In connection with the investment, the Company is entitled 51% voting rights for all decisions that most significantly affect the economic performance of Crane Creek. The 40% equity interest acquired entitles the Company to 40% of the profit or loss of Crank Creek.

40% equity interest along with the 51% voting rights acquired

4195000

7324630

4195000

4324630

3000000

straight-line method

2498398

2917884

636666

0.95

78000

34480

31835

26838

2521

5000

4775

5000

4775

1.35

0.00

1.3409

0.0212

P8Y8M1D

P5Y

215096

80661

0.99

0.006660

0.01

0.40

2150000

1500000

2000000

2500000

1000000

500000

0.12

0.0610

0.60

0.06

0.14002

100000

2000000

1500000

2500000

2000000

1500000

2016-12-31

The advance rate is defined as: 80% of all receivables to be 120 days or less at the net collection rate of approximately 27% of total billings, excluding patient billings and collections. Additionally, allowable accounts receivable will also include 50% of all accounts receivable protected by legal letters of protection.

At any time up until December 31,2016, the Lender may convert all or any portion of the outstanding principal amount or interest on the Loan into common stock of the Company at a conversion price of $0.75 per share.

1000000

The advance rate is defined as: 60% of Medicare and Medicaid receivables less than 90 days old multiplied by a factor of 0.25, plus all other receivables less than 90 days old multiplied by a factor of 0.50.

interest rate of one month Libor floating plus 2.75%, as published in The Wall Street Journal, with a floor of 2.96% per annum (2.96% at December 31, 2014 and 2013, respectively).

interest rate of Prime floating plus 1.0%, as published in The Wall Street Journal, with a floor of 4.50% per annum (the Loan).

1383000

995000

P45D

P60D

P30Y

P60M

950000

1000000

416888

439524

956

45753

124797

1771390

212389

11779 1384 0 0 0 38152 4575 2388 38152 4300 P48M 1036

P60M

2566888

2939524

416888

439524

130734

208514

1000000

0.00 0.60

23908983

NOTE 1 BASIS OF PRESENTATION   A summary of the significant accounting policies applied in the presentation of the accompanying unaudited condensed consolidated financial statements follows:   General   The (a) condensed consolidated balance sheet as of December 31, 2015, which has been derived from the audited financial statements of First Choice Healthcare Solutions, Inc. (FCHS and including, where appropriate, its consolidated subsidiaries and entities in which we have a controlling financial interest, the Company), and (b) the unaudited condensed consolidated interim financial statements as of March 31, 2016 of the Company have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. To determine if we hold a controlling financial interest in an entity, we first evaluate if we are required to apply the variable interest entity (VIE) model to the entity, otherwise the entity is evaluated under the voting interest model.   Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2016 are not necessarily indicative of results that may be expected for the year ending December 31, 2015. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2016 included in the Companys Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the SEC) on April 14, 2016.   Basis of Presentation   Effective April 4, 2012, Medical Billing Assistance, Inc., a Colorado corporation (Medical Billing), merged with and into the Company. The effect of the merger was that Medical Billing reincorporated from Colorado to Delaware (the Reincorporation). The Company is deemed to be the successor issuer of Medical Billing under Rule 12g-3 of the Securities Exchange Act of 1934, as amended (the Exchange Act).   As a result of the Reincorporation, the Company changed its name to First Choice Healthcare Solutions, Inc. and its shares underwent an effective four-for-one reverse split. Other than the foregoing, the Reincorporation did not result in any change in the business, management, fiscal year, accounting, and location of the principal executive offices, assets or liabilities of the Company.   On April 2, 2012, the Company, through its wholly owned subsidiary FCID Medical, Inc., completed its acquisition of First Choice Medical Group of Brevard, LLC (First Choice Brevard), pursuant to the Membership Interest Purchase Closing Agreement (the Purchase Agreement). The Company has been managing the practice of First Choice Brevard since November 1, 2011, pursuant to a Management Services Agreement.   Brevard Orthopaedic Spine & Pain Clinic, Inc.   Effective May 1, 2015, the Company, through its recently formed wholly owned subsidiary, TBC Holdings of Melbourne, Inc., entered into an Operation and Control Agreement (the Agreement) with Brevard Orthopaedic Spine & Pain Clinic, Inc. (The B.A.C.K. Center), whereby the Company will have sole and exclusive management and control of The B.A.C.K. Center, including, but not limited to, administrative, financial, facility and business operations, including the requirement to absorb losses or right to receive economic benefits. The initial term of the Agreement expires on December 31, 2016 with an option by the Company to extend the term until December 31, 2023.   The Agreement allows the Company to hold the current or potential rights that give it the power to direct the activities of the VIE that most significantly impact the VIEs economic performance, combined with a variable interest that gives the Company the right to receive potentially significant benefits or the obligation to absorb potentially significant losses. The Company has a controlling financial interest in the VIE. Rights held by others to remove the party with power over the VIE are not considered unless one party can exercise those rights unilaterally. When changes occur to the structure of the entity, the Company will reconsider whether it is subject to the VIE model. The Company continuously evaluates whether it has a controlling financial interest in the VIE.   Crane Creek Surgery Center   Effective October 1, 2015, the Company, through its recently formed wholly owned subsidiary, CCSC Holdings, Inc., acquireda 40% interest in Crane Creek Surgery Center (Crane Creek) in exchange for an investment of $560,000 comprised of $140,000 cash and a promissory note for $420,000 which bears 8% interest per annum, matures April 15, 2016 and is personally guaranteed by the Companys Chief Executive Officer. In connection with the investment, the Company is entitled 51% voting rights for all decisions that most significantly affect the economic performance of Crane Creek. The 40% equity interest acquired entitles the Company to 40% of the profit or loss of Crank Creek. This note was paid in full on April 15, 2016.   The unaudited condensed consolidated financial statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries FCID Holdings, Inc., MTMC of Melbourne, Inc., Marina Towers, LLC, FCID Medical Inc., TBC Holdings of Melbourne, Inc., First Choice Brevard, Surgical Partners of Melbourne, Inc. and CCSC Holdings, Inc., along with two VIE, The B.A.C.K. Center and Crane Creek. All significant intercompany balances and transactions, including those involving the VIE, have been eliminated in consolidation.

NOTE 2 SIGNIFICANT ACCOUNTING POLICIES   Use of estimates   The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Companys stock, and stock-based compensation. Actual results may differ from these estimates.   Revenue recognition   The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (ASC 605-10), which requires that four basic criteria be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on managements judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.   ASC 605-10 incorporates Accounting Standards Codification subtopic 605-25, Multiple-Element Arrangements (ASC 605-25). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. The effect of implementing ASC 605-25 on the Companys financial position and results of operations was not significant.   The Company recognizes in accordance with Accounting Standards Codification subtopic 954-310, Health Care Entities (ASC 954-310), significant patient service revenue at the time the services are rendered, even though it does not assess the patients ability to pay. Therefore, The Companys interim and annual periods reports disclose both, its policy for assessing and disclosing the timing and amount of uncollectable patient service revenue recognized as doubtful. Qualitative and quantitative information about significant changes in the allowance for doubtful accounts related to patient accounts receivable are disclosed in the Companys reports. These estimates are based upon the past history and identified trends for each of our payers.   Patient service revenue   The Company recognizes patient service revenue associated with services provided to patients who have third-party payer coverage on the basis of contractual rates for the services provided. For uninsured or self-pay patients that do not qualify for charity care, the Company recognizes revenue on the basis of its standard rates for services provided (or on the basis of discounted rates, if negotiated or provided by policy). On the basis of historical experience, a portion of the Companys patient service revenue may be potentially uncollectible due to patients who are unable or unwilling to pay for the services provided or the portion of their bill for which they are responsible. Thus, the Company records a provision for bad debts related to potentially uncollectible patient service revenue in the period the services are provided.   Rental revenue   FCID Holdings had one real estate holding, Marina Towers, a Class A 78,000 square foot, six-story building located on the Indian River in Melbourne, Florida. The address is 709 South Harbor City Boulevard, Melbourne, Florida 32901. In addition to housing our corporate headquarters and First Choice Medical Group, the building, which averages 95% annual occupancy, also leases commercial office space to tenants. Our corporate headquarters currently utilize 2,521 square feet on the fifth floor of Marina Towers; and First Choice Medical Group, including its MRI center and Physical Therapy center, currently occupies 26,838 square feet on the ground, first and second floors. Until March 2016, Marina Towers was owned by Marina Towers, LLC, a subsidiary owned by FCID Holdings (99%) and MTMC of Melbourne, Inc. (1%), both wholly owned subsidiaries of the Company.   On March 31, 2016, we completed the sale of Marina Towers to Global Medical REIT Inc. for a purchase price of $15.45 million. In addition, our wholly owned subsidiary, Marina Towers, LLC, leased back the entire facility via a 10-year absolute triple-net master lease agreement that will expire in 2026 and be renewable for two five-year periods on the same terms and conditions as the primary lease term with the exception of rent, which will be adjusted to the prevailing market rent at renewal and will escalate in successive years during the extended lease period.   Until Marina Towers sale on March 31, 2016, the Company recognized rental revenue associated with the period of time the facility is leased at the contractual lease rates (or on the basis of discounted rates, if negotiated).   In addition, beginning May 1, 2015, TBC Holdings of Melbourne, Inc., through The B.A.C.K. Center, subleases approximately 34,480 square feet of commercial office space to third party tenants.   Cash   Cash consists of cash held in bank demand deposits. The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. As of March 31, 2016, the Company had $10,051,999 cash, of which $1,624,203 held by VIE. As of December 31, 2015, the Company had $1,594,998 cash, of which $1,556,303 held by VIE.   Concentrations of credit risk   The Companys financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Occasionally, the Companys cash and cash equivalents in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.   Accounts receivable   Accounts receivables are carried at their estimated collectible amounts net of doubtful accounts. The Company analyzes its past history and identifies trends for each major payer sources of revenue to estimate the appropriate allowance for doubtful accounts and provision for bad debts. Management regularly reviews data about these major payer sources of revenue in evaluating the sufficiency of the allowance for doubtful accounts.   <table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="width: 24px; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 24px; font: 8pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">Rental receivables. Accounts receivables from rental activities are periodically evaluated for collectability in determining the appropriate allowance for doubtful account provision for bad debts and provision of bad debts.</td></tr> <tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">Patient receivables. Accounts receivables from services provided to patients who have third-party coverage, the Company analyzes contractually due amounts and provides a provision for bad debts, if necessary. The Company records a provision for bad debts in the period of service on the basis of past experience or when indications are the patients are unable or unwilling to pay the portion of their bill for which they are responsible. The difference between the standard rates (or the discounted rates if negotiated) and the amounts actually collected after all reasonable collection efforts have been exhausted, is charged off against the allowance for doubtful accounts.</td></tr> </table>   As of March 31, 2016 and December 31, 2015, the Companys provision for bad debts was $2,917,884 and $2,498,398, respectively.   Segment information   Accounting Standards Codification subtopic Segment Reporting 280-10 (ASC 280-10) establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders. ASC 280-10 also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein represents all of the material financial information related to the Companys principal operating segments (see Note 17 Segment Information).   Patents   Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are not amortized, but are tested for impairment annually. The Companys intangible assets with finite lives are patent costs, which are amortized over their economic or legal life, whichever is shorter. These patent costs were acquired on September 7, 2013 by the issuance of 636,666 shares of the Companys common stock to a related party. The shares of common stock were valued at $286,500, which was estimated to be approximately the fair value of the patent acquired and did not materially differ from the fair value of the common stock. The amortization for the three months ended March 31, 2016 and 2015 was $4,775 and $4,775, respectively. Accumulated amortization of patent costs was $42,975 and $38,200 at March 31, 2016 and December 31, 2015, respectively.   Patient list   Patient list is comprised of acquired patients in connection with the acquisition of First Choice - Brevard and is amortized ratably over the estimated useful life of 15 years. The amortization expenses for the three months ended March 31, 2016 and 2015 was $5,000 and $5,000, respectively. Accumulated amortization of patient list costs was $80,000 and $75,000 at March 31, 2016 and December 31, 2015, respectively.   Net income per share   The Company computes basic net income per share by dividing net income per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the treasury stock and/or if converted methods as applicable. The computation of basic and diluted income per share for the three months ended March 31, 2016 and 2015 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.   Potentially dilutive securities excluded from the computation of basic and diluted net income per share are as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-align: center; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" nowrap="nowrap" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> March 31, 2016</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" nowrap="nowrap" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> March 31, 2015</td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="width: 62%; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Warrants to purchase common stock</td> <td style="width: 7%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 12%; text-align: right; font: 8pt Times New Roman, Times, Serif">4,324,630</td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="width: 3%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 12%; text-align: right; font: 8pt Times New Roman, Times, Serif">4,195,000</td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Options to purchase common stock</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">3,000,000</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"></td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 20pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Totals</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">7,324,630</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">4,195,000</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>   Stock-based compensation   The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the consolidated statements of operations, as if such amounts were paid in cash.   Deferred costs   On May 1, 2015, in connection with the Operation and Control Agreement with Brevard Orthopaedic Spine & Pain Clinic, Inc. (The B.A.C.K. Center), the Company reserved 3,000,000 options to purchase the Companys common stock at $1.35 per share, expiring on December 31, 2023 and vesting contingent on The B.A.C.K. Center employees executing employment agreements with TBC Holding and the acquisition of the variable interest entity. The determined fair value of $3,226,427, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 134.09% and Risk free rate: 2.12%, is amortized ratably to operations over an estimated 8.67-year life. The amortization for the three months ended March 31, 2016 was $80,661. Accumulated amortization of the deferred costs was $295,757 at March 31, 2016.   Investments   The Company has adopted Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures (ASC 323-10), which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company owned a 0.6660% interest in a non-consolidated affiliate, Doctors Surgical Partnership, LTD. In accordance with the equity method of accounting, investments in non-consolidated affiliates are carried at cost and adjusted for the Companys proportionate share of their undistributed earnings or losses.   Income Taxes   The Company accounts for income taxes pursuant to Accounting Standards Codified 740 (ASC 740). Under ASC 740 deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.   Fair value   Accounting Standards Codification subtopic 825-10, Financial Instruments (ASC 825-10) requires disclosure of the fair value of certain financial instruments. ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="width: 24px; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 24px; text-align: justify; font: 8pt Times New Roman, Times, Serif">●</td> <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif">Level 1 - Quoted prices in active markets for identical assets or liabilities.</td></tr> <tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif">●</td> <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif">Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr> <tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif">●</td> <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif">Level 3 - Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.</td></tr> </table>   To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.   The carrying value of the Companys cash, accounts receivable, accounts payable, short-term borrowings (including lines of credit and notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity.   As of March 31, 2016 and December 31, 2015, the Company did not have any items that would be classified as level 1, 2 or 3 disclosures.   Recent accounting pronouncements   There are other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Companys financial position, results of operations or cash flows.   Subsequent events    The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed.

NOTE 3 LIQUIDITY   The Company incurred various non-recurring expenses in 2015 in connection with the planned development of its Healthcare Services Business. Management believes the continuing trend of positive growth before interest, taxes, depreciation and amortization in 2016 will support improved liquidity. In 2015, the Company converted to equity a total of $2,892,314 in outstanding debt, advances and accrued interest. Currently, the Company has four main sources of liquidity, its line of credit with CT Capital, LP; patient service revenue received from FCID Medical, Inc., TBC Holdings of Melbourne, Inc. and CCSC Holdings, Inc.; and rental revenue received from its real estate interests, FCID Holdings, Inc. and TBC Holdings of Melbourne, Inc.   On June 13, 2013, the Companys subsidiary, First Choice Brevard entered into a loan and security agreement with CT Capital, Ltd., d/b/a CT Capital, LP, a Florida limited liability partnership for an accounts receivable line of credit in the maximum aggregate amount of $1,500,000. Under the line of credit with CT Capital, the Company reduced the annual interest rate from 12% per annum to 6% per annum in exchange for the issuance to CT Capital of 100,000 restricted shares of the Companys common stock. On June 9, 2015, First Choice Brevard entered into a modification agreement amending the loan and security agreement, increasing the maximum aggregate amount available from $1,500,000 to $2,000,000 and on December 14, 2015, increasing the maximum aggregate available from $2,000,000 to $2,500,000 and extending the maturity date to July 30, 2017 in exchange for 100,000 restricted shares of the Companys common stock. The $500,000 increase may be repaid at any time, and is not subject to the conversion provision set forth in the loan agreement. All other terms and conditions of the loan agreement remain in full force and effect. As of March 31, 2016, the Company had used $2,500,000 of the amount available under the line of credit. (See Note 6 Lines of Credit)   FCID Holdings had one real estate holding, Marina Towers, a Class A 78,000 square foot, six-story building located on the Indian River in Melbourne, Florida. The address is 709 South Harbor City Boulevard, Melbourne, Florida 32901. In addition to housing our corporate headquarters and First Choice Medical Group, the building, which averages 95% annual occupancy, also leases commercial office space to tenants. Our corporate headquarters currently utilizes 2,521 square feet on the fifth floor of Marina Towers; and First Choice Medical Group, including its MRI center and Physical Therapy center, currently occupies 26,838 square feet on the ground, first and second floors. Until March 2016, Marina Towers was owned by Marina Towers, LLC, a subsidiary owned by FCID Holdings (99%) and MTMC of Melbourne, Inc. (1%), both wholly owned subsidiaries of the Company.   On March 31, 2016, we completed the sale of Marina Towers to Global Medical REIT Inc. for a purchase price of $15.45 million. In addition, our wholly owned subsidiary, Marina Towers, LLC, leased back the entire facility via a 10-year absolute triple-net master lease agreement that will expire in 2026 and be renewable for two five-year periods on the same terms and conditions as the primary lease term with the exception of rent, which will be adjusted to the prevailing market rent at renewal and will escalate in successive years during the extended lease period. Until Marina Towers sale on March 31, 2016, the Company recognized rental revenue associated with the period of time the facility is leased at the contractual lease rates (or on the basis of discounted rates, if negotiated).   In addition, beginning May 1, 2015, TBC Holdings of Melbourne, Inc., through The B.A.C.K. Center, subleases 31,835 square feet of commercial office space to third party tenants as of March 31, 2016.   The Company believes that the current positive cash balance, along with continued execution of its business development plan and the sale and leaseback of Marina Towers, will allow the Company to further improve its working capital and currently anticipates that it will have sufficient capital resources to meet projected cash flow requirements through the date that is one year and one day from the filing of this report.   However, in order to execute the Companys business development plan, which there can be no assurance it will do, the Company may need to raise additional funds through public or private equity offerings, debt financings, corporate collaborations or other means and potentially reduce operating expenditures. If the Company is unable to secure additional capital, it may be required to curtail its business development initiatives and take additional measures to reduce costs in order to conserve its cash.

NOTE 4 PROPERTY, PLANT, AND EQUIPMENT   Property, plant and equipment at March 31, 2016 and December 31, 2015 are as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-align: center; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" nowrap="nowrap" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> March 31, 2016</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" nowrap="nowrap" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> December 31, 2015</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="width: 63%; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Land</td> <td style="width: 7%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 12%; text-align: right; font: 8pt Times New Roman, Times, Serif">-</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 2%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 12%; text-align: right; font: 8pt Times New Roman, Times, Serif">1,000,000</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Building</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">-</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">3,055,168</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Building improvements</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">182,246</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">4,211,749</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Computer equipment</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">348,180</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">340,065</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Medical equipment</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">2,888,249</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">2,822,027</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Office equipment</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">260,141</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">260,141</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">3,678,816</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">11,689,150</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Less: accumulated depreciation</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">(989,481</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif">)</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">(3,075,648</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">2,689,335</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">8,613,502</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>   During the three months ended March 31, 2016 and 2015, depreciation expense charged to operations was $208,514 and $130,734, respectively.   Sale/Leaseback   On March 31, 2016, the Company sold Marina Towers, a 78,000 square-foot medical office building for a purchase price of $15.45 million to Global Medical REIT Inc. The acquisition includes the site and building, an easement on the adjacent property to the north for surface parking, all tenant leases, and above and below ground garages (the Property).   The entire facility was leased back to Marina Towers, LLC, a wholly owned subsidiary of the Company, via a 10-year absolute triple-net master lease agreement that expires in 2026. The Company has two successive options to renew the lease for five-year periods on the same terms and conditions as the primary non-revocable lease term with the exception of rent, which will be adjusted to the prevailing fair market rent at renewal and will escalate in successive years during the extended lease period. The Company does not have any residual interest nor the option to repurchase the facility at the end of the lease term.   The lease is classified as an operating lease and as such recorded a gain on sale of property of $9,188,968 during the three months ended March 31, 2016.   The following is a schedule of future minimum lease payments for the non-cancelable operating lease for each of the next five years ending December 31 and thereafter:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="font: 8pt Times New Roman, Times, Serif">Nine months ended December 31, 2016</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">828,506</td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2017</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,104,675</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2018</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,104,675</td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2019</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,121,246</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2020</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,143,670</td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2021 and thereafter</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">6,387,969</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="width: 77%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 3%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 3%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; width: 15%; font: 8pt Times New Roman, Times, Serif">11,690,741</td></tr> </table>   For the three months ended March 31, 2016, the Company collected $268,513 in net rental revenue from third party tenants of Marina Towers.

NOTE 5 ADVANCES    At March 31, 2016 and December 31, 2015, the Company received an aggregate of $133,796 and $43,082, respectively, as cash advances from non-related parties. The advances are due upon demand with an interest rate of 12% per annum.

NOTE 6 LINES OF CREDIT    Line of credit, CT Capital    On June 13, 2013, the Companys subsidiary, First Choice Brevard entered into a loan and security agreement (the Loan Agreement) with CT Capital, Ltd., d/b/a CT Capital, LP, a Florida limited liability partnership (the Lender). Under the Loan Agreement, the Lender committed to make an accounts receivable line of credit in the maximum aggregate amount of $1,500,000 to First Choice - Brevard with an interest rate of 12% per annum (the Loan). The maturity date of the Loan is December 31, 2016. Interest is due and payable monthly. Upon default, the interest may be adjusted to the highest rate permissible by law. The Loan is secured by the accounts receivable and assets of the Companys subsidiary, First Choice Brevard, which constitute the collateral for the repayment of the Loan. The Loan Agreement also includes covenants, representations, warranties, indemnities and events of default that are customary for facilities of this type. The advance rate is defined as: 80% of all receivables to be 120 days or less at the net collection rate of approximately 27% of total billings, excluding patient billings and collections. Additionally, allowable accounts receivable will also include 50% of all accounts receivable protected by legal letters of protection. At any time up until December 31, 2016, the Lender may convert all or any portion of the outstanding principal amount or interest on the Loan into common stock of the Company at a conversion price of $0.75 per share. The Company did not record an embedded beneficial conversion feature in the note since the fair value of the common stock did not exceed the conversion rate at the date of commitment.   On November 8, 2013, in consideration for the issuance of 100,000 restricted shares of the Companys common stock, the Lender agreed to modify its Loan. Under the Loan Agreement, as amended, the annual rate of interest of the Loan was reduced from 12% per annum to 6% per annum and will remain at 6% until November 1, 2015. All other terms under the Loan Agreement remain the same.    On June 9, 2015, First Choice Brevard and the Lender entered into a Modification Agreement (Modification) further amending the Loan Agreement dated June 13, 2013, thereby increasing the Companys accounts receivable line of credit from $1,500,000 to $2,000,000. All of the other terms and conditions of the Loan Agreement, as amended, remain in full force and effect.    On December 14, 2015, First Choice-Brevard entered into a Modification Agreement (Modification) amending the Loan and Security Agreement dated June 13, 2013. The Modification Agreement increased the Companys accounts receivable line of credit from $2,000,000 to $2,500,000 and extended the maturity date of the Loan Agreement to June 30, 2017 (Maturity Date). In addition, the Company agreed to maintain an outstanding balance of not less than $1,000,000 until the Maturity Date (Minimum Borrowing) and provide sixty (60) days prior written notice to prepay up to $1,000,000 of the outstanding indebtedness in excess of the Minimum Borrowing. All of the other terms and conditions of the Loan Agreement remain in full force and effect.   In consideration of the $500,000 increase in the accounts receivable line of credit, the Company issued the Lender 100,000 shares of its common stock, valued at $92,000. The $500,000 increase may be repaid by the Company at any time, and is not subject to the conversion provisions set forth in the Loan Agreement. The shares were accrued for as of December 31, 2015 and issued in the current quarter.   The obligations of the Company under the Loan Agreement, as amended, are guaranteed by certain affiliates of the Company, including a personal guarantee issued by the Companys Chief Executive Officer.   As of March 31, 2016 and December 31, 2015, the outstanding balance was $2,500,000 and $2,150,000, respectively.   Line of credit, Florida Business Bank    On June 27, 2012, The B.A.C.K. Center entered into a Promissory Note (the Loan Agreement) with Florida Business Bank, a Florida banking corporation (the Lender). Under the Loan Agreement, the Lender committed to make an accounts receivable line of credit in the maximum aggregate amount of $1,000,000, with an interest rate of Prime floating plus 1.0%, as published in The Wall Street Journal, with a floor of 4.50% per annum (the Loan).    The Loan was modified on April 9, 2013, allowing a temporary increase to $1,383,000 and allowing for a one-time draw of up to $995,000 to be distributed to the shareholders for the purposes of financing the capitalization of TBC Equipment Leasing, LLC. The one-time draw was repaid within 45 days and the availability under the Loan returned to $1,000,000. The modification allows for an interest rate of one month Libor floating plus 2.75%, as published in The Wall Street Journal, with a floor of 2.96% per annum.    Interest shall be due and payable monthly and principal is due on demand. The outstanding principal balance plus all accrued but unpaid interest shall be due on demand (the Maturity Date). Upon default, the interest may be adjusted to the highest rate permissible by law.    The Loan is secured by all assets of The B.A.C.K. Center now owned or hereafter acquired. The assets constitute the collateral for the repayment of the Loan.   The Loan Agreement also includes covenants, representations, warranties, indemnities and events of default that are customary for facilities of this type. The advance rate is defined as: 60% of eligible accounts receivables. Eligible receivables include all Medicare and Medicaid receivables less than 90 days old multiplied by a factor of 0.25, plus all other receivables less than 90 days old multiplied by a factor of 0.50. As of March 31, 2016, The B.A.C.K. Center had not violated the loan covenants.   The obligations of The B.A.C.K Center under the Loan Agreement are guaranteed by the shareholders of The B.A.C.K. Center. The Loan Agreement is also guaranteed in the amount of $950,000 by related parties of The B.A.C.K. Center. As of March 31, 2016 and December 31, 2015, the outstanding balance on the Loan was $439,524 and $416,888, respectively.

NOTE 7 SETTLEMENT PAYABLE   On November 2, 2015, the Company and MedTRX Collection Services, Inc. signed a settlement and mutual release agreement, whereby the parties have agreed to settle all disputes and the pending arbitration actions and release each other from all claims, counterclaims, liabilities and obligations, except for obligations stipulated in the settlement or as otherwise reserved.   In connection with the settlement, on November 6, 2015, the Company issued two non-interest bearing promissory notes in aggregate of $650,000, due the earlier of a) April 2, 2016, b) the date real estate (as identified) is sold, financed or transferred or c) date the stock payment (as described above) is redeemed. As of March 31, 2016 and December 31, 2015, the balance due on outstanding settlement promissory notes was $450,000 and $600,000, respectively. However, the company paid the notes in full on April 1, 2016.

NOTE 8 NOTE PAYABLE, RELATED PARTY   Effective October 1, 2016, the Company acquired a 40% interest in Crane Creek Surgery Center (Crane Creek) in exchange for an investment of $560,000 comprised of $140,000 cash and a promissory note for $420,000 which bears 8% interest per annum, matures April 15, 2016 and is personally guaranteed by the Companys Chief Executive Officer. The promissory note was issued to certain equity owners of The B.A.C.K. Center, an entity consolidated with the Company under VIE accounting. The outstanding principal and interest at March 31, 2015 and December 31, 2015 was $437,372 and $428,645, respectively. This note was paid in full on April 15, 2016.

NOTE 9 NOTES PAYABLE   Notes payable as of March 31, 2016 and December 31, 2015 are comprised of the following:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="text-align: center; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" nowrap="nowrap" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> March 31, 2016</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" nowrap="nowrap" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> December 31, 2015</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="width: 60%; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Mortgage Payable</td> <td style="width: 8%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 12%; text-align: right; font: 8pt Times New Roman, Times, Serif">-</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 2%; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 14%; text-align: right; font: 8pt Times New Roman, Times, Serif">7,153,262</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Note Payable, GE Capital (MRI)</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">746,390</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">844,098</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Note Payable, GE Capital (X-ray)</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">85,457</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">97,232</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Note Payable, GE Arm</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">61,080</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">67,455</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Capital Lease Equipment</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">21,112</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">26,716</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">914,039</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">8,188,763</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Less current portion</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">(507,209</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif">)</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">(7,652,941</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif">)</td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">406,830</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">535,822</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>   Mortgage payable   On August 12, 2011, the Company refinanced its existing mortgage note payable providing additional working capital funds. The aggregate amount of the note of $7,550,000 with 6.10% interest per annum with monthly payments of $45,753 beginning in October 2011 based on a 30-year amortization schedule with all remaining principal and interest due in full on September 16, 2016. The note is secured by land and the building along with first priority assignment of leases and rents. In connection with the sale/leaseback transaction (See Note 4), the Company paid off the outstanding balance as of March 31, 2016.   Note payable equipment financing   On May 21, 2012, the Company entered into a note payable with GE Healthcare Financial Services (GE Capital) in the amount of approximately $2.4 million for equipment financing.   On September 27, 2012, the Company accepted the delivery of MRI equipment under the equipment finance lease. As such, the component price accepted of $1,771,390 is due over 60 months and the associated monthly payment is $0 for the first three months and $38,152 per month for the remaining 57 months including interest at 7.9375% per annum. On March 8, 2013, the Company amended the equipment finance lease to interest only payments of $11,779 for the first three months and $38,152 per month for the remaining monthly payments.   On August 22, 2012, the Company accepted the delivery of X-ray equipment under the equipment finance lease. As such, the component price accepted of $212,389 is due over 60 months and the associated monthly payment is $0 for the first three months and $4,300 per month for the remaining 57 months including interest at 7.9375% per annum. On March 8, 2013, the Company amended the equipment finance lease to interest only payments of $1,384 for the first three months and $4,575 per month for the remaining monthly payments.   On February 25, 2013, the Company accepted the delivery of C-arm equipment under the equipment finance lease. As such, the component price accepted of $124,797 is due over 63 months and the associated monthly payment is $0 for the first three months and $2,388 for the remaining 60 months, including interest at 7.39% per annum.   Capital leases equipment   On June 11, 2013, the Company entered into a lease agreement to acquire equipment with 48 monthly payments of $956 payable through June 1, 2017 with an effective interest rate of 14.002% per annum. The Company may elect to acquire the leased equipment at a nominal amount at the end of the lease.   On October 25, 2011, The B.A.C.K. Center entered into a lease agreement to acquire equipment with 60 monthly payments of $1,036 payable through October 26, 2016, with no stated interest rate. The B.A.C.K. Center may elect to acquire the leased equipment at a nominal amount at the end of the lease.   Aggregate principal maturities of long-term debt as of March 31, 2016:    <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Amount</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="width: 75%; font: 8pt Times New Roman, Times, Serif">Nine months ended December 31, 2016</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 3%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 19%; text-align: right; font: 8pt Times New Roman, Times, Serif">378,217</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2017</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">519,226</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2018</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">16,596</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif">Total</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">914,039</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>

NOTE 10 RELATED PARTY TRANSACTIONS    Effective October 1, 2015, the Company acquired a 40% interest in Crane Creek Surgery Center (Crane Creek) in exchange for an investment of $560,000 comprised of $140,000 cash and a promissory note for $420,000 which bears 8% interest per annum, matures April 15, 2016 and is personally guaranteed by the Companys Chief Executive Officer. The promissory note was issued to certain equity owners of The B.A.C.K. Center, an entity consolidated with the Company under VIE accounting. This note was paid in full on April 15, 2016.   As of March 31, 2016, the Company received an aggregate of $133,796 as cash advances from related parties. The advances are due upon demand with an interest rate of 12% per annum. On April 6, 2016, the Company paid the advances in full. (See Note 20 Subsequent Events.)

NOTE 11 CAPITAL STOCK   During the three months ended March 31, 2016, the Company issued an aggregate of 100,000 shares of its common stock in connection with an increase in credit line, valued at $92,000. (see Note 6 Lines of Credit.)   Stock-based payable   The Company was obligated to issue its common stock to officers and consultants for past and future services as of March 31, 2016. The estimated liability as of March 31, 2016 of $1,280,200 ($0.78 per share) was determined based on services rendered. The shares were issued in reliance upon the exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the Securities Act).

NOTE 12 STOCK OPTIONS AND WARRANTS    Warrants    The following table summarizes the warrants outstanding and the related exercise prices for the underlying shares of the Companys common stock as of March 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td colspan="7" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Warrants Outstanding</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: center; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="text-align: center; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="7" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Warrants Exercisable</td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Price</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Outstanding</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Expiration Date</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Weighted Price</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Exercisable</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Weighted Price</td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td colspan="3" style="text-align: center; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="text-align: center; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: center; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="text-align: center; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="text-align: center; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="text-align: center; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 10%; text-align: right; font: 8pt Times New Roman, Times, Serif">1.35</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 10%; text-align: right; font: 8pt Times New Roman, Times, Serif">2,449,630</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 35%; font: 8pt Times New Roman, Times, Serif">November 2018 ~ November 2020</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 10%; text-align: right; font: 8pt Times New Roman, Times, Serif">1.35</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 10%; text-align: right; font: 8pt Times New Roman, Times, Serif">2,449,630</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 10%; text-align: right; font: 8pt Times New Roman, Times, Serif">1.35</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">3.60</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">1,875,000</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">December 23, 2018</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">3.60</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">1,875,000</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">3.60</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">4,324,630</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">2.32</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">4,324,630</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">2.32</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>   The warrant to purchase up to 2,449,630 shares of the Companys common stock may be exercised on a cashless basis. The warrant to purchase up to 1,875,000 shares of the Companys common stock may not be exercised on a cashless basis.   Transactions involving stock warrants issued are summarized as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="text-align: center; font: 8pt Times New Roman, Times, Serif">Number of Shares</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="text-align: center; font: 8pt Times New Roman, Times, Serif">Weighted Average Price Per Share</td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif; width: 59%">Outstanding at December 31, 2015:</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; width: 15%">4,324,630</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; width: 15%">2.32</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Granted</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"></td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"></td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Exercised</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"></td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"></td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Expired</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"></td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"></td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Outstanding at March 31, 2016</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">4,324,630</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">2.32</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>   Options    The following table presents information related to stock options at March 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td colspan="10" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Options Outstanding</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="text-align: center; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Number of Options</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining Life in Years</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Exercisable Number of Options</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif; width: 2%">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; width: 15%">1.35</td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; width: 15%">3,000,000</td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; width: 22%">7.75</td> <td style="font: 8pt Times New Roman, Times, Serif; width: 4%"> </td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 8pt Times New Roman, Times, Serif; width: 7%"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; width: 22%"></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 7%"> </td></tr> </table>   Transactions involving stock options issued are summarized as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Number of Shares</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Weighted Average Price Per Share</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; width: 59%; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Outstanding at December 31, 2015:</td> <td style="padding-left: 7.5pt; width: 1%; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 3%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 15%; text-align: right; font: 8pt Times New Roman, Times, Serif">3,000,000</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 3%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 15%; text-align: right; font: 8pt Times New Roman, Times, Serif">1.35</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Granted</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"></td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"></td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Exercised</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"></td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"></td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Expired</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"></td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"></td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Outstanding at March 31, 2016</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">3,000,000</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1.35</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>

NOTE 15 VARIABLE INTEREST ENTITY   Brevard Orthopaedic Spine & Pain Clinic, Inc.   Effective May 1, 2015, the Company, through its recently formed wholly owned subsidiary, TBC Holdings of Melbourne, Inc., entered into an Operation and Control Agreement (the Agreement) with Brevard Orthopaedic Spine & Pain Clinic, Inc. (The B.A.C.K. Center), whereby the Company will have sole and exclusive management and control of The B.A.C.K. Center, including, but not limited to, administrative, financial, facility and business operations including the requirement to absorb losses or right to receive economic benefits The initial term of the Agreement expires on December 31, 2016, with an option by the Company to extend the term until December 31, 2023. The Company issued 3,000,000 options to purchase the Companys common stock, vesting contingent on The B.A.C.K. Center employees signing employment contracts with First Choice Brevard.   The Company has determined that The B.A.C.K. Center is a Variable Interest Entity (VIE) in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 810, Consolidation. In evaluating whether the Company has the power to direct the activities of a VIE that most significantly impact its economic performance, the Company considers the purpose for which the VIE was created, the importance of each of the activities in which it is engaged and the Companys decision-making role, if any, in those activities that significantly determine the entitys economic performance as compared to other economic interest holders.   This evaluation requires consideration of all facts and circumstances relevant to decision-making that affects the entitys future performance and the exercise of professional judgment in deciding which decision-making rights are most important.   In determining whether the Company has the right to receive benefits or the obligation to absorb losses that could potentially be significant to the VIE, the Company evaluates all of its economic interests in the entity, regardless of form (debt, equity, management and servicing fees, and other contractual arrangements). This evaluation considers all relevant factors of the entitys structure, including: the entitys capital structure, contractual rights to earnings (losses), subordination of our interests relative to those of other investors, contingent payments, as well as other contractual arrangements that have potential to be economically significant. The evaluation of each of these factors in reaching a conclusion about the potential significance of the Companys economic interests is a matter that requires the exercise of professional judgment. The assets of The B.A.C.K. Center can only be used to settle obligations of the VIE, additionally, creditors of The B.A.C.K. Center do not have recourse against the general credit of the primary beneficiary.    The table below summarizes the assets and liabilities associated with The B.A.C.K. Center as of March 31, 2016 and as of December 31, 2015:    <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="text-align: center; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">March 31,  2016</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">December 31,  2015</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; width: 61%; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Current assets:</td> <td style="width: 8%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 12%; text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 3%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 12%; text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Cash</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,120,942</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">996,986</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Accounts receivable</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">3,915,553</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">3,727,419</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Other current assets</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">1,034,157</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">819,757</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 20pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Total current assets</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">6,070,652</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">5,544,162</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Property and equipment, net</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">57,579</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">60,978</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Other assets</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">22,334</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">18,231</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; padding-left: 20pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Total assets</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">6,150,565</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">5,623,371</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Current liabilities:</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Accounts payable and accrued liabilities</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,997,207</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,877,690</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Due to First Choice Healthcare Solutions, Inc.</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">2,058,624</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,729,882</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Other current liabilities</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">446,759</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">427,229</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 20pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Total current liabilities</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">4,502,590</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">4,034,801</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Long term debt</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">1,786,661</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">1,727,256</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 20pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Total liabilities</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">6,289,251</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">5,762,057</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Non-controlling interest</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">(138,686</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif">)</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">(138,686</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif">)</td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; padding-left: 20pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Total liabilities and deficit</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">6,150,565</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">5,623,371</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>   Total revenues from The B.A.C.K. Center were $3,449,722 for the three months ended March 31, 2016. Related expenses consisted primarily of salaries and benefits of $1,457,911, general and administrative expenses of $1,654,107, depreciation of $5,515 and interest and financing costs of $3,447. (See Note 17 Segment Reporting)   Crane Creek Surgery Center    Effective October 1, 2015, the Company, through its recently formed wholly owned subsidiary, CCSC Holdings, Inc., acquired a 40% interest in Crane Creek Surgery Center (Crane Creek) in exchange for an investment of $560,000 comprised of $140,000 cash and a promissory note for $420,000 which bears 8% interest per annum, matures April 15, 2016 and is personally guaranteed by the Companys Chief Executive Officer. In connection with the investment, the Company is entitled 51% voting rights for all decisions that most significantly affect the economic performance of Crane Creek. The 40% equity interest acquired entitles the Company to 40% of the profit or loss of Crank Creek.   The Company has determined that Crane Creek is a Variable Interest Entity (VIE) in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 810, Consolidation. In evaluating whether the Company has the power to direct the activities of a VIE that most significantly impact its economic performance, the Company considers the purpose for which the VIE was created, the importance of each of the activities in which it is engaged and the Companys decision-making role, if any, in those activities that significantly determine the entitys economic performance as compared to other economic interest holders.    This evaluation requires consideration of all facts and circumstances relevant to decision-making that affects the entitys future performance and the exercise of professional judgment in deciding which decision-making rights are most important.    In determining whether the Company has the right to receive benefits or the obligation to absorb losses that could potentially be significant to the VIE, the Company evaluates all of its economic interests in the entity, regardless of form (debt, equity, management and servicing fees, and other contractual arrangements). This evaluation considers all relevant factors of the entitys structure, including: the entitys capital structure, contractual rights to earnings (losses), subordination of our interests relative to those of other investors, contingent payments, as well as other contractual arrangements that have potential to be economically significant. The evaluation of each of these factors in reaching a conclusion about the potential significance of the Companys economic interests is a matter that requires the exercise of professional judgment.    The assets of Crane Creek can only be used to settle obligations of the VIE, additionally, creditors of the Crane Creek do not have recourse against the general credit of the primary beneficiary.   The table below summarizes the assets and liabilities associated with the Crane Creek as of March 31, 2016 and December 31, 2015:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="text-align: center; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">March 31,   2016</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">December 31,  2015</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; width: 63%; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Current assets:</td> <td style="width: 7%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 12%; text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 2%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 12%; text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Cash</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">503,262</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">559,318</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Accounts receivable</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">891,070</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">816,889</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 20pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Total current assets</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,394,332</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,376,207</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Property and equipment, net</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">667,280</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">712,830</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Goodwill</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">899,465</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">899,465</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; padding-left: 20pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Total assets</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">2,961,077</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">2,988,502</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Current liabilities:</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Accounts payable and accrued liabilities</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">324,764</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">441,368</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Other current liabilities</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">251,588</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">251,588</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 20pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Total current liabilities</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">576,352</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">692,956</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Deferred rent</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">532,754</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">532,752</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 20pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Total liabilities</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,109,106</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,225,708</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Equity-First Choice Healthcare Solutions, Inc</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">740,788</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">705,118</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Non-controlling interest</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">1,111,183</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">1,057,676</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; padding-left: 20pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Total liabilities and deficit</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">2,961,077</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">2,988,502</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>   Total revenues from the Crane Creek were $1,271,308 for the three months ended March 31, 2016. Related expenses consisted primarily of salaries and benefits of $293,337, practice supplies and operating of $709,646, general and administrative expenses of $109,275, depreciation of $71,256 and miscellaneous income of $1,382. (See Note 17 Segment Reporting)

NOTE 16 NON-CONTROLLING INTEREST   Effective May 1, 2015, the Company, through its recently formed wholly owned subsidiary, TBC Holdings of Melbourne, Inc. entered into an Operation and Control Agreement (the Agreement) with Brevard Orthopaedic Spine & Pain Clinic, Inc. (The B.A.C.K. Center), whereby the Company will have sole and exclusive management and control of The B.A.C.K. Center, including, but not limited to, administrative, financial, facility and business operations, including the requirement to absorb losses or right to receive economic benefits. The initial term of the Agreement expires on December 31, 2016 with an option by the Company to extend the term until December 31, 2023.   A reconciliation of the non-controlling income attributable to the Company:   Net loss attributable to non-controlling interest for the three months ended March 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="width: 72%; font: 8pt Times New Roman, Times, Serif">Net income</td> <td style="width: 9%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 17%; text-align: right; font: 8pt Times New Roman, Times, Serif">328,741</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif">Average Non-controlling interest percentage of profit/losses</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-0-</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif">Net income attributable to the non-controlling interest</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">-0-</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>    The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif">Balance, December 31, 2015</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-top: black 1pt solid; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-top: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">(138,686</td> <td style="font: 8pt Times New Roman, Times, Serif">)</td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif">Transfer (to) from the non-controlling interest as a result of change in ownership</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"></td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif">Net income attributable to the non-controlling interest</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"></td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif">Balance, March 31, 2016</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">(138,686</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif">)</td></tr> </table>   Effective October 1, 2015, the Company, through its recently formed wholly owned subsidiary, CCSC Holdings, Inc., acquired a 40% interest in Crane Creek Surgery Center (Crane Creek) in exchange for an investment of $560,000 comprised of $140,000 cash and a promissory note for $420,000 which bears 8% interest per annum, matures April 15, 2016 and is personally guaranteed by the Companys Chief Executive Officer. In connection with the investment, the Company is entitled 51% voting rights for all decisions that most significantly affect the economic performance of Crane Creek. The 40% equity interest acquired entitles the Company to 40% of the profit or loss of Crank Creek. This note was paid in full on April 15, 2016.   A reconciliation of the non-controlling income attributable to the Company:   Net income attributable to non-controlling interest for the three months ended March 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="width: 72%; font: 8pt Times New Roman, Times, Serif">Net income</td> <td style="width: 9%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 17%; text-align: right; font: 8pt Times New Roman, Times, Serif">89,177</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif">Average Non-controlling interest percentage of profit/losses</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">60</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif">Net incomeloss attributable to the non-controlling interest</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">53,507</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>   The following table summarizes the changes in non-controlling interest from October 1, 2015 to December 31, 2015:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif">Balance, December 31, 2015</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-top: black 1pt solid; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-top: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">1,057,676</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif">Transfer (to) from the non-controlling interest as a result of change in ownership</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"></td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif">Net income attributable to the non-controlling interest</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">53,507</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif">Balance, March 31, 2016</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">1,111,183</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>

NOTE 17 SEGMENT REPORTING    The Company reports segment information based on the management approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of the Companys reportable segments. The Company has four reportable segments: Marina Towers, LLC, FCID Medical, Inc., CCSC Holdings, Inc. and The B.A.C.K Center.    The Marina Towers, LLC segment derives revenue from the operating leases of its owned building; FCID Medical and the CCSC Holdings segments derives revenue for medical services provided to patients; and The B.A.C.K Center derives revenue for subleasing space within its building and medical services provided to patients.    Information concerning the operations of the Companys reportable segments is as follows:    Summary Statement of Operations for the three months ended March 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="width: 25%; font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: center">Marina</td> <td nowrap="nowrap" style="width: 10%; font: 8pt Times New Roman, Times, Serif; text-align: center">FCID</td> <td nowrap="nowrap" style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: center">Brevard</td> <td nowrap="nowrap" style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: center">The Crane</td> <td nowrap="nowrap" style="width: 10%; font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: center">Intercompany</td> <td nowrap="nowrap" style="width: 11%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Towers</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Medical</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Orthopaedic</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Center</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Corporate</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Eliminations</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Total</td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Revenue:</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Net Patient Service Revenue</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right"> $           -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right"> $ 2,308,935 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right"> $ 3,034,898 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right"> $   1,271,308 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right"> $           -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right"> $             -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right"> $  6,615,141 </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Rental revenue</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">      428,246 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">      358,099 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"> </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">       (159,733)</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">        626,612 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">  Total Revenue</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      428,246 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   2,308,935 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   3,392,997 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      1,271,308 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">       (159,733)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">     7,241,753 </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Operating expenses:</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Salaries & benefits</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">         3,000 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      829,220 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   1,457,911 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">        293,337 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      197,101 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">     2,780,569 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Other operating expenses</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      105,954 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      531,407 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">        709,646 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">       (159,733)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">     1,187,274 </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">General and administrative</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">        23,907 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      361,803 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   1,581,793 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">        109,275 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      329,099 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">     2,405,877 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Depreciation and amortization</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">        69,951 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">        66,792 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">         5,515 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          71,256 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">        85,436 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">        298,950 </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">  Total operating expenses</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      202,812 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   1,789,222 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   3,045,219 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      1,183,514 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      611,636 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">       (159,733)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">     6,672,670 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Net income (loss) from operations:</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      225,434 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      519,713 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      347,778 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">          87,794 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">    (611,636)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">        569,083 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Interest expense</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">    (110,156)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      (56,818)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">        (2,459)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">          (8,726)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">        (2,976)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      (181,135)</td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Amortization of financing costs</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      (14,337)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">          (988)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">        (15,325)</td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Gain on sale of property</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   9,188,968 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">     9,188,968 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Other income (expense)</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">            750 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">        56,725 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">            1,382 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">         58,857 </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Net Income (loss) before income taxes:</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   9,290,659 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      462,895 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      401,056 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">          80,450 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">    (614,612)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">     9,620,448 </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Income taxes</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"> </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"> </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Net income (loss)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   9,290,659 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      462,895 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      401,056 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">          80,450 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">    (614,612)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">     9,620,448 </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Non-controlling interest</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">        (53,507)</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">        (53,507)</td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif">Net income (loss) attributable to First Choice Healthcare Solutions</td> <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"> $ 9,290,659 </td> <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"> $   462,895 </td> <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"> $   401,056 </td> <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"> $       26,943 </td> <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"> $  (614,612)</td> <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"> $             -   </td> <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"> $  9,566,941 </td></tr> </table>   Summary Statement of Operations for the three months ended March 31, 2015:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="width: 39%; font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="width: 12%; font: 8pt Times New Roman, Times, Serif; text-align: center">Marina</td> <td nowrap="nowrap" style="width: 12%; font: 8pt Times New Roman, Times, Serif; text-align: center">FCID</td> <td nowrap="nowrap" style="width: 12%; font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="width: 13%; font: 8pt Times New Roman, Times, Serif; text-align: center">Intercompany</td> <td nowrap="nowrap" style="width: 12%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Towers</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Medical</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Corporate</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Eliminations</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Total</td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Revenue:</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Net Patient Service Revenue</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right"> $           -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right"> $ 2,240,064 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right"> $           -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right"> $             -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right"> $ 2,240,064 </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Rental revenue</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">      375,321 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">       (110,218)</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">      265,103 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">  Total Revenue</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      375,321 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   2,240,064 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">       (110,218)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   2,505,167 </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Operating expenses:</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Salaries & benefits</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">         3,000 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      836,987 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      106,133 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      946,120 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Other operating expenses</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      103,331 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      458,372 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">       (110,218)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      451,485 </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">General and administrative</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">        22,642 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      291,159 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      239,483 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      553,284 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Depreciation and amortization</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">        69,219 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">        66,515 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">         4,775 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">      140,509 </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">  Total operating expenses</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      198,192 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   1,653,033 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      350,391 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">       (110,218)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   2,091,398 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Net income (loss) from operations:</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      177,129 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      587,031 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">    (350,391)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      413,769 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Interest expense</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">    (110,496)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      (51,784)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">    (200,864)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">    (363,144)</td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Amortization of financing costs</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      (14,337)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">        (6,349)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      (20,686)</td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Other income (expense)</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">            750 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">            750 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Net Income (loss):</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">        53,046 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      528,898 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">    (551,255)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">        30,689 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Income taxes</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Net income (loss)</td> <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"> $     53,046 </td> <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"> $   528,898 </td> <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"> $  (551,255)</td> <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"> $             -   </td> <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"> $     30,689 </td></tr> </table>   Selected financial data:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="width: 33%; font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: center">Marina</td> <td nowrap="nowrap" style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: center">FCID</td> <td nowrap="nowrap" style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: center">Brevard</td> <td nowrap="nowrap" style="width: 12%; font: 8pt Times New Roman, Times, Serif; text-align: center">The Crane</td> <td nowrap="nowrap" style="width: 11%; font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="width: 11%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Towers</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Medical</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Orthopaedic</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Center</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Corporate</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Total</td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Assets:</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">At March 31, 2016:</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $ 8,642,412 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $ 4,872,351 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $ 6,176,738 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $   2,961,076 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $ 3,194,588 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $ 25,847,165 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">At December 31, 2015:</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $ 6,309,955 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $ 4,391,192 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $ 5,623,370 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $   3,013,011 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $ 3,286,460 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $ 22,623,988 </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Assets acquired</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Three months ended March 31, 2016</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $     49,824 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $     49,893 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $       2,116 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $       24,240 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $           -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $     126,073 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Three months ended March 31, 2015</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $       6,628 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $       1,656 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $           -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $             -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $           -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $        8,284 </td></tr> </table>

NOTE 18 - COMMITMENTS AND CONTINGENCIES   Litigation Health First Management    The B.A.C.K. Center has a claim filed in Brevard County, Florida Circuit Court against Health First Management, Inc. due to a contract dispute. A counterclaim was filed against the Company. The case has been litigated for a substantial amount of time and a trial is anticipated to take place within the next 12 months. The Company has vigorously defended against the counterclaim. The Company has accrued a possible loss contingency of approximately $118,000 during the year ended December 31, 2015.    From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.   Operating leases  . The B.A.C.K. Center leases office space under various non-cancelable operating leases that expire at various dates through June 2026. Terms of the lease agreements provide for rental payments ranging from approximately $4,200 to $200,000 per month. Certain leases include charges for sales and real estate taxes and a proration of common area maintenance expenses. Under generally accepted accounting principles (GAAP), all rental payments, including fixed rent increases, are recognized on a straight-line basis over the life of the lease. The GAAP rent expense and the actual lease payments are reflected as deferred rent on the accompanying balance sheet. From the date of the Operation and Control Agreement through December 31, 2015, lease expense amounted to $2,360,986.   The following is a schedule of future minimum lease payments for all non-cancelable operating leases for each of the next five years ending December 31 and thereafter:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="width: 70%; font: 8pt Times New Roman, Times, Serif">Nine months ended December 31, 2016</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 7%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 20%; text-align: right; font: 8pt Times New Roman, Times, Serif">2,620,910</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2017</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">3,444,197</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2018</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">3,444,209</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2019</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">3,444,221</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">12,953,537</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>   Sale/Leaseback   Effective March 31, 2016, the Company leased Marina Towers under a sale/leaseback transaction (See Note 4), via a 10-year absolute triple-net master lease agreement that expires in 2026. The Company has two successive options to renew the lease for five-year periods on the same terms and conditions as the primary non-revocable lease term with the exception of rent, which will be adjusted to the prevailing fair market rent at renewal and will escalate in successive years during the extended lease period. The Company does not have any residual interest nor the option to repurchase the facility at the end of the lease term.   The following is a schedule of future minimum lease payments for the non-cancelable operating lease for each of the next five years ending December 31 and thereafter:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Nine months ended December 31, 2016</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">828,506</td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2017</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,104,675</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2018</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,104,675</td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2019</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,121,246</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2020</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,143,670</td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2021 and thereafter</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">6,387,969</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif; width: 70%"> </td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 8pt Times New Roman, Times, Serif; width: 7%"> </td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; width: 20%">11,690,741</td></tr> </table>   For the three months ended March 31, 2016, the Company collected $268,513 in net rental revenue from third party tenants of Marina Towers.   Guarantees   The B.A.C.K. Centers shareholders and a related party have guaranteed the full and prompt payment of the base rent, the additional rent and any all other sums and charges payable by a tenant, its successors and assigns under the lease, and the full performance and observance of all the covenants, terms, conditions and agreements for one of the above mentioned operating leases.

NOTE 20 SUBSEQUENT EVENTS   On April 1, 2016, the Company paid the following notes in full. In connection with the MedTRX Collection Services, Inc. settlement, on November 6, 2015, the Company issued two non-interest bearing promissory notes in aggregate of $650,000, due the earlier of a) April 2, 2016, b) the date real estate (as identified) is sold, financed or transferred or c) date the stock payment (as described above) is redeemed. As of March 31, 2016, the balance due on outstanding settlement promissory notes was $450,000.   On April 6, 2016, the Company paid the following advances in full. As of March 31, 2016, the Company received an aggregate of $133,796 as cash advances from related parties. The advances are due upon demand with an interest rate of 12% per annum.   On April 15, 2016, the Company paid the following note in full. The promissory note was issued to certain equity owners of The B.A.C.K. Center, an entity consolidated with the Company under VIE accounting. Effective October 1, 2015, the Company acquired a 40% interest in Crane Creek Surgery Center (Crane Creek) in exchange for an investment of $560,000 comprised of $140,000 cash and a promissory note for $420,000 which bears 8% interest per annum, matures April 15, 2016 and is personally guaranteed by the Companys Chief Executive Officer.

Use of estimates   The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Companys stock, and stock-based compensation. Actual results may differ from these estimates.

Revenue recognition   The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (ASC 605-10), which requires that four basic criteria be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on managements judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.   ASC 605-10 incorporates Accounting Standards Codification subtopic 605-25, Multiple-Element Arrangements (ASC 605-25). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. The effect of implementing ASC 605-25 on the Companys financial position and results of operations was not significant.   The Company recognizes in accordance with Accounting Standards Codification subtopic 954-310, Health Care Entities (ASC 954-310), significant patient service revenue at the time the services are rendered, even though it does not assess the patients ability to pay. Therefore, The Companys interim and annual periods reports disclose both, its policy for assessing and disclosing the timing and amount of uncollectable patient service revenue recognized as doubtful. Qualitative and quantitative information about significant changes in the allowance for doubtful accounts related to patient accounts receivable are disclosed in the Companys reports. These estimates are based upon the past history and identified trends for each of our payers.   Patient service revenue   The Company recognizes patient service revenue associated with services provided to patients who have third-party payer coverage on the basis of contractual rates for the services provided. For uninsured or self-pay patients that do not qualify for charity care, the Company recognizes revenue on the basis of its standard rates for services provided (or on the basis of discounted rates, if negotiated or provided by policy). On the basis of historical experience, a portion of the Companys patient service revenue may be potentially uncollectible due to patients who are unable or unwilling to pay for the services provided or the portion of their bill for which they are responsible. Thus, the Company records a provision for bad debts related to potentially uncollectible patient service revenue in the period the services are provided.   Rental revenue   FCID Holdings had one real estate holding, Marina Towers, a Class A 78,000 square foot, six-story building located on the Indian River in Melbourne, Florida. The address is 709 South Harbor City Boulevard, Melbourne, Florida 32901. In addition to housing our corporate headquarters and First Choice Medical Group, the building, which averages 95% annual occupancy, also leases commercial office space to tenants. Our corporate headquarters currently utilize 2,521 square feet on the fifth floor of Marina Towers; and First Choice Medical Group, including its MRI center and Physical Therapy center, currently occupies 26,838 square feet on the ground, first and second floors. Until March 2016, Marina Towers was owned by Marina Towers, LLC, a subsidiary owned by FCID Holdings (99%) and MTMC of Melbourne, Inc. (1%), both wholly owned subsidiaries of the Company.   On March 31, 2016, we completed the sale of Marina Towers to Global Medical REIT Inc. for a purchase price of $15.45 million. In addition, our wholly owned subsidiary, Marina Towers, LLC, leased back the entire facility via a 10-year absolute triple-net master lease agreement that will expire in 2026 and be renewable for two five-year periods on the same terms and conditions as the primary lease term with the exception of rent, which will be adjusted to the prevailing market rent at renewal and will escalate in successive years during the extended lease period.   Until Marina Towers sale on March 31, 2016, the Company recognized rental revenue associated with the period of time the facility is leased at the contractual lease rates (or on the basis of discounted rates, if negotiated).   In addition, beginning May 1, 2015, TBC Holdings of Melbourne, Inc., through The B.A.C.K. Center, subleases approximately 34,480 square feet of commercial office space to third party tenants.

Cash   Cash consists of cash held in bank demand deposits. The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. As of March 31, 2016, the Company had $10,051,999 cash, of which $1,624,203 held by VIE. As of December 31, 2015, the Company had $1,594,998 cash, of which $1,556,303 held by VIE.

Concentrations of credit risk   The Companys financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Occasionally, the Companys cash and cash equivalents in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.

Accounts receivable   Accounts receivables are carried at their estimated collectible amounts net of doubtful accounts. The Company analyzes its past history and identifies trends for each major payer sources of revenue to estimate the appropriate allowance for doubtful accounts and provision for bad debts. Management regularly reviews data about these major payer sources of revenue in evaluating the sufficiency of the allowance for doubtful accounts.   <table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="width: 24px; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 24px; font: 8pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">Rental receivables. Accounts receivables from rental activities are periodically evaluated for collectability in determining the appropriate allowance for doubtful account provision for bad debts and provision of bad debts.</td></tr> <tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">Patient receivables. Accounts receivables from services provided to patients who have third-party coverage, the Company analyzes contractually due amounts and provides a provision for bad debts, if necessary. The Company records a provision for bad debts in the period of service on the basis of past experience or when indications are the patients are unable or unwilling to pay the portion of their bill for which they are responsible. The difference between the standard rates (or the discounted rates if negotiated) and the amounts actually collected after all reasonable collection efforts have been exhausted, is charged off against the allowance for doubtful accounts.</td></tr> </table>   As of March 31, 2016 and December 31, 2015, the Companys provision for bad debts was $2,917,884 and $2,498,398, respectively.

Segment information   Accounting Standards Codification subtopic Segment Reporting 280-10 (ASC 280-10) establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders. ASC 280-10 also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein represents all of the material financial information related to the Companys principal operating segments (see Note 17 Segment Information).

Patents   Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are not amortized, but are tested for impairment annually. The Companys intangible assets with finite lives are patent costs, which are amortized over their economic or legal life, whichever is shorter. These patent costs were acquired on September 7, 2013 by the issuance of 636,666 shares of the Companys common stock to a related party. The shares of common stock were valued at $286,500, which was estimated to be approximately the fair value of the patent acquired and did not materially differ from the fair value of the common stock. The amortization for the three months ended March 31, 2016 and 2015 was $4,775 and $4,775, respectively. Accumulated amortization of patent costs was $42,975 and $38,200 at March 31, 2016 and December 31, 2015, respectively.

Patient list   Patient list is comprised of acquired patients in connection with the acquisition of First Choice - Brevard and is amortized ratably over the estimated useful life of 15 years. The amortization expenses for the three months ended March 31, 2016 and 2015 was $5,000 and $5,000, respectively. Accumulated amortization of patient list costs was $80,000 and $75,000 at March 31, 2016 and December 31, 2015, respectively.

Net income per share   The Company computes basic net income per share by dividing net income per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the treasury stock and/or if converted methods as applicable. The computation of basic and diluted income per share for the three months ended March 31, 2016 and 2015 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.   Potentially dilutive securities excluded from the computation of basic and diluted net income per share are as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-align: center; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" nowrap="nowrap" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> March 31, 2016</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" nowrap="nowrap" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> March 31, 2015</td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="width: 59%; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Warrants to purchase common stock</td> <td style="width: 7%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 0%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 13%; text-align: right; font: 8pt Times New Roman, Times, Serif">4,324,630</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 14%; text-align: right; font: 8pt Times New Roman, Times, Serif">4,195,000</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Options to purchase common stock</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">3,000,000</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"></td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 20pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Totals</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">7,324,630</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">4,195,000</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>

Stock-based compensation   The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the consolidated statements of operations, as if such amounts were paid in cash.

Deferred costs   On May 1, 2015, in connection with the Operation and Control Agreement with Brevard Orthopaedic Spine & Pain Clinic, Inc. (The B.A.C.K. Center), the Company reserved 3,000,000 options to purchase the Companys common stock at $1.35 per share, expiring on December 31, 2023 and vesting contingent on The B.A.C.K. Center employees executing employment agreements with TBC Holding and the acquisition of the variable interest entity. The determined fair value of $3,226,427, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 134.09% and Risk free rate: 2.12%, is amortized ratably to operations over an estimated 8.67-year life. The amortization for the three months ended March 31, 2016 was $80,661. Accumulated amortization of the deferred costs was $295,757 at March 31, 2016.

Investments   The Company has adopted Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures (ASC 323-10), which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company owned a 0.6660% interest in a non-consolidated affiliate, Doctors Surgical Partnership, LTD. In accordance with the equity method of accounting, investments in non-consolidated affiliates are carried at cost and adjusted for the Companys proportionate share of their undistributed earnings or losses.

Fair value   Accounting Standards Codification subtopic 825-10, Financial Instruments (ASC 825-10) requires disclosure of the fair value of certain financial instruments. ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="width: 24px; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 24px; text-align: justify; font: 8pt Times New Roman, Times, Serif">●</td> <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif">Level 1 - Quoted prices in active markets for identical assets or liabilities.</td></tr> <tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif">●</td> <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif">Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr> <tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif">●</td> <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif">Level 3 - Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.</td></tr> </table>   To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.   The carrying value of the Companys cash, accounts receivable, accounts payable, short-term borrowings (including lines of credit and notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity.   As of March 31, 2016 and December 31, 2015, the Company did not have any items that would be classified as level 1, 2 or 3 disclosures.

Recent accounting pronouncements   There are other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Companys financial position, results of operations or cash flows.

Subsequent events    The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed.

Potentially dilutive securities excluded from the computation of basic and diluted net income per share are as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-align: center; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" nowrap="nowrap" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> March 31, 2016</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" nowrap="nowrap" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> March 31, 2015</td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="width: 62%; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Warrants to purchase common stock</td> <td style="width: 7%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 12%; text-align: right; font: 8pt Times New Roman, Times, Serif">4,324,630</td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="width: 3%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 12%; text-align: right; font: 8pt Times New Roman, Times, Serif">4,195,000</td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Options to purchase common stock</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">3,000,000</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"></td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 20pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Totals</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">7,324,630</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">4,195,000</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>

Property, plant and equipment at March 31, 2016 and December 31, 2015 are as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-align: center; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" nowrap="nowrap" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> March 31, 2016</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" nowrap="nowrap" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> December 31, 2015</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="width: 60%; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Land</td> <td style="width: 7%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 12%; text-align: right; font: 8pt Times New Roman, Times, Serif">-</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 2%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 15%; text-align: right; font: 8pt Times New Roman, Times, Serif">1,000,000</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Building</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">-</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">3,055,168</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Building improvements</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">182,246</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">4,211,749</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Computer equipment</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">348,180</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">340,065</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Medical equipment</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">2,888,249</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">2,822,027</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Office equipment</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">260,141</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">260,141</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">3,678,816</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">11,689,150</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Less: accumulated depreciation</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">(989,481</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif">)</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">(3,075,648</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">2,689,335</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">8,613,502</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>

Notes payable as of March 31, 2016 and December 31, 2015 are comprised of the following:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="text-align: center; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" nowrap="nowrap" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> March 31, 2016</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" nowrap="nowrap" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> December 31, 2015</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="width: 60%; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Mortgage Payable</td> <td style="width: 8%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 12%; text-align: right; font: 8pt Times New Roman, Times, Serif">-</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 2%; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 14%; text-align: right; font: 8pt Times New Roman, Times, Serif">7,153,262</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Note Payable, GE Capital (MRI)</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">746,390</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">844,098</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Note Payable, GE Capital (X-ray)</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">85,457</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">97,232</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Note Payable, GE Arm</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">61,080</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">67,455</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Capital Lease Equipment</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">21,112</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">26,716</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">914,039</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">8,188,763</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Less current portion</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">(507,209</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif">)</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">(7,652,941</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif">)</td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">406,830</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">535,822</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>

Aggregate principal maturities of long-term debt as of March 31, 2016:    <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Amount</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="width: 75%; font: 8pt Times New Roman, Times, Serif">Nine months ended December 31, 2016</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 3%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 19%; text-align: right; font: 8pt Times New Roman, Times, Serif">378,217</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2017</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">519,226</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2018</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">16,596</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif">Total</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">914,039</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>

The following table summarizes the warrants outstanding and the related exercise prices for the underlying shares of the Companys common stock as of March 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td colspan="7" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Warrants Outstanding</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: center; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="text-align: center; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="7" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Warrants Exercisable</td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Price</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Outstanding</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Expiration Date</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Weighted Price</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Exercisable</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Weighted Price</td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td colspan="3" style="text-align: center; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="text-align: center; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: center; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="text-align: center; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="text-align: center; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="text-align: center; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 10%; text-align: right; font: 8pt Times New Roman, Times, Serif">1.35</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 10%; text-align: right; font: 8pt Times New Roman, Times, Serif">2,449,630</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 35%; font: 8pt Times New Roman, Times, Serif">November 2018 ~ November 2020</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 10%; text-align: right; font: 8pt Times New Roman, Times, Serif">1.35</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 10%; text-align: right; font: 8pt Times New Roman, Times, Serif">2,449,630</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 10%; text-align: right; font: 8pt Times New Roman, Times, Serif">1.35</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">3.60</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">1,875,000</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">December 23, 2018</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">3.60</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">1,875,000</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">3.60</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">4,324,630</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">2.32</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">4,324,630</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">2.32</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> </table> Transactions involving stock warrants issued are summarized as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="text-align: center; font: 8pt Times New Roman, Times, Serif">Number of Shares</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="text-align: center; font: 8pt Times New Roman, Times, Serif">Weighted Average Price Per Share</td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif; width: 59%">Outstanding at December 31, 2015:</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; width: 15%">4,324,630</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; width: 15%">2.32</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Granted</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"></td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"></td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Exercised</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"></td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"></td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Expired</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"></td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"></td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Outstanding at March 31, 2016</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">4,324,630</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">2.32</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>

The following table presents information related to stock options at March 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td colspan="10" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Options Outstanding</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="text-align: center; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Number of Options</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining Life in Years</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Exercisable Number of Options</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif; width: 2%">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; width: 7%">1.35</td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; width: 12%">3,000,000</td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; width: 29%">7.75</td> <td style="font: 8pt Times New Roman, Times, Serif; width: 4%"> </td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 8pt Times New Roman, Times, Serif; width: 7%"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; width: 26%"></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 7%"> </td></tr> </table>

Transactions involving stock options issued are summarized as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Number of Shares</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Weighted Average Price Per Share</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; width: 59%; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Outstanding at December 31, 2015:</td> <td style="padding-left: 7.5pt; width: 1%; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 3%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 15%; text-align: right; font: 8pt Times New Roman, Times, Serif">3,000,000</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 3%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 15%; text-align: right; font: 8pt Times New Roman, Times, Serif">1.35</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Granted</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"></td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"></td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Exercised</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"></td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"></td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Expired</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"></td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"></td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Outstanding at March 31, 2016</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">3,000,000</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1.35</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>

The table below summarizes the assets and liabilities associated with The B.A.C.K. Center as of March 31, 2016 and as of December 31, 2015:    <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="text-align: center; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">March 31,  2016</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">December 31,  2015</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; width: 61%; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Current assets:</td> <td style="width: 8%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 12%; text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 3%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 12%; text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Cash</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,120,942</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">996,986</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Accounts receivable</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">3,915,553</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">3,727,419</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Other current assets</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">1,034,157</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">819,757</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 20pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Total current assets</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">6,070,652</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">5,544,162</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Property and equipment, net</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">57,579</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">60,978</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Other assets</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">22,334</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">18,231</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; padding-left: 20pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Total assets</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">6,150,565</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">5,623,371</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Current liabilities:</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Accounts payable and accrued liabilities</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,997,207</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,877,690</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Due to First Choice Healthcare Solutions, Inc.</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">2,058,624</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,729,882</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Other current liabilities</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">446,759</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">427,229</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 20pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Total current liabilities</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">4,502,590</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">4,034,801</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Long term debt</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">1,786,661</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">1,727,256</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 20pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Total liabilities</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">6,289,251</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">5,762,057</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Non-controlling interest</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">(138,686</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif">)</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">(138,686</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif">)</td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; padding-left: 20pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Total liabilities and deficit</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">6,150,565</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">5,623,371</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>   The table below summarizes the assets and liabilities associated with the Crane Creek as of March 31, 2016 and December 31, 2015:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="text-align: center; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">March 31,   2016</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">December 31,  2015</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; width: 61%; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Current assets:</td> <td style="width: 8%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 12%; text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 3%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 12%; text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Cash</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">503,262</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">559,318</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Accounts receivable</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">891,070</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">816,889</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 20pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Total current assets</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,394,332</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,376,207</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Property and equipment, net</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">667,280</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">712,830</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Goodwill</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">899,465</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">899,465</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; padding-left: 20pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Total assets</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">2,961,077</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">2,988,502</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Current liabilities:</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Accounts payable and accrued liabilities</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">324,764</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">441,368</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Other current liabilities</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">251,588</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">251,588</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 20pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Total current liabilities</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">576,352</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">692,956</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Deferred rent</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">532,754</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">532,752</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 20pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Total liabilities</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,109,106</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,225,708</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Equity-First Choice Healthcare Solutions, Inc</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">740,788</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">705,118</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Non-controlling interest</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">1,111,183</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">1,057,676</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; padding-left: 20pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Total liabilities and deficit</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">2,961,077</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">2,988,502</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>

Net loss attributable to non-controlling interest for the three months ended March 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="width: 72%; font: 8pt Times New Roman, Times, Serif">Net income</td> <td style="width: 9%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 17%; text-align: right; font: 8pt Times New Roman, Times, Serif">328,741</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif">Average Non-controlling interest percentage of profit/losses</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-0-</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif">Net income attributable to the non-controlling interest</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">-0-</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>   The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif">Balance, December 31, 2015</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-top: black 1pt solid; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-top: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">(138,686</td> <td style="font: 8pt Times New Roman, Times, Serif">)</td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif">Transfer (to) from the non-controlling interest as a result of change in ownership</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"></td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif">Net income attributable to the non-controlling interest</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"></td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif">Balance, March 31, 2016</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">(138,686</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif">)</td></tr> </table>   A reconciliation of the non-controlling income attributable to the Company:   Net income attributable to non-controlling interest for the three months ended March 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="width: 72%; font: 8pt Times New Roman, Times, Serif">Net income</td> <td style="width: 9%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 17%; text-align: right; font: 8pt Times New Roman, Times, Serif">89,177</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif">Average Non-controlling interest percentage of profit/losses</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">60</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif">Net incomeloss attributable to the non-controlling interest</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">53,507</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>   The following table summarizes the changes in non-controlling interest from October 1, 2015 to December 31, 2015:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif">Balance, December 31, 2015</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-top: black 1pt solid; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-top: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">1,057,676</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif">Transfer (to) from the non-controlling interest as a result of change in ownership</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"></td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif">Net income attributable to the non-controlling interest</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">53,507</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif">Balance, March 31, 2016</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">1,111,183</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>

Summary Statement of Operations for the three months ended March 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="width: 25%; font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: center">Marina</td> <td nowrap="nowrap" style="width: 10%; font: 8pt Times New Roman, Times, Serif; text-align: center">FCID</td> <td nowrap="nowrap" style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: center">Brevard</td> <td nowrap="nowrap" style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: center">The Crane</td> <td nowrap="nowrap" style="width: 10%; font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: center">Intercompany</td> <td nowrap="nowrap" style="width: 11%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Towers</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Medical</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Orthopaedic</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Center</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Corporate</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Eliminations</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Total</td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Revenue:</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Net Patient Service Revenue</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right"> $           -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right"> $ 2,308,935 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right"> $ 3,034,898 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right"> $   1,271,308 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right"> $           -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right"> $             -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right"> $  6,615,141 </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Rental revenue</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">      428,246 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">      358,099 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"> </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">       (159,733)</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">        626,612 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">  Total Revenue</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      428,246 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   2,308,935 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   3,392,997 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      1,271,308 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">       (159,733)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">     7,241,753 </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Operating expenses:</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Salaries & benefits</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">         3,000 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      829,220 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   1,457,911 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">        293,337 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      197,101 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">     2,780,569 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Other operating expenses</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      105,954 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      531,407 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">        709,646 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">       (159,733)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">     1,187,274 </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">General and administrative</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">        23,907 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      361,803 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   1,581,793 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">        109,275 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      329,099 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">     2,405,877 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Depreciation and amortization</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">        69,951 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">        66,792 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">         5,515 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">          71,256 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">        85,436 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">        298,950 </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">  Total operating expenses</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      202,812 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   1,789,222 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   3,045,219 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      1,183,514 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      611,636 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">       (159,733)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">     6,672,670 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Net income (loss) from operations:</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      225,434 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      519,713 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      347,778 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">          87,794 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">    (611,636)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">        569,083 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Interest expense</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">    (110,156)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      (56,818)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">        (2,459)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">          (8,726)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">        (2,976)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      (181,135)</td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Amortization of financing costs</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      (14,337)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">          (988)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">        (15,325)</td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Gain on sale of property</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   9,188,968 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">     9,188,968 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Other income (expense)</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">            750 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">        56,725 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">            1,382 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">         58,857 </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Net Income (loss) before income taxes:</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   9,290,659 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      462,895 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      401,056 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">          80,450 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">    (614,612)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">     9,620,448 </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Income taxes</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"> </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"> </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Net income (loss)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   9,290,659 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      462,895 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      401,056 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">          80,450 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">    (614,612)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">     9,620,448 </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Non-controlling interest</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">        (53,507)</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">        (53,507)</td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif">Net income (loss) attributable to First Choice Healthcare Solutions</td> <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"> $ 9,290,659 </td> <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"> $   462,895 </td> <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"> $   401,056 </td> <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"> $       26,943 </td> <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"> $  (614,612)</td> <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"> $             -   </td> <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"> $  9,566,941 </td></tr> </table>   Summary Statement of Operations for the three months ended March 31, 2015:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="width: 39%; font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="width: 12%; font: 8pt Times New Roman, Times, Serif; text-align: center">Marina</td> <td nowrap="nowrap" style="width: 12%; font: 8pt Times New Roman, Times, Serif; text-align: center">FCID</td> <td nowrap="nowrap" style="width: 12%; font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="width: 13%; font: 8pt Times New Roman, Times, Serif; text-align: center">Intercompany</td> <td nowrap="nowrap" style="width: 12%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Towers</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Medical</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Corporate</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Eliminations</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Total</td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Revenue:</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Net Patient Service Revenue</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right"> $           -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right"> $ 2,240,064 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right"> $           -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right"> $             -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right"> $ 2,240,064 </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Rental revenue</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">      375,321 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">       (110,218)</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">      265,103 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">  Total Revenue</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      375,321 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   2,240,064 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">       (110,218)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   2,505,167 </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Operating expenses:</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Salaries & benefits</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">         3,000 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      836,987 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      106,133 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      946,120 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Other operating expenses</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      103,331 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      458,372 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">       (110,218)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      451,485 </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">General and administrative</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">        22,642 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      291,159 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      239,483 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      553,284 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Depreciation and amortization</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">        69,219 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">        66,515 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">         4,775 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">      140,509 </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">  Total operating expenses</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      198,192 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   1,653,033 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      350,391 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">       (110,218)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">   2,091,398 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Net income (loss) from operations:</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      177,129 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      587,031 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">    (350,391)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      413,769 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Interest expense</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">    (110,496)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      (51,784)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">    (200,864)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">    (363,144)</td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Amortization of financing costs</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      (14,337)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">        (6,349)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      (20,686)</td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Other income (expense)</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">            750 </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">            750 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Net Income (loss):</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">        53,046 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">      528,898 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">    (551,255)</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-align: right">        30,689 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Income taxes</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">                -   </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">              -   </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Net income (loss)</td> <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"> $     53,046 </td> <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"> $   528,898 </td> <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"> $  (551,255)</td> <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"> $             -   </td> <td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"> $     30,689 </td></tr> </table>   Selected financial data:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="width: 33%; font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: center">Marina</td> <td nowrap="nowrap" style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: center">FCID</td> <td nowrap="nowrap" style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: center">Brevard</td> <td nowrap="nowrap" style="width: 12%; font: 8pt Times New Roman, Times, Serif; text-align: center">The Crane</td> <td nowrap="nowrap" style="width: 11%; font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="width: 11%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Towers</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Medical</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Orthopaedic</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Center</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Corporate</td> <td nowrap="nowrap" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Total</td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Assets:</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">At March 31, 2016:</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $ 8,642,412 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $ 4,872,351 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $ 6,176,738 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $   2,961,076 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $ 3,194,588 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $ 25,847,165 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">At December 31, 2015:</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $ 6,309,955 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $ 4,391,192 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $ 5,623,370 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $   3,013,011 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $ 3,286,460 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $ 22,623,988 </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Assets acquired</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Three months ended March 31, 2016</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $     49,824 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $     49,893 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $       2,116 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $       24,240 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $           -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $     126,073 </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif">Three months ended March 31, 2015</td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $       6,628 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $       1,656 </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $           -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $             -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $           -   </td> <td nowrap="nowrap" style="font: 8pt Times New Roman, Times, Serif; text-decoration: underline; text-align: right"> $        8,284 </td></tr> </table>

The following is a schedule of future minimum lease payments for all non-cancelable operating leases for each of the next five years ending December 31 and thereafter:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="width: 70%; font: 8pt Times New Roman, Times, Serif">Nine months ended December 31, 2016</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 7%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 20%; text-align: right; font: 8pt Times New Roman, Times, Serif">2,620,910</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2017</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">3,444,197</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2018</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">3,444,209</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2019</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">3,444,221</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">12,953,537</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>   The following is a schedule of future minimum lease payments for the non-cancelable operating lease for each of the next five years ending December 31 and thereafter:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Nine months ended December 31, 2016</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">828,506</td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2017</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,104,675</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2018</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,104,675</td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2019</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,121,246</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2020</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,143,670</td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2021 and thereafter</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">6,387,969</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif; width: 70%"> </td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 8pt Times New Roman, Times, Serif; width: 7%"> </td> <td style="font: 8pt Times New Roman, Times, Serif; width: 1%">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; width: 20%">11,690,741</td></tr> </table>

437372 428645 15450000 15450000

1556303

1624203

4544308

4806623

636293 882226

1317

329

16914

22005

7652941

507209

10341

7235

2119743

11778684

-19274917

-9707976

21196792

21288692

175000

2744453

2674865

535822

406830

67432

42704

600000

450000

43082

133796

1198900

1280200

4403581

4513697

2571

17003

16914

22005

248300

243525

225000

220000

3011331

2930670

39533

329

672293

918226

359414

22090565

26219641

18062046

22886307

0.00

0.36

0.00

0.42

-383080

9051365

45224

262524

2285288

6877665

15000

264144

181135

-166293

8457001

15922

-6802647

198078

7265997

140000

372636

74000

90714

-8284

14942424

8284

126073

15068497

-173931

317224

12876

-59404

-14432

0 150000

-38121

122628

245933

66478

-359414

-26075

-91623

492641

1087059

-99000 -92000

9188968

45224

262524

140509

298950

P15Y

16596

519226

378217

1143670

6387969

828506

1104675

1121246

The following is a schedule of future minimum lease payments for the non-cancelable operating lease for each of the next five years ending December 31 and thereafter:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="font: 8pt Times New Roman, Times, Serif">Nine months ended December 31, 2016</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">828,506</td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2017</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,104,675</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2018</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,104,675</td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2019</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,121,246</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2020</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">1,143,670</td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="font: 8pt Times New Roman, Times, Serif">Year ended December 31, 2021 and thereafter</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">6,387,969</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="width: 77%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 3%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 3%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; width: 15%; font: 8pt Times New Roman, Times, Serif">11,690,741</td></tr> </table>

9188968 9188968

8284

126073

49824

49893

2116

24240

6628

1656

2620910

3444197

3444209

3444221

828506

1104675

1121246

1143670

6387969

11690741

118000

4200

200000

2360986

650000

420000

0.12

0.08

133796 First Choice Healthcare Solutions, Inc. 0001416876 10-Q 2016-03-31 false --12-31 Smaller Reporting Company Q1 2016

2026-12-31

Our corporate headquarters currently utilizes 2,521 square feet on the fifth floor of Marina Towers; and First Choice Medical Group, including its MRI center and Physical Therapy center, currently occupies 26,838 square feet on the ground, first and second floors. Until March 2016, Marina Towers was owned by Marina Towers, LLC, a subsidiary owned by FCID Holdings (99%) and MTMC of Melbourne, Inc. (1%), both wholly owned subsidiaries of the Company.

2023-12-31 2026-12-31

43082

133796

500000

92000

500000

3000000

5515

71256

1382

709646

100000 92000 560000 140000

P7Y9M

Income Taxes   The Company accounts for income taxes pursuant to Accounting Standards Codified 740 (ASC 740). Under ASC 740 deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

NOTE 19 INCOME TAXES   In the first quarter of 2016, effective March 31, 2016, we sold and leased back Marina Towers under a sale/leaseback transaction (See Gain on Sale of Property and Improvements). In connection with the sale, the Company reported a gain on sale of the property of $9,188,968 (GAAP Basis) for the three months ended March 31, 2016. There was a Tax Basis gain of approximate $9,051,430. The difference between the GAPP Basis and Tax Basis gain was mainly attributable to depreciation. The gain was offset by Net Operation Losses the Company has generated in prior periods, so no income tax was recorded, but an estimated Alternative Minimum Tax liability of $181,089 was recorded. Offsetting the Alternative Minimum tax recorded is a Deferred Tax Asset of the same amount related to the Alternative Minimum Tax Liability (Alternative Minimum Tax Credit Carryforward). Management believes the Company will utilize the Alternative Minimum Tax Carryforward in future periods, as of the March 31, 2016 reporting period.   The Companys effective tax rate in the first quarter of 2016 is approximately 38.6% See Note 20, Income Taxes, in the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2015, for additional information.

0.386

9188968

181089

9051430

181029

0.40

268513

EX-101.SCH 7 fchs-20160331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - LIQUIDITY link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - ADVANCES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - LINES OF CREDIT link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - SETTLEMENT PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - NOTE PAYABLE, RELATED PARTY link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - CAPITAL STOCK link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - STOCK OPTIONS AND WARRANTS link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - VARIABLE INTEREST ENTITY link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - NON-CONTROLLING INTEREST link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - SEGMENT REPORTING link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - VARIABLE INTEREST ENTITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - NON-CONTROLLING INTEREST (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - SEGMENT REPORTING (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - BASIS OF PRESENTATION (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - LIQUIDITY (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - ADVANCES (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - LINES OF CREDIT (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - SETTLEMENT PAYABLE (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - NOTE PAYABLE, RELATED PARTY (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - NOTES PAYABLE (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - NOTES PAYABLE (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - RELATED PARTY TRANSACTIONS (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - CAPITAL STOCK (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - STOCK OPTIONS AND WARRANTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - STOCK OPTIONS AND WARRANTS (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - STOCK OPTIONS AND WARRANTS (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - STOCK OPTIONS AND WARRANTS (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - STOCK OPTIONS AND WARRANTS (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - VARIABLE INTEREST ENTITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - VARIABLE INTEREST ENTITY (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - VARIABLE INTEREST ENTITY (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - NON-CONTROLLING INTEREST (Details) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - NON-CONTROLLING INTEREST (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - NON-CONTROLLING INTEREST (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - SEGMENT REPORTING (Details) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000063 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000064 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000065 - Disclosure - INCOME TAXES (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000066 - Disclosure - SUBSEQUENT EVENTS (Details Textual) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 fchs-20160331_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 fchs-20160331_def.xml XBRL DEFINITION FILE EX-101.LAB 10 fchs-20160331_lab.xml XBRL LABEL FILE Patient Lists [Member] Finite-Lived Intangible Assets By Major Class [Axis] Patents [Member] Preferred Stock [Member] Equity Components [Axis] Common Stock [Member] Hillair Extension Agreement [Member] Debt Instrument [Axis] Employee Stock Option [Member] Option Indexed to Issuer's Equity [Axis] Additional Paid in Capital Accumulated Deficit Non-controlling Interest Line of Credit [Member] Short-term Debt, Type [Axis] Preferred Stock Doctor's Surgical Partnership, LTD [Member] Related Party [Axis] Brevard Orthopaedic Spine Pain Clinic, Inc. [Member] TBC Holdings of Melbourne, Inc [Member] Third Party Tenants [Member] Marina Towers [Member] Segments [Axis] Brevard Orthopaedic [Member] FCID Medical [Member] Hillair Capital Investments L P [Member] Accounts Receivable [Member] Concentration Risk Benchmark [Axis] Maximum [Member] Range [Axis] CT Capital LTD [Member] Minimum [Member] Land [Member] Property, Plant and Equipment, Type [Axis] Building [Member] Building improvements [Member] Automobiles [Member] Computer equipment [Member] Medical equipment [Member] Office equipment [Member] Line of Credit, Florida Business Bank [Member] Lender Name [Axis] TBC Equipment Leasing, LLC member [Member] Debenture [Member] Mortgage Payable [Member] Long-Term Debt, Type [Axis] Note Payable GE Capital Construction Two [Member] Note Payable Ge Capital Construction Mri [Member] Note Payable, GE Capital (MRI) [Member] Note Payable, GE Capital (X-ray) [Member] Note Payable GE Arm [Member] Note Payable Auto [Member] Note payable, Florida Business Bank [Member] Note payable, SRS Software, LLC [Member] Capital lease, Equipment [Member] Equipment Capital Lease [Member] Lease [Axis] X Ray Equipment [Member] Products and Services [Axis] C-Arm Equipment [Member] Mri Equipment [Member] Florida Business Bank [Member] GE Healthcare Financial Services [Member] Note Payable Ge Capital [Member] Equipment Finance Lease [Member] Officers, Employees And Service Providers [Member] Convertible Notes Payable [Member] Convertible Advance [Member] Exercise Price Range One [Member] Exercise Price Range [Axis] Warrant [Member] Exercise Price Range Two [Member] Warrants Not Settleable in Cash [Member] Class of Warrant or Right [Axis] Warrants Settleable in Cash [Member] B.A.C.K. Center [Member] Legal Entity [Axis] Corporate [Member] Intersegment Elimination [Member] Subsequent Event [Member] Subsequent Event Type [Axis] MedTRX Collection Services [Member] Restricted Stock [Member] Award Type [Axis] Second non-interest bearing promissory notes [Member] Related Party [Axis] First non-interest bearing promissory notes [Member] MedTRX [Member] CCSC Holdings, Inc [Member] Chief Executive Officer [Member] Title of Individual [Axis] CCSC Holdings and TBC Group [Member] Sale Securities [Member] Debt Security Category [Axis] Common Stock Subscriptions Advances from Non-related Parties [Member] Other Convertible Notes [Member] Line of Credit MTI Capital [Member] Notes Payable, Other Payables [Member] Ccr Of Melbourne Inc [Member] Note Payable Hs Real Llc [Member] Non Employees [Member] Warrant Two [Member] Warrant One [Member] Donald Bittar [Member] The Crane Center [Member] Employment Agreement with Christian Romandetti [Member] Terminated Services of Elite [Member] Consulting Services [Member] Type Of Agreement [Axis] Consultants and Employees [Member] Employee Incentives [Member] Retained Earnings [Member] Common Stock Subscriptions [Member] Crane Creek Surgery Center [Member] Convertible notes and line of credit [Member] Antidilutive Securities [Axis] Warrants to purchase common stock [Member] Options to purchase common stock [Member] Two non-interest bearing promissory notes [Member] Pro Forma [Member] Scenario [Axis] VIE [Member] Future Services [Member] Employees [Member] Officers and employees [Member] Board of director [Member] Fifth Floor Marina Towers [Member] First and Second Floors Marina Towers [Member] MTMC Melbourne, Inc. [Member] Promissory Note One [Member] Promissory Note Two [Member] Two Promissory Notes [Member] B.A.C.K. Center [Member] Crane Creek Surgery Center [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current assets Cash (amounts related to VIE of $1,624,203 and $1,556,303) Cash-restricted Accounts receivable, net (amounts related to VIE of $4,806,623 and $4,544,308) Employee loans (amounts related to VIE of $882,226 and $636,293) Prepaid and other current assets (amounts related to VIE of $151,931 and $183,465) Capitalized financing costs, current portion (amounts related to VIE of $329 and $1,317) Total current assets Property, plant and equipment, net of accumulated depreciation of $989,481 and $3,075,648 (amounts related to VIE of $724,859 and $773,808) Other assets Goodwill (amount relating to VIE of $899,465) Deferred costs, net of amortization of $295,757 and $215,096 Patient list, net of accumulated amortization of $80,000 and $75,000 Patents, net of accumulated amortization of $42,975 and $38,200 Investments (amounts related to VIE of $22,005 and $16,914) Deferred Tax Asset Deposits Total other assets Total assets LIABILITIES AND EQUITY Current liabilities Accounts payable and accrued expenses (amounts related to VIE of $2,321,972 and $2,319,056) Accounts payable, related party (amount related to VIE of $251,588) Stock based payable Advances, related party AMT Tax Payable Settlement payable Line of credit, short term (amount related to VIE of $439,524 and $416,888) Note payable, related party, current portion (amount related to VIE of $437,372 and $428,645) Notes payable, current portion (amount related to VIE of $7,235 and $10,341) Unearned revenue Deferred rent, short term portion (amount related to VIE of $118,810) Total current liabilities Long term debt: Deposits held Notes payable, long term portion Deferred rent, long term portion (amount related to VIE of $2,200,603 and $2,141,199) Total long term debt Total liabilities Equity Preferred stock, $0.01 par value; 1,000,000 shares authorized, Nil issued and outstanding Common stock, $0.001 par value; 100,000,000 shares authorized, 22,967,626 and 22,867,626 shares issued and outstanding as of March 31, 2016 and December 31, 2015, respectively Common stock subscription EX-101.PRE 11 fchs-20160331_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2016	May. 12, 2016
Document And Entity Information
Entity Registrant Name	First Choice Healthcare Solutions, Inc.
Entity Central Index Key	0001416876
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		23,908,983
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2016

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current assets
Cash (amounts related to VIE of $1,624,203 and $1,556,303)	$ 10,051,999	$ 1,594,998
Cash-restricted	0	359,414
Accounts receivable, net (amounts related to VIE of $4,806,623 and $4,544,308)	7,448,429	6,623,894
Employee loans (amounts related to VIE of $882,226 and $636,293)	918,226	672,293
Prepaid and other current assets (amounts related to VIE of $151,931 and $183,465)	225,150	316,773
Capitalized financing costs, current portion (amounts related to VIE of $329 and $1,317)	329	39,533
Total current assets	18,644,133	9,606,905
Property, plant and equipment, net of accumulated depreciation of $989,481 and $3,075,648 (amounts related to VIE of $724,859 and $773,808)	2,689,335	8,613,502
Other assets
Goodwill (amount relating to VIE of $899,465)	899,465	899,465
Deferred costs, net of amortization of $295,757 and $215,096	2,930,670	3,011,331
Patient list, net of accumulated amortization of $80,000 and $75,000	220,000	225,000
Patents, net of accumulated amortization of $42,975 and $38,200	243,525	248,300
Investments (amounts related to VIE of $22,005 and $16,914)	22,005	16,914
Deferred Tax Asset	181,029	0
Deposits	17,003	2,571
Total other assets	4,513,697	4,403,581
Total assets	25,847,165	22,623,988
Current liabilities
Accounts payable and accrued expenses (amounts related to VIE of $2,321,972 and $2,319,056)	4,078,887	3,937,244
Accounts payable, related party (amount related to VIE of $251,588)	251,588	251,588
Stock based payable	1,280,200	1,198,900
Advances, related party	133,796	$ 43,082
AMT Tax Payable	181,029
Settlement payable	450,000	$ 600,000
Line of credit, short term (amount related to VIE of $439,524 and $416,888)	2,939,524	2,566,888
Note payable, related party, current portion (amount related to VIE of $437,372 and $428,645)	437,372	428,645
Notes payable, current portion (amount related to VIE of $7,235 and $10,341)	507,209	7,652,941
Unearned revenue	42,704	42,704
Deferred rent, short term portion (amount related to VIE of $118,810)	118,810	118,810
Total current liabilities	10,421,119	16,840,802
Long term debt:
Deposits held	67,432	67,432
Notes payable, long term portion	406,830	535,822
Deferred rent, long term portion (amount related to VIE of $2,200,603 and $2,141,199)	2,200,603	2,141,199
Total long term debt	2,674,865	2,744,453
Total liabilities	13,095,984	19,585,255
Equity
Preferred stock, $0.01 par value; 1,000,000 shares authorized, Nil issued and outstanding	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized, 22,967,626 and 22,867,626 shares issued and outstanding as of March 31, 2016 and December 31, 2015, respectively	22,968	22,868
Common stock subscription	175,000	175,000
Additional paid in capital	21,288,692	21,196,792
Accumulated deficit	(9,707,976)	(19,274,917)
Total stockholders' equity attributable to First Choice Healthcare Solutions, Inc.	11,778,684	2,119,743
Non-controlling interest	972,497	918,990
Total equity	12,751,181	3,038,733
Total liabilities and equity	$ 25,847,165	$ 22,623,988

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Prepaid and other current assets	$ 225,150	$ 316,773
Accumulated depreciation of property plant and equipment (in dollars)	989,481	3,075,648
Goodwill	899,465	899,465
Amortization of Deferred Charges, Total	295,757	215,096
Patient list, net of accumulated amortization	80,000	75,000
Accounts payable and accrued expenses	4,078,887	3,937,244
Accounts payable, related party	251,588	251,588
Line of credit, short term	2,939,524	2,566,888
Note payable, related party	437,372	428,645
Notes payable, current portion	507,209	7,652,941
Deferred rent, short term portion	118,810	118,810
Deferred rent, long term portion	$ 2,200,603	$ 2,141,199
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	22,967,626	22,867,626
Common stock, shares outstanding	22,967,626	22,867,626
Patents [Member]
Patient list, net of accumulated amortization	$ 42,975	$ 38,200
VIE [Member]
Cash Related to VIE	1,624,203	1,556,303
Accounts receivable	4,806,623	4,544,308
Employee loans	882,226	636,293
Prepaid and other current assets	151,931	183,465
Accumulated Capitalized Interest Costs	329	1,317
Accumulated depreciation of property plant and equipment (in dollars)	724,859	773,808
Goodwill	899,465	899,465
Investments	22,005	16,914
Accounts payable and accrued expenses	2,321,972	2,319,056
Accounts payable, related party	251,588	251,588
Line of credit, short term	439,524	416,888
Note payable, related party	437,372	428,645
Notes payable, current portion	7,235	10,341
Deferred rent, short term portion	118,810	118,810
Deferred rent, long term portion	$ 2,200,603	$ 2,141,199

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues:
Patient service revenue	$ 6,877,665	$ 2,285,288
Provision for bad debts	(262,524)	(45,224)
Net patient service revenue less provision for bad debts	6,615,141	2,240,064
Rental revenue	626,612	265,103
Total revenue	7,241,753	2,505,167
Operating expenses:
Salaries and benefits	2,780,569	946,120
Other operating expenses	1,187,274	451,485
General and administrative	2,405,877	553,284
Depreciation and amortization	298,950	140,509
Total operating expenses	6,672,670	2,091,398
Net income from operations	569,083	413,769
Other income (expense):
Gain on sale of property and improvements	9,188,968	0
Miscellaneous income (expense)	58,857	750
Amortization financing costs	(15,325)	(20,686)
Interest expense, net	(181,135)	(363,144)
Total other expense	9,051,365	(383,080)
Net income before provision for income taxes	9,620,448	30,689
Income taxes (benefit)	0	0
Net income	9,620,448	30,689
Non-controlling interest (note 15)	(53,507)
NET INCOME ATTRIBUTABLE TO FIRST CHOICE HEALTHCARE SOLUTIONS, INC.	$ 9,566,941	$ 30,689
Net income per common share, basic	$ 0.42	$ 0.00
Net income per common share, diluted	$ 0.36	$ 0.00
Weighted average number of common shares outstanding, basic	22,886,307	18,062,046
Weighted average number of common shares outstanding, diluted	26,219,641	22,090,565

XML 16 R5.htm IDEA: XBRL DOCUMENT

STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) - 3 months ended Mar. 31, 2016 - USD ($)	Common Stock [Member]	Additional Paid in Capital	Common Stock Subscriptions	Accumulated Deficit	Non-controlling Interest	Total
Balance at Dec. 31, 2015	$ 22,868	$ 21,196,792	$ 175,000	$ (19,274,917)	$ 918,990	$ 3,038,733
Balance (in shares) at Dec. 31, 2015	22,867,626
Common stock issued in connection with loan extension	$ 100	$ 91,900				92,000
Common stock issued in connection with loan extension (in shares)	100,000
Net income				$ 9,566,941	$ 53,507	9,566,941
Balance at Mar. 31, 2016	$ 22,968	$ 21,288,692	$ 175,000	$ (9,707,976)	$ 972,497	$ 12,751,181
Balance (in shares) at Mar. 31, 2016	22,967,626

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income	$ 9,620,448	$ 30,689
Adjustments to reconcile net loss to cash provided by operating activities:
Depreciation and amortization	298,950	140,509
Amortization of financing costs	15,325	20,686
Bad debt expense	262,524	45,224
Gain on sale of property	(9,188,968)	0
Common stock issued in connection with loan extension	92,000	99,000
Stock based compensation	81,300	48,250
Changes in operating assets and liabilities:
Accounts receivable	(1,087,059)	(492,641)
Prepaid expenses and other	91,623	26,075
Restricted funds	359,414	(66,478)
Employee loans	(245,933)	0
Accounts payable and accrued expenses	122,628	(38,121)
Settlement payable	(150,000)	0
Deposits	(14,432)	0
Deferred rent	59,404	0
Unearned income	0	12,876
Net cash provided by (used in) operating activities	317,224	(173,931)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of property	15,068,497
Purchase of equipment	(126,073)	(8,284)
Net cash provided by (used in) investing activities	14,942,424	(8,284)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from advances	90,714	74,000
Proceeds from lines of credit	372,636	140,000
Net payments on notes payable	(7,265,997)	(198,078)
Net cash (used in) provided by financing activities	(6,802,647)	15,922
Net increase (decrease) in cash and cash equivalents	8,457,001	(166,293)
Cash and cash equivalents, beginning of period	1,594,998	279,087
Cash and cash equivalents, end of period	10,051,999	112,794
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the period for interest	181,135	264,144
Cash paid during the period for taxes	0	0
Supplemental disclosure on non-cash investing and financing activities:
Common stock issued in settlement of accrued expenses	$ 0	$ 15,000

XML 18 R7.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION

3 Months Ended

Mar. 31, 2016

Basis Of Presentation

BASIS OF PRESENTATION

NOTE 1 —BASIS OF PRESENTATION

A summary of the significant accounting policies applied in the presentation of the accompanying unaudited condensed consolidated financial statements follows:

General

Basis of Presentation

Brevard Orthopaedic Spine & Pain Clinic, Inc.

Crane Creek Surgery Center

Effective October 1, 2015, the Company, through its recently formed wholly owned subsidiary, CCSC Holdings, Inc., acquireda 40% interest in Crane Creek Surgery Center (“Crane Creek”) in exchange for an investment of $560,000 comprised of $140,000 cash and a promissory note for $420,000 which bears 8% interest per annum, matures April 15, 2016 and is personally guaranteed by the Company’s Chief Executive Officer. In connection with the investment, the Company is entitled 51% voting rights for all decisions that most significantly affect the economic performance of Crane Creek. The 40% equity interest acquired entitles the Company to 40% of the profit or loss of Crank Creek. This note was paid in full on April 15, 2016.

XML 19 R8.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2016

Significant Accounting Policies

SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES

Use of estimates

Revenue recognition

Patient service revenue

Rental revenue

In addition, beginning May 1, 2015, TBC Holdings of Melbourne, Inc., through The B.A.C.K. Center, subleases approximately 34,480 square feet of commercial office space to third party tenants.

Cash

Concentrations of credit risk

Accounts receivable

	●	Rental receivables. Accounts receivables from rental activities are periodically evaluated for collectability in determining the appropriate allowance for doubtful account provision for bad debts and provision of bad debts.

	●	Patient receivables. Accounts receivables from services provided to patients who have third-party coverage, the Company analyzes contractually due amounts and provides a provision for bad debts, if necessary. The Company records a provision for bad debts in the period of service on the basis of past experience or when indications are the patients are unable or unwilling to pay the portion of their bill for which they are responsible. The difference between the standard rates (or the discounted rates if negotiated) and the amounts actually collected after all reasonable collection efforts have been exhausted, is charged off against the allowance for doubtful accounts.

As of March 31, 2016 and December 31, 2015, the Company’s provision for bad debts was $2,917,884 and $2,498,398, respectively.

Segment information

Patents

Patient list

Net income per share

Potentially dilutive securities excluded from the computation of basic and diluted net income per share are as follows:

	March 31, 2016		March 31, 2015
Warrants to purchase common stock		4,324,630		4,195,000
Options to purchase common stock		3,000,000		—
Totals		7,324,630		4,195,000

Stock-based compensation

Deferred costs

Investments

Income Taxes

Fair value

	●	Level 1 - Quoted prices in active markets for identical assets or liabilities.

	●	Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

	●	Level 3 - Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

As of March 31, 2016 and December 31, 2015, the Company did not have any items that would be classified as level 1, 2 or 3 disclosures.

Recent accounting pronouncements

Subsequent events

XML 20 R9.htm IDEA: XBRL DOCUMENT

LIQUIDITY

3 Months Ended

Mar. 31, 2016

Liquidity Disclosures [Abstract]

LIQUIDITY

NOTE 3 – LIQUIDITY

FCID Holdings had one real estate holding, Marina Towers, a Class A 78,000 square foot, six-story building located on the Indian River in Melbourne, Florida. The address is 709 South Harbor City Boulevard, Melbourne, Florida 32901. In addition to housing our corporate headquarters and First Choice Medical Group, the building, which averages 95% annual occupancy, also leases commercial office space to tenants. Our corporate headquarters currently utilizes 2,521 square feet on the fifth floor of Marina Towers; and First Choice Medical Group, including its MRI center and Physical Therapy center, currently occupies 26,838 square feet on the ground, first and second floors. Until March 2016, Marina Towers was owned by Marina Towers, LLC, a subsidiary owned by FCID Holdings (99%) and MTMC of Melbourne, Inc. (1%), both wholly owned subsidiaries of the Company.

In addition, beginning May 1, 2015, TBC Holdings of Melbourne, Inc., through The B.A.C.K. Center, subleases 31,835 square feet of commercial office space to third party tenants as of March 31, 2016.

XML 21 R10.htm IDEA: XBRL DOCUMENT

PROPERTY, PLANT, AND EQUIPMENT

3 Months Ended

Mar. 31, 2016

Property, Plant and Equipment [Abstract]

PROPERTY, PLANT, AND EQUIPMENT

NOTE 4 — PROPERTY, PLANT, AND EQUIPMENT

Property, plant and equipment at March 31, 2016 and December 31, 2015 are as follows:

	March 31, 2016			December 31, 2015
Land	$	-		$	1,000,000
Building		-			3,055,168
Building improvements		182,246			4,211,749
Computer equipment		348,180			340,065
Medical equipment		2,888,249			2,822,027
Office equipment		260,141			260,141
		3,678,816			11,689,150
Less: accumulated depreciation		(989,481	)		(3,075,648	)
	$	2,689,335		$	8,613,502

During the three months ended March 31, 2016 and 2015, depreciation expense charged to operations was $208,514 and $130,734, respectively.

Sale/Leaseback

The lease is classified as an operating lease and as such recorded a gain on sale of property of $9,188,968 during the three months ended March 31, 2016.

The following is a schedule of future minimum lease payments for the non-cancelable operating lease for each of the next five years ending December 31 and thereafter:

Nine months ended December 31, 2016	$	828,506
Year ended December 31, 2017		1,104,675
Year ended December 31, 2018		1,104,675
Year ended December 31, 2019		1,121,246
Year ended December 31, 2020		1,143,670
Year ended December 31, 2021 and thereafter		6,387,969
	$	11,690,741

For the three months ended March 31, 2016, the Company collected $268,513 in net rental revenue from third party tenants of Marina Towers.

XML 22 R11.htm IDEA: XBRL DOCUMENT

ADVANCES

3 Months Ended

Mar. 31, 2016

Advances

ADVANCES

NOTE 5 — ADVANCES

XML 23 R12.htm IDEA: XBRL DOCUMENT

LINES OF CREDIT

3 Months Ended

Mar. 31, 2016

Line of Credit Facility [Abstract]

LINES OF CREDIT

NOTE 6 — LINES OF CREDIT

Line of credit, CT Capital

As of March 31, 2016 and December 31, 2015, the outstanding balance was $2,500,000 and $2,150,000, respectively.

Line of credit, Florida Business Bank

The Loan is secured by all assets of The B.A.C.K. Center now owned or hereafter acquired. The assets constitute the collateral for the repayment of the Loan.

XML 24 R13.htm IDEA: XBRL DOCUMENT

SETTLEMENT PAYABLE

3 Months Ended

Mar. 31, 2016

Settlement Payable

SETTLEMENT PAYABLE

NOTE 7 — SETTLEMENT PAYABLE

XML 25 R14.htm IDEA: XBRL DOCUMENT

NOTE PAYABLE, RELATED PARTY

3 Months Ended

Mar. 31, 2016

Note Payable Related Party

NOTE PAYABLE, RELATED PARTY

NOTE 8 — NOTE PAYABLE, RELATED PARTY

XML 26 R15.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE

3 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

NOTES PAYABLE

NOTE 9— NOTES PAYABLE

Notes payable as of March 31, 2016 and December 31, 2015 are comprised of the following:

	March 31, 2016			December 31, 2015
Mortgage Payable	$	-		$	7,153,262
Note Payable, GE Capital (MRI)		746,390			844,098
Note Payable, GE Capital (X-ray)		85,457			97,232
Note Payable, GE Arm		61,080			67,455
Capital Lease Equipment		21,112			26,716
		914,039			8,188,763
Less current portion		(507,209	)		(7,652,941	)
	$	406,830		$	535,822

Mortgage payable

Note payable — equipment financing

On May 21, 2012, the Company entered into a note payable with GE Healthcare Financial Services (“GE Capital”) in the amount of approximately $2.4 million for equipment financing.

Capital leases — equipment

Aggregate principal maturities of long-term debt as of March 31, 2016:

	Amount
Nine months ended December 31, 2016	$	378,217
Year ended December 31, 2017		519,226
Year ended December 31, 2018		16,596
Total	$	914,039

XML 27 R16.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

3 Months Ended

Mar. 31, 2016

RELATED PARTY TRANSACTIONS

NOTE 10 — RELATED PARTY TRANSACTIONS

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

XML 28 R17.htm IDEA: XBRL DOCUMENT

CAPITAL STOCK

3 Months Ended

Mar. 31, 2016

Stockholders' Equity Note [Abstract]

CAPITAL STOCK

NOTE 11 — CAPITAL STOCK

Stock-based payable

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

XML 29 R18.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS

3 Months Ended

Mar. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK OPTIONS AND WARRANTS

NOTE 12 — STOCK OPTIONS AND WARRANTS

Warrants

The following table summarizes the warrants outstanding and the related exercise prices for the underlying shares of the Company’s common stock as of March 31, 2016:

Warrants Outstanding							Warrants Exercisable
Price		Outstanding		Expiration Date	Weighted Price		Exercisable		Weighted Price

$	1.35		2,449,630	November 2018 ~ November 2020	$	1.35		2,449,630	$	1.35
$	3.60		1,875,000	December 23, 2018	$	3.60		1,875,000	$	3.60
			4,324,630		$	2.32		4,324,630	$	2.32

Transactions involving stock warrants issued are summarized as follows:

	Number of Shares		Weighted Average Price Per Share
Outstanding at December 31, 2015:		4,324,630	$	2.32
Granted		—		—
Exercised		—		—
Expired		—		—
Outstanding at March 31, 2016		4,324,630	$	2.32

Options

The following table presents information related to stock options at March 31, 2016:

Options Outstanding
Exercise Price		Number of Options		Weighted Average Remaining Life in Years	Exercisable Number of Options
$	1.35		3,000,000	7.75		—

Transactions involving stock options issued are summarized as follows:

	Number of Shares		Weighted Average Price Per Share
Outstanding at December 31, 2015:		3,000,000	$	1.35
Granted		—		—
Exercised		—		—
Expired		—		—
Outstanding at March 31, 2016		3,000,000	$	1.35

XML 30 R19.htm IDEA: XBRL DOCUMENT

VARIABLE INTEREST ENTITY

3 Months Ended

Mar. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

VARIABLE INTEREST ENTITY

NOTE 15 — VARIABLE INTEREST ENTITY

Brevard Orthopaedic Spine & Pain Clinic, Inc.

Effective May 1, 2015, the Company, through its recently formed wholly owned subsidiary, TBC Holdings of Melbourne, Inc., entered into an Operation and Control Agreement (the Agreement”) with Brevard Orthopaedic Spine & Pain Clinic, Inc. (“The B.A.C.K. Center”), whereby the Company will have sole and exclusive management and control of The B.A.C.K. Center, including, but not limited to, administrative, financial, facility and business operations including the requirement to absorb losses or right to receive economic benefits The initial term of the Agreement expires on December 31, 2016, with an option by the Company to extend the term until December 31, 2023. The Company issued 3,000,000 options to purchase the Company’s common stock, vesting contingent on The B.A.C.K. Center employees signing employment contracts with First Choice – Brevard.

The table below summarizes the assets and liabilities associated with The B.A.C.K. Center as of March 31, 2016 and as of December 31, 2015:

	March 31, 2016			December 31, 2015
Current assets:
Cash	$	1,120,942		$	996,986
Accounts receivable		3,915,553			3,727,419
Other current assets		1,034,157			819,757
Total current assets		6,070,652			5,544,162
Property and equipment, net		57,579			60,978
Other assets		22,334			18,231
Total assets	$	6,150,565		$	5,623,371

Current liabilities:
Accounts payable and accrued liabilities	$	1,997,207		$	1,877,690
Due to First Choice Healthcare Solutions, Inc.		2,058,624			1,729,882
Other current liabilities		446,759			427,229
Total current liabilities		4,502,590			4,034,801
Long term debt		1,786,661			1,727,256
Total liabilities		6,289,251			5,762,057
Non-controlling interest		(138,686	)		(138,686	)
Total liabilities and deficit	$	6,150,565		$	5,623,371

Crane Creek Surgery Center

The assets of Crane Creek can only be used to settle obligations of the VIE, additionally, creditors of the Crane Creek do not have recourse against the general credit of the primary beneficiary.

The table below summarizes the assets and liabilities associated with the Crane Creek as of March 31, 2016 and December 31, 2015:

	March 31, 2016		December 31, 2015
Current assets:
Cash	$	503,262	$	559,318
Accounts receivable		891,070		816,889
Total current assets		1,394,332		1,376,207
Property and equipment, net		667,280		712,830
Goodwill		899,465		899,465
Total assets	$	2,961,077	$	2,988,502

Current liabilities:
Accounts payable and accrued liabilities	$	324,764	$	441,368
Other current liabilities		251,588		251,588
Total current liabilities		576,352		692,956
Deferred rent		532,754		532,752
Total liabilities		1,109,106		1,225,708

Equity-First Choice Healthcare Solutions, Inc		740,788		705,118
Non-controlling interest		1,111,183		1,057,676
Total liabilities and deficit	$	2,961,077	$	2,988,502

XML 31 R20.htm IDEA: XBRL DOCUMENT

NON-CONTROLLING INTEREST

3 Months Ended

Mar. 31, 2016

Noncontrolling Interest [Abstract]

NON-CONTROLLING INTEREST

NOTE 16 — NON-CONTROLLING INTEREST

A reconciliation of the non-controlling income attributable to the Company:

Net loss attributable to non-controlling interest for the three months ended March 31, 2016:

Net income	$	328,741
Average Non-controlling interest percentage of profit/losses		-0-	%
Net income attributable to the non-controlling interest	$	-0-

The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2016:

Balance, December 31, 2015	$	(138,686	)
Transfer (to) from the non-controlling interest as a result of change in ownership		—
Net income attributable to the non-controlling interest		—
Balance, March 31, 2016	$	(138,686	)

A reconciliation of the non-controlling income attributable to the Company:

Net income attributable to non-controlling interest for the three months ended March 31, 2016:

Net income	$	89,177
Average Non-controlling interest percentage of profit/losses		60	%
Net incomeloss attributable to the non-controlling interest	$	53,507

The following table summarizes the changes in non-controlling interest from October 1, 2015 to December 31, 2015:

Balance, December 31, 2015	$	1,057,676
Transfer (to) from the non-controlling interest as a result of change in ownership		—
Net income attributable to the non-controlling interest		53,507
Balance, March 31, 2016	$	1,111,183

XML 32 R21.htm IDEA: XBRL DOCUMENT

SEGMENT REPORTING

3 Months Ended

Mar. 31, 2016

Segment Reporting [Abstract]

SEGMENT REPORTING

NOTE 17 — SEGMENT REPORTING

Information concerning the operations of the Company’s reportable segments is as follows:

Summary Statement of Operations for the three months ended March 31, 2016:

	Marina	FCID	Brevard	The Crane		Intercompany
	Towers	Medical	Orthopaedic	Center	Corporate	Eliminations	Total
Revenue:
Net Patient Service Revenue	$ -	$ 2,308,935	$ 3,034,898	$ 1,271,308	$ -	$ -	$ 6,615,141
Rental revenue	428,246	-	358,099		-	(159,733)	626,612
Total Revenue	428,246	2,308,935	3,392,997	1,271,308	-	(159,733)	7,241,753

Operating expenses:
Salaries & benefits	3,000	829,220	1,457,911	293,337	197,101	-	2,780,569
Other operating expenses	105,954	531,407		709,646	-	(159,733)	1,187,274
General and administrative	23,907	361,803	1,581,793	109,275	329,099	-	2,405,877
Depreciation and amortization	69,951	66,792	5,515	71,256	85,436	-	298,950
Total operating expenses	202,812	1,789,222	3,045,219	1,183,514	611,636	(159,733)	6,672,670

Net income (loss) from operations:	225,434	519,713	347,778	87,794	(611,636)	-	569,083

Interest expense	(110,156)	(56,818)	(2,459)	(8,726)	(2,976)	-	(181,135)
Amortization of financing costs	(14,337)	-	(988)	-	-	-	(15,325)
Gain on sale of property	9,188,968	-	-	-	-	-	9,188,968
Other income (expense)	750	-	56,725	1,382	-	-	58,857

Net Income (loss) before income taxes:	9,290,659	462,895	401,056	80,450	(614,612)	-	9,620,448

Income taxes	-	-			-	-	-

Net income (loss)	9,290,659	462,895	401,056	80,450	(614,612)	-	9,620,448

Non-controlling interest	-	-	-	(53,507)	-	-	(53,507)

Net income (loss) attributable to First Choice Healthcare Solutions	$ 9,290,659	$ 462,895	$ 401,056	$ 26,943	$ (614,612)	$ -	$ 9,566,941

Summary Statement of Operations for the three months ended March 31, 2015:

	Marina	FCID		Intercompany
	Towers	Medical	Corporate	Eliminations	Total
Revenue:
Net Patient Service Revenue	$ -	$ 2,240,064	$ -	$ -	$ 2,240,064
Rental revenue	375,321	-	-	(110,218)	265,103
Total Revenue	375,321	2,240,064	-	(110,218)	2,505,167

Operating expenses:
Salaries & benefits	3,000	836,987	106,133	-	946,120
Other operating expenses	103,331	458,372	-	(110,218)	451,485
General and administrative	22,642	291,159	239,483	-	553,284
Depreciation and amortization	69,219	66,515	4,775	-	140,509
Total operating expenses	198,192	1,653,033	350,391	(110,218)	2,091,398

Net income (loss) from operations:	177,129	587,031	(350,391)	-	413,769

Interest expense	(110,496)	(51,784)	(200,864)	-	(363,144)
Amortization of financing costs	(14,337)	(6,349)	-	-	(20,686)
Other income (expense)	750	-	-	-	750

Net Income (loss):	53,046	528,898	(551,255)	-	30,689

Income taxes	-	-	-	-	-

Net income (loss)	$ 53,046	$ 528,898	$ (551,255)	$ -	$ 30,689

Selected financial data:

	Marina	FCID	Brevard	The Crane
	Towers	Medical	Orthopaedic	Center	Corporate	Total
Assets:
At March 31, 2016:	$ 8,642,412	$ 4,872,351	$ 6,176,738	$ 2,961,076	$ 3,194,588	$ 25,847,165
At December 31, 2015:	$ 6,309,955	$ 4,391,192	$ 5,623,370	$ 3,013,011	$ 3,286,460	$ 22,623,988

Assets acquired
Three months ended March 31, 2016	$ 49,824	$ 49,893	$ 2,116	$ 24,240	$ -	$ 126,073
Three months ended March 31, 2015	$ 6,628	$ 1,656	$ -	$ -	$ -	$ 8,284

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

XML 33 R22.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Mar. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 18 - COMMITMENTS AND CONTINGENCIES

Litigation – Health First Management

Operating leases

The following is a schedule of future minimum lease payments for all non-cancelable operating leases for each of the next five years ending December 31 and thereafter:

Nine months ended December 31, 2016		2,620,910
Year ended December 31, 2017		3,444,197
Year ended December 31, 2018		3,444,209
Year ended December 31, 2019		3,444,221
	$	12,953,537

Sale/Leaseback

The following is a schedule of future minimum lease payments for the non-cancelable operating lease for each of the next five years ending December 31 and thereafter:

Nine months ended December 31, 2016	$	828,506
Year ended December 31, 2017		1,104,675
Year ended December 31, 2018		1,104,675
Year ended December 31, 2019		1,121,246
Year ended December 31, 2020		1,143,670
Year ended December 31, 2021 and thereafter		6,387,969
	$	11,690,741

For the three months ended March 31, 2016, the Company collected $268,513 in net rental revenue from third party tenants of Marina Towers.

Guarantees

XML 34 R23.htm IDEA: XBRL DOCUMENT

INCOME TAXES

3 Months Ended

Mar. 31, 2016

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 19 – INCOME TAXES

XML 35 R24.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2016

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 20 – SUBSEQUENT EVENTS

XML 36 R25.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Use of estimates

Revenue recognition

Patient service revenue

Rental revenue

In addition, beginning May 1, 2015, TBC Holdings of Melbourne, Inc., through The B.A.C.K. Center, subleases approximately 34,480 square feet of commercial office space to third party tenants.

Cash

Concentrations of credit risk

Accounts receivable

	●	Rental receivables. Accounts receivables from rental activities are periodically evaluated for collectability in determining the appropriate allowance for doubtful account provision for bad debts and provision of bad debts.

	●	Patient receivables. Accounts receivables from services provided to patients who have third-party coverage, the Company analyzes contractually due amounts and provides a provision for bad debts, if necessary. The Company records a provision for bad debts in the period of service on the basis of past experience or when indications are the patients are unable or unwilling to pay the portion of their bill for which they are responsible. The difference between the standard rates (or the discounted rates if negotiated) and the amounts actually collected after all reasonable collection efforts have been exhausted, is charged off against the allowance for doubtful accounts.

As of March 31, 2016 and December 31, 2015, the Company’s provision for bad debts was $2,917,884 and $2,498,398, respectively.

Potentially dilutive securities excluded from the computation of basic and diluted net income per share are as follows:

	March 31, 2016		March 31, 2015
Warrants to purchase common stock		4,324,630		4,195,000
Options to purchase common stock		3,000,000		—
Totals		7,324,630		4,195,000

Stock-based compensation

	●	Level 1 - Quoted prices in active markets for identical assets or liabilities.

	●	Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

	●	Level 3 - Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

As of March 31, 2016 and December 31, 2015, the Company did not have any items that would be classified as level 1, 2 or 3 disclosures.

Recent accounting pronouncements

Subsequent events

XML 37 R26.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2016

Significant Accounting Policies Tables

Net Income per share

Potentially dilutive securities excluded from the computation of basic and diluted net income per share are as follows:

	March 31, 2016		March 31, 2015
Warrants to purchase common stock		4,324,630		4,195,000
Options to purchase common stock		3,000,000		—
Totals		7,324,630		4,195,000

XML 38 R27.htm IDEA: XBRL DOCUMENT

PROPERTY, PLANT, AND EQUIPMENT (Tables)

3 Months Ended

Mar. 31, 2016

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Property, plant and equipment at March 31, 2016 and December 31, 2015 are as follows:

	March 31, 2016			December 31, 2015
Land	$	-		$	1,000,000
Building		-			3,055,168
Building improvements		182,246			4,211,749
Computer equipment		348,180			340,065
Medical equipment		2,888,249			2,822,027
Office equipment		260,141			260,141
		3,678,816			11,689,150
Less: accumulated depreciation		(989,481	)		(3,075,648	)
	$	2,689,335		$	8,613,502

Schedule Of Future Minimum Lease Payments Table

The following is a schedule of future minimum lease payments for the non-cancelable operating lease for each of the next five years ending December 31 and thereafter:

Nine months ended December 31, 2016	$	828,506
Year ended December 31, 2017		1,104,675
Year ended December 31, 2018		1,104,675
Year ended December 31, 2019		1,121,246
Year ended December 31, 2020		1,143,670
Year ended December 31, 2021 and thereafter		6,387,969
	$	11,690,741

XML 39 R28.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Tables)

3 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Schedule of Long-term Debt Instruments

Notes payable as of March 31, 2016 and December 31, 2015 are comprised of the following:

	March 31, 2016			December 31, 2015
Mortgage Payable	$	-		$	7,153,262
Note Payable, GE Capital (MRI)		746,390			844,098
Note Payable, GE Capital (X-ray)		85,457			97,232
Note Payable, GE Arm		61,080			67,455
Capital Lease Equipment		21,112			26,716
		914,039			8,188,763
Less current portion		(507,209	)		(7,652,941	)
	$	406,830		$	535,822

Schedule of Maturities of Long-term Debt

Aggregate principal maturities of long-term debt as of March 31, 2016:

	Amount
Nine months ended December 31, 2016	$	378,217
Year ended December 31, 2017		519,226
Year ended December 31, 2018		16,596
Total	$	914,039

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

XML 40 R29.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS (Tables)

3 Months Ended

Mar. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Warrants Outstanding And Related Exercise Prices

The following table summarizes the warrants outstanding and the related exercise prices for the underlying shares of the Company’s common stock as of March 31, 2016:

Warrants Outstanding							Warrants Exercisable
Price		Outstanding		Expiration Date	Weighted Price		Exercisable		Weighted Price

$	1.35		2,449,630	November 2018 ~ November 2020	$	1.35		2,449,630	$	1.35
$	3.60		1,875,000	December 23, 2018	$	3.60		1,875,000	$	3.60
			4,324,630		$	2.32		4,324,630	$	2.32

Schedule of Transactions Involving Stock Warrants Issued To Non-employees

Transactions involving stock warrants issued are summarized as follows:

	Number of Shares		Weighted Average Price Per Share
Outstanding at December 31, 2015:		4,324,630	$	2.32
Granted		—		—
Exercised		—		—
Expired		—		—
Outstanding at March 31, 2016		4,324,630	$	2.32

Schedule of Share-based Compensation, Stock Options, Activity

The following table presents information related to stock options at March 31, 2016:

Options Outstanding
Exercise Price		Number of Options		Weighted Average Remaining Life in Years	Exercisable Number of Options
$	1.35		3,000,000	7.75		—

Schedule of Stock Options Information

Transactions involving stock options issued are summarized as follows:

	Number of Shares		Weighted Average Price Per Share
Outstanding at December 31, 2015:		3,000,000	$	1.35
Granted		—		—
Exercised		—		—
Expired		—		—
Outstanding at March 31, 2016		3,000,000	$	1.35

XML 41 R30.htm IDEA: XBRL DOCUMENT

VARIABLE INTEREST ENTITY (Tables)

3 Months Ended

Mar. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Variable Interest Entities [Table Text Block]

The table below summarizes the assets and liabilities associated with The B.A.C.K. Center as of March 31, 2016 and as of December 31, 2015:

	March 31, 2016			December 31, 2015
Current assets:
Cash	$	1,120,942		$	996,986
Accounts receivable		3,915,553			3,727,419
Other current assets		1,034,157			819,757
Total current assets		6,070,652			5,544,162
Property and equipment, net		57,579			60,978
Other assets		22,334			18,231
Total assets	$	6,150,565		$	5,623,371

Current liabilities:
Accounts payable and accrued liabilities	$	1,997,207		$	1,877,690
Due to First Choice Healthcare Solutions, Inc.		2,058,624			1,729,882
Other current liabilities		446,759			427,229
Total current liabilities		4,502,590			4,034,801
Long term debt		1,786,661			1,727,256
Total liabilities		6,289,251			5,762,057
Non-controlling interest		(138,686	)		(138,686	)
Total liabilities and deficit	$	6,150,565		$	5,623,371

The table below summarizes the assets and liabilities associated with the Crane Creek as of March 31, 2016 and December 31, 2015:

	March 31, 2016		December 31, 2015
Current assets:
Cash	$	503,262	$	559,318
Accounts receivable		891,070		816,889
Total current assets		1,394,332		1,376,207
Property and equipment, net		667,280		712,830
Goodwill		899,465		899,465
Total assets	$	2,961,077	$	2,988,502

Current liabilities:
Accounts payable and accrued liabilities	$	324,764	$	441,368
Other current liabilities		251,588		251,588
Total current liabilities		576,352		692,956
Deferred rent		532,754		532,752
Total liabilities		1,109,106		1,225,708

Equity-First Choice Healthcare Solutions, Inc		740,788		705,118
Non-controlling interest		1,111,183		1,057,676
Total liabilities and deficit	$	2,961,077	$	2,988,502

- Definition

Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.

+ References + Details

XML 42 R31.htm IDEA: XBRL DOCUMENT

NON-CONTROLLING INTEREST (Tables)

3 Months Ended

Mar. 31, 2016

Non-controlling Interest Tables

Schedule of Net loss attributable to non-controlling interest

Net loss attributable to non-controlling interest for the three months ended March 31, 2016:

Net income	$	328,741
Average Non-controlling interest percentage of profit/losses		-0-	%
Net income attributable to the non-controlling interest	$	-0-

The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2016:

Balance, December 31, 2015	$	(138,686	)
Transfer (to) from the non-controlling interest as a result of change in ownership		—
Net income attributable to the non-controlling interest		—
Balance, March 31, 2016	$	(138,686	)

A reconciliation of the non-controlling income attributable to the Company:

Net income attributable to non-controlling interest for the three months ended March 31, 2016:

Net income	$	89,177
Average Non-controlling interest percentage of profit/losses		60	%
Net incomeloss attributable to the non-controlling interest	$	53,507

The following table summarizes the changes in non-controlling interest from October 1, 2015 to December 31, 2015:

Balance, December 31, 2015	$	1,057,676
Transfer (to) from the non-controlling interest as a result of change in ownership		—
Net income attributable to the non-controlling interest		53,507
Balance, March 31, 2016	$	1,111,183

XML 43 R32.htm IDEA: XBRL DOCUMENT

SEGMENT REPORTING (Tables)

3 Months Ended

Mar. 31, 2016

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

Summary Statement of Operations for the three months ended March 31, 2016:

	Marina	FCID	Brevard	The Crane		Intercompany
	Towers	Medical	Orthopaedic	Center	Corporate	Eliminations	Total
Revenue:
Net Patient Service Revenue	$ -	$ 2,308,935	$ 3,034,898	$ 1,271,308	$ -	$ -	$ 6,615,141
Rental revenue	428,246	-	358,099		-	(159,733)	626,612
Total Revenue	428,246	2,308,935	3,392,997	1,271,308	-	(159,733)	7,241,753

Operating expenses:
Salaries & benefits	3,000	829,220	1,457,911	293,337	197,101	-	2,780,569
Other operating expenses	105,954	531,407		709,646	-	(159,733)	1,187,274
General and administrative	23,907	361,803	1,581,793	109,275	329,099	-	2,405,877
Depreciation and amortization	69,951	66,792	5,515	71,256	85,436	-	298,950
Total operating expenses	202,812	1,789,222	3,045,219	1,183,514	611,636	(159,733)	6,672,670

Net income (loss) from operations:	225,434	519,713	347,778	87,794	(611,636)	-	569,083

Interest expense	(110,156)	(56,818)	(2,459)	(8,726)	(2,976)	-	(181,135)
Amortization of financing costs	(14,337)	-	(988)	-	-	-	(15,325)
Gain on sale of property	9,188,968	-	-	-	-	-	9,188,968
Other income (expense)	750	-	56,725	1,382	-	-	58,857

Net Income (loss) before income taxes:	9,290,659	462,895	401,056	80,450	(614,612)	-	9,620,448

Income taxes	-	-			-	-	-

Net income (loss)	9,290,659	462,895	401,056	80,450	(614,612)	-	9,620,448

Non-controlling interest	-	-	-	(53,507)	-	-	(53,507)

Net income (loss) attributable to First Choice Healthcare Solutions	$ 9,290,659	$ 462,895	$ 401,056	$ 26,943	$ (614,612)	$ -	$ 9,566,941

Summary Statement of Operations for the three months ended March 31, 2015:

	Marina	FCID		Intercompany
	Towers	Medical	Corporate	Eliminations	Total
Revenue:
Net Patient Service Revenue	$ -	$ 2,240,064	$ -	$ -	$ 2,240,064
Rental revenue	375,321	-	-	(110,218)	265,103
Total Revenue	375,321	2,240,064	-	(110,218)	2,505,167

Operating expenses:
Salaries & benefits	3,000	836,987	106,133	-	946,120
Other operating expenses	103,331	458,372	-	(110,218)	451,485
General and administrative	22,642	291,159	239,483	-	553,284
Depreciation and amortization	69,219	66,515	4,775	-	140,509
Total operating expenses	198,192	1,653,033	350,391	(110,218)	2,091,398

Net income (loss) from operations:	177,129	587,031	(350,391)	-	413,769

Interest expense	(110,496)	(51,784)	(200,864)	-	(363,144)
Amortization of financing costs	(14,337)	(6,349)	-	-	(20,686)
Other income (expense)	750	-	-	-	750

Net Income (loss):	53,046	528,898	(551,255)	-	30,689

Income taxes	-	-	-	-	-

Net income (loss)	$ 53,046	$ 528,898	$ (551,255)	$ -	$ 30,689

Selected financial data:

	Marina	FCID	Brevard	The Crane
	Towers	Medical	Orthopaedic	Center	Corporate	Total
Assets:
At March 31, 2016:	$ 8,642,412	$ 4,872,351	$ 6,176,738	$ 2,961,076	$ 3,194,588	$ 25,847,165
At December 31, 2015:	$ 6,309,955	$ 4,391,192	$ 5,623,370	$ 3,013,011	$ 3,286,460	$ 22,623,988

Assets acquired
Three months ended March 31, 2016	$ 49,824	$ 49,893	$ 2,116	$ 24,240	$ -	$ 126,073
Three months ended March 31, 2015	$ 6,628	$ 1,656	$ -	$ -	$ -	$ 8,284

XML 44 R33.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Tables)

3 Months Ended

Mar. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases

The following is a schedule of future minimum lease payments for all non-cancelable operating leases for each of the next five years ending December 31 and thereafter:

Nine months ended December 31, 2016		2,620,910
Year ended December 31, 2017		3,444,197
Year ended December 31, 2018		3,444,209
Year ended December 31, 2019		3,444,221
	$	12,953,537

The following is a schedule of future minimum lease payments for the non-cancelable operating lease for each of the next five years ending December 31 and thereafter:

Nine months ended December 31, 2016	$	828,506
Year ended December 31, 2017		1,104,675
Year ended December 31, 2018		1,104,675
Year ended December 31, 2019		1,121,246
Year ended December 31, 2020		1,143,670
Year ended December 31, 2021 and thereafter		6,387,969
	$	11,690,741

XML 45 R34.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION (Details Textual) - USD ($)			1 Months Ended	3 Months Ended
BASIS OF PRESENTATION (Details Textual) - USD ($)	Dec. 14, 2015	Jun. 09, 2015	Oct. 31, 2015	Mar. 31, 2016
Matures date	Jul. 30, 2017	Jul. 30, 2017		Apr. 01, 2016
Crane Creek Surgery Center [Member]
Amount paid in exchange of investment				$ 560,000
Cash paid				140,000
Promissory note				$ 420,000
Bearing interest rate				8.00%
Matures date			Apr. 15, 2016	Apr. 15, 2016
Voting Rights, Description				In connection with the investment, the Company is entitled 51% voting rights for all decisions that most significantly affect the economic performance of Crane Creek. The 40% equity interest acquired entitles the Company to 40% of the profit or loss of Crank Creek.

XML 46 R35.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Details) - shares	3 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Details) - shares	Mar. 31, 2016	Mar. 31, 2015
Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share	7,324,630	4,195,000
Options to purchase common stock [Member]
Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share	3,000,000
Warrants to purchase common stock [Member]
Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share	4,324,630	4,195,000

XML 47 R36.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Details Textual)			1 Months Ended	3 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Details Textual)	Sep. 07, 2013 USD ($)	Sep. 07, 2013 shares	May. 31, 2015 USD ($) ft² $ / shares shares	Mar. 31, 2016 USD ($) ft² shares	Mar. 31, 2015 USD ($) shares	Dec. 31, 2015 USD ($) shares	Dec. 31, 2014 USD ($)
Summary of Significant Accounting Policies [Line Items]
Amortization Financing Costs				$ 15,325	$ 20,686
Property, Plant and Equipment, Depreciation Methods					straight-line method
Allowance for Doubtful Accounts Receivable				$ 2,917,884		$ 2,498,398
Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount \| shares				7,324,630	4,195,000
Cash and Cash Equivalents, at Carrying Value, Total				$ 10,051,999	$ 112,794	1,594,998	$ 279,087
Health Care Organization, Other Revenue				626,612	265,103
Finite-Lived Intangible Assets, Accumulated Amortization				80,000		$ 75,000
Options to purchase common stock \| shares						129,630
Purchase price				15,450,000
VIE [Member]
Summary of Significant Accounting Policies [Line Items]
Cash and Cash Equivalents, at Carrying Value, Total				1,624,203		$ 1,556,303
Patient Lists [Member]
Summary of Significant Accounting Policies [Line Items]
Amortization of Intangible Assets				5,000	5,000
Finite-Lived Intangible Assets, Accumulated Amortization				$ 80,000		75,000
Finite-Lived Intangible Asset, Useful Life				15 years
Patents [Member]
Summary of Significant Accounting Policies [Line Items]
Amortization of Intangible Assets				$ 4,775	4,775
Finite-Lived Intangible Assets, Accumulated Amortization				$ 42,975		$ 38,200
Donald Bittar [Member]
Summary of Significant Accounting Policies [Line Items]
Stock Issued During Period, Shares, Purchase of Assets \| shares		636,666
Donald Bittar [Member] \| Patents [Member]
Summary of Significant Accounting Policies [Line Items]
Health Care Organization, Other Revenue	$ 286,500
Doctor's Surgical Partnership, LTD [Member]
Summary of Significant Accounting Policies [Line Items]
Equity Method Investment, Ownership Percentage				0.666%
Brevard Orthopaedic Spine Pain Clinic, Inc. [Member]
Summary of Significant Accounting Policies [Line Items]
Amortization Financing Costs				$ 295,757
Share Price \| $ / shares			$ 1.35
Options to purchase common stock \| shares			3,000,000
Adjustments to Additional Paid in Capital, Fair Value			$ 3,226,427
Fair Value Assumptions, Expected Dividend Rate			0.00%
Fair Value Assumptions, Expected Volatility Rate			134.09%
Fair Value Assumptions, Risk Free Interest Rate			2.12%
Fair Value Assumptions, Expected Term			8 years 8 months 1 day
Amortization of Deferred Charges, Total			$ 215,096	80,661
Options Expiration Date			Dec. 31, 2023
TBC Holdings of Melbourne, Inc [Member]
Summary of Significant Accounting Policies [Line Items]
Area of Land \| ft²			34,480
Marina Towers [Member]
Summary of Significant Accounting Policies [Line Items]
Amortization Financing Costs				14,337	14,337
Health Care Organization, Other Revenue				$ 428,246	375,321
Area of Land, Percentage of Occupancy				95.00%
Area of Land \| ft²				78,000
Fair Value Assumptions, Expected Term				5 years
Options Expiration Date				Dec. 31, 2026
Purchase price				$ 15,450,000
Fifth Floor Marina Towers [Member]
Summary of Significant Accounting Policies [Line Items]
Area of Land \| ft²				2,521
First and Second Floors Marina Towers [Member]
Summary of Significant Accounting Policies [Line Items]
Area of Land \| ft²				26,838
FCID Medical [Member]
Summary of Significant Accounting Policies [Line Items]
Amortization Financing Costs					$ 6,349
Health Care Organization, Other Revenue
Equity Method Investment, Ownership Percentage				99.00%
MTMC Melbourne, Inc. [Member]
Summary of Significant Accounting Policies [Line Items]
Equity Method Investment, Ownership Percentage				1.00%

XML 48 R37.htm IDEA: XBRL DOCUMENT

LIQUIDITY (Details Textual)					1 Months Ended	3 Months Ended		12 Months Ended
LIQUIDITY (Details Textual)	Dec. 14, 2015 USD ($)	Jun. 09, 2015 USD ($)	Nov. 08, 2013 shares	Jun. 13, 2013 USD ($) shares	Mar. 31, 2016 USD ($) ft²	Mar. 31, 2016 USD ($) ft² shares	Mar. 31, 2015 USD ($)	Dec. 31, 2015 USD ($)	May. 01, 2015 ft²
Liquidity Disclosures [Line Items]
Long-term Line of Credit	$ 1,000,000	$ 500,000		$ 2,000,000
Debt Instrument, Interest Rate, Effective Percentage					60.00%	60.00%
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total \| shares						100,000
Debt Conversion, Converted Instrument, Amount							$ 2,236,907
Matures date	Jul. 30, 2017	Jul. 30, 2017				Apr. 01, 2016
Purchase price					$ 15,450,000	$ 15,450,000
Lease agreement expireation date								Dec. 31, 2026
B.A.C.K. Center [Member]
Liquidity Disclosures [Line Items]
Area of Land \| ft²									31,835
Maximum [Member]
Liquidity Disclosures [Line Items]
Increasing the maximum aggregate amount	$ 2,500,000	$ 2,000,000
Minimum [Member]
Liquidity Disclosures [Line Items]
Increasing the maximum aggregate amount	$ 2,000,000	$ 1,500,000
CT Capital LTD [Member]
Liquidity Disclosures [Line Items]
Long-term Line of Credit				$ 1,500,000	$ 2,500,000	$ 2,500,000		$ 2,150,000
Debt Instrument, Interest Rate During Period			12.00%	12.00%
Debt Instrument, Interest Rate, Effective Percentage			6.00%	6.00%				6.00%
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total \| shares			100,000	100,000
Debt Conversion, Converted Instrument, Amount								$ 2,892,314
Marina Towers [Member]
Liquidity Disclosures [Line Items]
Area of Land, Percentage of Occupancy						95.00%
Area of Land \| ft²					78,000	78,000
Purchase price					$ 15,450,000	$ 15,450,000
Lease agreement expireation date					Dec. 31, 2026
Lease agreement description					Our corporate headquarters currently utilizes 2,521 square feet on the fifth floor of Marina Towers; and First Choice Medical Group, including its MRI center and Physical Therapy center, currently occupies 26,838 square feet on the ground, first and second floors. Until March 2016, Marina Towers was owned by Marina Towers, LLC, a subsidiary owned by FCID Holdings (99%) and MTMC of Melbourne, Inc. (1%), both wholly owned subsidiaries of the Company.
FCID Medical [Member]
Liquidity Disclosures [Line Items]
Equity Method Investment, Ownership Percentage					99.00%	99.00%
MTMC Melbourne, Inc. [Member]
Liquidity Disclosures [Line Items]
Equity Method Investment, Ownership Percentage					1.00%	1.00%

XML 49 R38.htm IDEA: XBRL DOCUMENT

PROPERTY, PLANT, AND EQUIPMENT (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 3,678,816	$ 11,689,150
Less: accumulated depreciation	(989,481)	(3,075,648)
Property, plant and equipment, net	$ 2,689,335	8,613,502
Land [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross		1,000,000
Building [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross		3,055,168
Building improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 182,246	4,211,749
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	348,180	340,065
Medical equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	2,888,249	2,822,027
Office equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 260,141	$ 260,141

XML 50 R39.htm IDEA: XBRL DOCUMENT

PROPERTY, PLANT, AND EQUIPMENT (Details 1) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Property Plant And Equipment Details 1
Nine months ended December 31, 2016	$ 828,506
Year ended December 31, 2017	1,104,675
Year ended December 31, 2018	1,104,675
Year ended December 31, 2019	1,121,246
Year ended December 31, 2020	1,143,670
Year ended December 31, 2021 and thereafter	6,387,969
Total	$ 11,690,741	$ 12,953,537

XML 51 R40.htm IDEA: XBRL DOCUMENT

PROPERTY, PLANT, AND EQUIPMENT (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Depreciation	$ 208,514	$ 130,734
Gain on sale of property	9,188,968	$ 0
Purchase price	15,450,000
Rental revenue from third party tenants of Marina Towers	$ 268,513

XML 52 R41.htm IDEA: XBRL DOCUMENT

ADVANCES (Details Textual) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
Debt Instrument, Face Amount	$ 133,796	$ 43,082
Debt Instrument, Interest Rate, Stated Percentage	12.00%	12.00%

XML 53 R42.htm IDEA: XBRL DOCUMENT

LINES OF CREDIT (Details Textual) - USD ($)						1 Months Ended	3 Months Ended	12 Months Ended
LINES OF CREDIT (Details Textual) - USD ($)	Dec. 14, 2015	Jun. 09, 2015	Nov. 08, 2013	Jun. 13, 2013	Apr. 09, 2013	Jun. 27, 2012	Mar. 31, 2016	Dec. 31, 2015
Line of Credit Facility [Line Items]
Line Of Credit Facility, Expiration Date				Dec. 31, 2016
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total							100,000
Debt Instrument, Interest Rate, Effective Percentage							60.00%
Line of Credit Facility, Minimum Borrowing Capacity	$ 1,000,000
Line Of Credit Facility, Amount Outstanding	$ 1,000,000	$ 500,000		$ 2,000,000
Line of Credit Facility, Interest Rate Description							The advance rate is defined as: 60% of Medicare and Medicaid receivables less than 90 days old multiplied by a factor of 0.25, plus all other receivables less than 90 days old multiplied by a factor of 0.50.
Debt Instrument, Term	60 days
Matures date	Jul. 30, 2017	Jul. 30, 2017					Apr. 01, 2016
Increase in the accounts receivable line of credit							$ 500,000
Agreed to issue shares of common stock							500,000
Agreed to issue shares of common stock, amount							$ 92,000
Minimum [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 2,000,000	$ 1,500,000
Maximum [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 2,500,000	2,000,000
Accounts Receivable [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Line Of Credit Facility, Amount Outstanding		1,500,000
Accounts Receivable [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Line Of Credit Facility, Amount Outstanding		$ 2,000,000
CT Capital LTD [Member]
Line of Credit Facility [Line Items]
Short-term Debt, Maximum Amount Outstanding During Period				$ 1,500,000
Line of Credit Facility, Collateral				The advance rate is defined as: 80% of all receivables to be 120 days or less at the net collection rate of approximately 27% of total billings, excluding patient billings and collections. Additionally, allowable accounts receivable will also include 50% of all accounts receivable protected by legal letters of protection.
Debt Instrument, Convertible, Terms of Conversion Feature				At any time up until December 31,2016, the Lender may convert all or any portion of the outstanding principal amount or interest on the Loan into common stock of the Company at a conversion price of $0.75 per share.
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total			100,000	100,000
Debt Instrument, Interest Rate During Period			12.00%	12.00%
Debt Instrument, Interest Rate, Effective Percentage			6.00%	6.00%				6.00%
Line Of Credit Facility, Amount Outstanding				$ 1,500,000			2,500,000	$ 2,150,000
TBC Equipment Leasing, LLC member [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Interest Rate Description					interest rate of one month Libor floating plus 2.75%, as published in The Wall Street Journal, with a floor of 2.96% per annum (2.96% at December 31, 2014 and 2013, respectively).
Line of Credit Facility, Increase (Decrease), Net, Total					$ 1,383,000
Line of Credit Facility, Increase (Decrease), Other, Net					$ 995,000
Debt Instrument, Term					45 days
Line of Credit Facility, Average Outstanding Amount					$ 1,000,000
Line of Credit, Florida Business Bank [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Covenant Terms						The advance rate is defined as: 60% of Medicare and Medicaid receivables less than 90 days old multiplied by a factor of 0.25, plus all other receivables less than 90 days old multiplied by a factor of 0.50. As of June 30, 2015, The B.A.C.K. Center had not violated the loan covenants.
Line Of Credit Guaranteed Amount							950,000
Line of Credit Facility, Average Outstanding Amount							$ 439,524	$ 416,888
Line of Credit, Florida Business Bank [Member] \| Accounts Receivable [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Interest Rate Description						interest rate of Prime floating plus 1.0%, as published in The Wall Street Journal, with a floor of 4.50% per annum (the Loan).
Line of Credit Facility, Capacity Available for Specific Purpose Other than for Trade Purchases						$ 1,000,000

XML 54 R43.htm IDEA: XBRL DOCUMENT

SETTLEMENT PAYABLE (Details Textual) - USD ($)			3 Months Ended
SETTLEMENT PAYABLE (Details Textual) - USD ($)	Dec. 14, 2015	Jun. 09, 2015	Mar. 31, 2016	Dec. 31, 2015	Nov. 06, 2015
Subsequent Event [Line Items]
Debt Instrument, Maturity Date	Jul. 30, 2017	Jul. 30, 2017	Apr. 01, 2016
Outstanding settlement promissory notes			$ 450,000	$ 600,000
MedTRX Collection Services [Member] \| Two non-interest bearing promissory notes [Member]
Subsequent Event [Line Items]
Promissory note					$ 650,000

XML 55 R44.htm IDEA: XBRL DOCUMENT

NOTE PAYABLE, RELATED PARTY (Details Textual) - USD ($)			1 Months Ended	3 Months Ended	12 Months Ended
NOTE PAYABLE, RELATED PARTY (Details Textual) - USD ($)	Dec. 14, 2015	Jun. 09, 2015	Oct. 31, 2015	Mar. 31, 2016	Dec. 31, 2015	Oct. 01, 2015
Matures date	Jul. 30, 2017	Jul. 30, 2017		Apr. 01, 2016
Crane Creek Surgery Center [Member]
Amount paid in exchange of investment				$ 560,000
Cash paid				140,000
Promissory note				$ 420,000
Bearing interest rate				8.00%
Matures date			Apr. 15, 2016	Apr. 15, 2016
Promissory note principal and interest outstanding				$ 437,372	$ 428,645
Crane Creek Surgery Center [Member]
Interest acquire in subsidiary						40.00%
Amount paid in exchange of investment						$ 560,000
Cash paid						$ 140,000
Bearing interest rate						8.00%

XML 56 R45.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Notes Payable	$ 914,039	$ 8,188,763
Less: current portion	(507,209)	(7,652,941)
Notes payable, long term portion	$ 406,830	535,822
Mortgage Payable [Member]
Debt Instrument [Line Items]
Notes Payable		7,153,262
Note Payable, GE Capital (MRI) [Member]
Debt Instrument [Line Items]
Notes Payable	$ 746,390	844,098
Note Payable, GE Capital (X-ray) [Member]
Debt Instrument [Line Items]
Notes Payable	85,457	97,232
Note Payable GE Arm [Member]
Debt Instrument [Line Items]
Notes Payable	61,080	67,455
Capital lease, Equipment [Member]
Debt Instrument [Line Items]
Notes Payable	$ 21,112	$ 26,716

XML 57 R46.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details 1)	Mar. 31, 2016 USD ($)
Aggregate maturities of long-term debt:
Nine months ended December 31, 2016	$ 378,217
Year ended December 31, 2017	519,226
Year ended December 31, 2018	16,596
Total	$ 914,039

XML 58 R47.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details Textual) - USD ($)					1 Months Ended			3 Months Ended
NOTES PAYABLE (Details Textual) - USD ($)	Dec. 14, 2015	Jun. 09, 2015	Jun. 11, 2013	Aug. 12, 2011	Sep. 27, 2012	Aug. 22, 2012	Oct. 25, 2011	Mar. 31, 2016	Dec. 31, 2015	Mar. 08, 2013	Feb. 25, 2013	May. 21, 2012
Debt Instrument [Line Items]
Debt Instrument, Maturity Date	Jul. 30, 2017	Jul. 30, 2017						Apr. 01, 2016
Debt Instrument, Interest Rate, Stated Percentage								12.00%	12.00%
Debt Instrument, Interest Rate, Effective Percentage								60.00%
Debt Instrument, Term	60 days
C-Arm Equipment [Member]
Debt Instrument [Line Items]
Capital Lease Obligations											$ 124,797
Debt Instrument, Interest Rate, Stated Percentage											7.39%
Capital Lease Obligations Due In First 3 Months											$ 0
Capital Lease Obligations Due For Remaining Months											$ 2,388
X Ray Equipment [Member]
Debt Instrument [Line Items]
Capital Lease Obligations						$ 212,389
Debt Instrument, Interest Rate, Stated Percentage						7.9375%
Capital Lease Obligations Due In First 3 Months						$ 0				$ 1,384
Capital Lease Obligations Due For Remaining Months						$ 4,300				4,575
Debt Instrument, Term						60 months
Mri Equipment [Member]
Debt Instrument [Line Items]
Capital Lease Obligations					$ 1,771,390
Debt Instrument, Interest Rate, Stated Percentage					7.9375%
Capital Lease Obligations Due In First 3 Months					$ 0					11,779
Capital Lease Obligations Due For Remaining Months					$ 38,152					$ 38,152
Debt Instrument, Term					60 months
GE Healthcare Financial Services [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount												$ 2,400,000
Mortgage Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period				6.10%
Debt Instrument, Periodic Payment				$ 45,753
Debt Instrument, Maturity Date				Sep. 16, 2016
Debt Instrument, Term				30 years
Debt Instrument, Face Amount				$ 7,550,000
Equipment Capital Lease [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment			$ 956
Debt Instrument, Maturity Date			Jun. 01, 2017
Debt Instrument, Interest Rate, Effective Percentage			14.002%
Capital Lease Equipment, Lease Term			48 months
Lease To Acquire Equipment							$ 1,036
Lease agreement term							60 months

XML 59 R48.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details Textual) - USD ($)			1 Months Ended	3 Months Ended
RELATED PARTY TRANSACTIONS (Details Textual) - USD ($)	Dec. 14, 2015	Jun. 09, 2015	Oct. 31, 2015	Mar. 31, 2016	Dec. 31, 2015	Oct. 01, 2015
Matures date	Jul. 30, 2017	Jul. 30, 2017		Apr. 01, 2016
Cash advances				$ 133,796	$ 43,082
Interest rate				12.00%
Crane Creek Surgery Center [Member]
Amount paid in exchange of investment				$ 560,000
Cash paid				140,000
Promissory note				$ 420,000
Bearing interest rate				8.00%
Matures date			Apr. 15, 2016	Apr. 15, 2016
Crane Creek Surgery Center [Member]
Interest acquire in subsidiary						40.00%
Amount paid in exchange of investment						$ 560,000
Cash paid						$ 140,000
Bearing interest rate						8.00%

XML 60 R49.htm IDEA: XBRL DOCUMENT

CAPITAL STOCK (Details Textual) - USD ($)	3 Months Ended
CAPITAL STOCK (Details Textual) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Common Stock, Par Or Stated Value Per Share (in dollars per share)	$ 0.001	$ 0.001
Line of Credit [Member] \| Common Stock [Member]
Common Stock , Shares, Issued for increase Credit Line	100,000
Common Stock , Shares, Issued for increase Credit Line value	$ 92,000
Future Services [Member] \| Common Stock [Member]
Common Stock, Par Or Stated Value Per Share (in dollars per share)	$ 0.78
Common Stock, Shares, Issued for Services Amount	$ 1,280,200

XML 61 R50.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS (Details) - $ / shares	3 Months Ended
STOCK OPTIONS AND WARRANTS (Details) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding	3,000,000	3,000,000
Warrants Outstanding, Weighted Price	$ 1.35	$ 1.35
Warrants Exercisable	(0)
Non Employees [Member] \| Warrant One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Prices	$ 1.35
Warrants Outstanding	2,449,630
Warrants Outstanding, Weighted Price	$ 1.35
Warrants Exercisable	2,449,630
Warrants Exercisable, Weighted Price	$ 1.35
Non Employees [Member] \| Warrant One [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Expiration Date	Nov. 08, 2020
Non Employees [Member] \| Warrant One [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Expiration Date	Nov. 08, 2018
Non Employees [Member] \| Warrant Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Prices	$ 3.60
Warrants Outstanding	1,875,000
Warrants Outstanding, Expiration Date	Dec. 23, 2018
Warrants Outstanding, Weighted Price	$ 3.60
Warrants Exercisable	1,875,000
Warrants Exercisable, Weighted Price	$ 3.60
Non Employees [Member] \| Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding	4,324,630	4,324,630
Warrants Outstanding, Weighted Price	$ 2.32	$ 2.32
Warrants Exercisable	4,324,630
Warrants Exercisable, Weighted Price	$ 2.32

XML 62 R51.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS (Details 1)	3 Months Ended
STOCK OPTIONS AND WARRANTS (Details 1)	Mar. 31, 2016 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding \| shares	3,000,000
Number of Shares, Granted \| shares	0
Number of Shares, Exercised \| shares	0
Number of Shares, Outstanding \| shares	3,000,000
Weighted Average Price Per Share, Outstanding	$ 1.35
Weighted Average Price Per Share, Granted	0.00
Weighted Average Price Per Share, Exercised	0.00
Weighted Average Price Per Share, Expired	0.00
Weighted Average Price Per Share, Outstanding	$ 1.35
Non Employees [Member] \| Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding \| shares	4,324,630
Number of Shares, Granted \| shares	0
Number of Shares, Exercised \| shares	0
Number of Shares, Expired \| shares	0
Number of Shares, Outstanding \| shares	4,324,630
Weighted Average Price Per Share, Outstanding	$ 2.32
Weighted Average Price Per Share, Granted	0.00
Weighted Average Price Per Share, Exercised	0.00
Weighted Average Price Per Share, Expired	0.00
Weighted Average Price Per Share, Outstanding	$ 2.32

XML 63 R52.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS (Details 2) - $ / shares	3 Months Ended
STOCK OPTIONS AND WARRANTS (Details 2) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options Outstanding Exercise Price	$ 1.35	$ 1.35
Options Outstanding Number of Options	3,000,000	3,000,000
Options Outstanding Weighted Average Remaining Life in Years	7 years 9 months
Exercisable Number of Options	0

XML 64 R53.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS (Details 3)	3 Months Ended
STOCK OPTIONS AND WARRANTS (Details 3)	Mar. 31, 2016 $ / shares shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Shares, Outstanding \| shares	3,000,000
Number of Shares, Granted \| shares	0
Number of Shares, Exercised \| shares	0
Number of Shares, Expired \| shares	0
Number of Shares, Outstanding \| shares	3,000,000
Weighted Average Price Per Share, Outstanding \| $ / shares	$ 1.35
Weighted Average Price Per Share, Granted \| $ / shares	0.00
Weighted Average Price Per Share, Exercised \| $ / shares	0.00
Weighted Average Price Per Share, Expired \| $ / shares	0.00
Weighted Average Price Per Share, Outstanding \| $ / shares	$ 1.35

XML 65 R54.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS (Details Textual) - shares	Mar. 31, 2016	Dec. 31, 2015
Warrant to purchase common stock		129,630
Warrants Settleable in Cash [Member]
Warrant to purchase common stock	1,875,000
Warrants Not Settleable in Cash [Member]
Warrant to purchase common stock	2,449,630

XML 66 R55.htm IDEA: XBRL DOCUMENT

VARIABLE INTEREST ENTITY (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash	$ 10,051,999	$ 1,594,998	$ 112,794	$ 279,087
Accounts receivable	7,448,429	6,623,894
Total current assets	18,644,133	9,606,905
Property and equipment, net	2,689,335	8,613,502
Total assets	25,847,165	22,623,988	$ 25,847,165
Current liabilities:
Accounts payable and accrued liabilities	4,078,887	3,937,244
Total current liabilities	10,421,119	16,840,802
Long term debt	914,039
Total liabilities	13,095,984	19,585,255
Non-controlling interest	972,497	918,990
Total liabilities and deficit	25,847,165	22,623,988
B.A.C.K. Center [Member]
Current assets:
Cash	1,120,942	996,986
Accounts receivable	3,915,553	3,727,419
Other current assets	1,034,157	819,757
Total current assets	6,070,652	5,544,162
Property and equipment, net	57,579	60,978
Other assets	22,334	18,231
Total assets	6,150,565	5,623,371
Current liabilities:
Accounts payable and accrued liabilities	1,997,207	1,877,690
Due to First Choice Healthcare Solutions, Inc.	2,058,624	1,729,882
Other current liabilities	446,759	427,229
Total current liabilities	4,502,590	4,034,801
Long term debt	1,786,661	1,727,256
Total liabilities	6,289,251	5,762,057
Non-controlling interest	(138,686)	(138,686)
Total liabilities and deficit	$ 6,150,565	$ 5,623,371

XML 67 R56.htm IDEA: XBRL DOCUMENT

VARIABLE INTEREST ENTITY (Details 1) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash	$ 10,051,999	$ 1,594,998	$ 112,794	$ 279,087
Accounts receivable	7,448,429	6,623,894
Total current assets	18,644,133	9,606,905
Property and equipment, net	2,689,335	8,613,502
Goodwill	899,465	899,465
Total assets	25,847,165	22,623,988	$ 25,847,165
Current liabilities:
Accounts payable and accrued liabilities	4,078,887	3,937,244
Total current liabilities	10,421,119	16,840,802
Deferred rent	2,200,603	2,141,199
Total liabilities	13,095,984	19,585,255
Equity-First Choice Healthcare Solutions, Inc	22,968	22,868
Non-controlling interest	972,497	918,990
Total liabilities and deficit	25,847,165	22,623,988
Crane Creek Surgery Center [Member]
Current assets:
Cash	503,262	559,318
Accounts receivable	891,070	816,889
Total current assets	1,394,332	1,376,207
Property and equipment, net	667,280	712,830
Goodwill	899,465	899,465
Total assets	2,961,077	2,988,502
Current liabilities:
Accounts payable and accrued liabilities	324,764	441,368
Other current liabilities	251,588	251,588
Total current liabilities	576,352	692,956
Deferred rent	532,754	532,752
Total liabilities	1,109,106	1,225,708
Equity-First Choice Healthcare Solutions, Inc	740,788	705,118
Non-controlling interest	1,111,183	1,057,676
Total liabilities and deficit	$ 2,961,077	$ 2,988,502

XML 68 R57.htm IDEA: XBRL DOCUMENT

VARIABLE INTEREST ENTITY (Details Textual) - USD ($)			1 Months Ended	3 Months Ended		8 Months Ended
VARIABLE INTEREST ENTITY (Details Textual) - USD ($)	Dec. 14, 2015	Jun. 09, 2015	Oct. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Total revenues				$ 7,241,753	$ 2,505,167
Salaries and benefits				2,780,569	946,120
General and administrative expenses				2,405,877	553,284
Interest and financing costs				$ (181,135)	$ (363,144)
Matures date	Jul. 30, 2017	Jul. 30, 2017		Apr. 01, 2016
Crane Creek Surgery Center [Member]
Total revenues				$ 1,271,308
Salaries and benefits				293,337
General and administrative expenses				109,275
Depreciation				71,256
Miscellaneous income				1,382
Supplies and operating practices				709,646
Amount paid in exchange of investment				560,000
Cash paid				140,000
Promissory note				$ 420,000
Bearing interest rate				8.00%
Matures date			Apr. 15, 2016	Apr. 15, 2016
Voting Rights, Description				In connection with the investment, the Company is entitled 51% voting rights for all decisions that most significantly affect the economic performance of Crane Creek. The 40% equity interest acquired entitles the Company to 40% of the profit or loss of Crank Creek.
Acquisition voting rights, Description				40% equity interest along with the 51% voting rights acquired
B.A.C.K. Center [Member]
Options issued to purchase the Company's common stock						3,000,000
Total revenues				$ 3,449,722
Salaries and benefits				1,457,911
General and administrative expenses				1,654,107
Depreciation				5,515
Interest and financing costs				$ 3,447

XML 69 R58.htm IDEA: XBRL DOCUMENT

NON-CONTROLLING INTEREST (Details) - USD ($)	3 Months Ended
NON-CONTROLLING INTEREST (Details) - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Net income	$ 9,566,941	$ 30,689
Net income loss attributable to the non-controlling interest	(53,507)
B.A.C.K. Center [Member]
Net income	$ 328,741
Average Non-controlling interest percentage of profit/losses	0.00%
Net income loss attributable to the non-controlling interest	$ 0
Crane Creek Surgery Center [Member]
Net income	$ 89,177
Average Non-controlling interest percentage of profit/losses	60.00%
Net income loss attributable to the non-controlling interest	$ 53,507

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 70 R59.htm IDEA: XBRL DOCUMENT

NON-CONTROLLING INTEREST (Details 1)	3 Months Ended
NON-CONTROLLING INTEREST (Details 1)	Mar. 31, 2016 USD ($)
Balance, December 31, 2015	$ 918,990
Net income loss attributable to the non-controlling interest	(53,507)
Balance, March 31, 2016	972,497
B.A.C.K. Center [Member]
Balance, December 31, 2015	(138,686)
Transfer (to) from the non-controlling interest as a result of change in ownership	0
Net income loss attributable to the non-controlling interest	0
Balance, March 31, 2016	(138,686)
Crane Creek Surgery Center [Member]
Balance, December 31, 2015	1,057,676
Transfer (to) from the non-controlling interest as a result of change in ownership	0
Net income loss attributable to the non-controlling interest	53,507
Balance, March 31, 2016	$ 1,111,183

XML 71 R60.htm IDEA: XBRL DOCUMENT

NON-CONTROLLING INTEREST (Details Textual) - USD ($)			1 Months Ended	3 Months Ended
NON-CONTROLLING INTEREST (Details Textual) - USD ($)	Dec. 14, 2015	Jun. 09, 2015	Oct. 31, 2015	Mar. 31, 2016
Matures date	Jul. 30, 2017	Jul. 30, 2017		Apr. 01, 2016
Crane Creek Surgery Center [Member]
Amount paid in exchange of investment				$ 560,000
Cash paid				140,000
Promissory note				$ 420,000
Bearing interest rate				8.00%
Matures date			Apr. 15, 2016	Apr. 15, 2016
Voting Rights, Description				In connection with the investment, the Company is entitled 51% voting rights for all decisions that most significantly affect the economic performance of Crane Creek. The 40% equity interest acquired entitles the Company to 40% of the profit or loss of Crank Creek.
Acquisition voting rights, Description				40% equity interest along with the 51% voting rights acquired

XML 72 R61.htm IDEA: XBRL DOCUMENT

SEGMENT REPORTING (Details) - USD ($)	3 Months Ended
SEGMENT REPORTING (Details) - USD ($)	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Revenue:
Net Patient Service Revenue	$ 6,615,141	$ 2,240,064
Rental revenue	626,612	265,103
Total Revenue	7,241,753	2,505,167
Operating expenses:
Salaries & benefits	2,780,569	946,120
Other operating expenses	1,187,274	451,485
General and administrative	2,405,877	553,284
Depreciation and amortization	298,950	140,509
Total operating expenses	6,672,670	2,091,398
Net income (loss) from operations:	569,083	413,769
Interest expense	(181,135)	(363,144)
Amortization of financing costs	(15,325)	(20,686)
Gain on sale of property	9,188,968
Other income (expense)	58,857	750
Net Income (loss) before income taxes:	9,620,448	30,689
Income taxes	0	0
Net income (loss)	9,620,448	30,689
Non-controlling interest	(53,507)
Net income (loss) attributable to First Choice Healthcare Solutions	9,566,941	30,689
Assets:	25,847,165	25,847,165	$ 22,623,988
Assets acquired	$ 126,073	$ 8,284
Marina Towers [Member]
Revenue:
Net Patient Service Revenue
Rental revenue	$ 428,246	$ 375,321
Total Revenue	428,246	375,321
Operating expenses:
Salaries & benefits	3,000	3,000
Other operating expenses	105,954	103,331
General and administrative	23,907	22,642
Depreciation and amortization	69,951	69,219
Total operating expenses	202,812	198,192
Net income (loss) from operations:	225,434	177,129
Interest expense	(110,156)	(110,496)
Amortization of financing costs	(14,337)	(14,337)
Gain on sale of property	9,188,968
Other income (expense)	750	$ 750
Net Income (loss) before income taxes:	$ 9,290,659
Income taxes
Net income (loss)	$ 9,290,659	$ 53,046
Non-controlling interest
Net income (loss) attributable to First Choice Healthcare Solutions	$ 9,290,659	53,046
Assets:	8,642,412		6,309,955
Assets acquired	49,824	6,628
FCID Medical [Member]
Revenue:
Net Patient Service Revenue	$ 2,308,935	$ 2,240,064
Rental revenue
Total Revenue	$ 2,308,935	$ 2,240,064
Operating expenses:
Salaries & benefits	829,220	836,987
Other operating expenses	531,407	458,372
General and administrative	361,803	291,159
Depreciation and amortization	66,792	66,515
Total operating expenses	1,789,222	1,653,033
Net income (loss) from operations:	519,713	587,031
Interest expense	$ (56,818)	(51,784)
Amortization of financing costs		$ (6,349)
Gain on sale of property
Other income (expense)
Net Income (loss) before income taxes:	$ 462,895
Income taxes
Net income (loss)	$ 462,895	$ 528,898
Non-controlling interest
Net income (loss) attributable to First Choice Healthcare Solutions	$ 462,895	528,898
Assets:	4,872,351		4,391,192
Assets acquired	49,893	$ 1,656
Brevard Orthopaedic [Member]
Revenue:
Net Patient Service Revenue	3,034,898
Rental revenue	358,099
Total Revenue	3,392,997
Operating expenses:
Salaries & benefits	1,457,911
General and administrative	1,581,793
Depreciation and amortization	5,515
Total operating expenses	3,045,219
Net income (loss) from operations:	347,778
Interest expense	(2,459)
Amortization of financing costs	$ (988)
Gain on sale of property
Other income (expense)	$ 56,725
Net Income (loss) before income taxes:	401,056
Net income (loss)	$ 401,056
Non-controlling interest
Net income (loss) attributable to First Choice Healthcare Solutions	$ 401,056
Assets:	6,176,738		5,623,370
Assets acquired	2,116
The Crane Center [Member]
Revenue:
Net Patient Service Revenue	1,271,308
Total Revenue	1,271,308
Operating expenses:
Salaries & benefits	293,337
Other operating expenses	709,646
General and administrative	109,275
Depreciation and amortization	71,256
Total operating expenses	1,183,514
Net income (loss) from operations:	87,794
Interest expense	$ (8,726)
Amortization of financing costs
Gain on sale of property
Other income (expense)	$ 1,382
Net Income (loss) before income taxes:	80,450
Net income (loss)	80,450
Non-controlling interest	(53,507)
Net income (loss) attributable to First Choice Healthcare Solutions	26,943
Assets:	2,961,076		3,013,011
Assets acquired	$ 24,240
Corporate [Member]
Revenue:
Net Patient Service Revenue
Rental revenue
Total Revenue
Operating expenses:
Salaries & benefits	$ 197,101	$ 106,133
Other operating expenses
General and administrative	$ 329,099	$ 239,483
Depreciation and amortization	85,436	4,775
Total operating expenses	611,636	350,391
Net income (loss) from operations:	(611,636)	(350,391)
Interest expense	$ (2,976)	$ (200,864)
Amortization of financing costs
Gain on sale of property
Other income (expense)
Net Income (loss) before income taxes:	$ (614,612)
Income taxes
Net income (loss)	$ (614,612)	$ (551,255)
Non-controlling interest
Net income (loss) attributable to First Choice Healthcare Solutions	$ (614,612)	$ (551,255)
Assets:	$ 3,194,588		$ 3,286,460
Assets acquired
Intersegment Elimination [Member]
Revenue:
Net Patient Service Revenue
Rental revenue	$ (159,733)	$ (110,218)
Total Revenue	$ (159,733)	$ (110,218)
Operating expenses:
Salaries & benefits
Other operating expenses	$ (159,733)	$ (110,218)
General and administrative
Depreciation and amortization
Total operating expenses	$ (159,733)	$ (110,218)
Net income (loss) from operations:
Interest expense
Amortization of financing costs
Gain on sale of property
Other income (expense)
Net Income (loss) before income taxes:
Income taxes
Net income (loss)
Non-controlling interest
Net income (loss) attributable to First Choice Healthcare Solutions

XML 73 R62.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Operating Leases, Future Minimum Payments Due, Rolling Maturity [Abstract]
Nine months ended December 31, 2016		$ 2,620,910
Year ended December 31, 2017		3,444,197
Year ended December 31, 2018		3,444,209
Year ended December 31, 2019		3,444,221
Operating Leases, Future Minimum Payments Due, Total	$ 11,690,741	$ 12,953,537

XML 74 R63.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Details 1)	Dec. 31, 2015 USD ($)
Operating Leases, Future Minimum Payments Due, Rolling Maturity [Abstract]
Nine months ended December 31, 2016	$ 828,506
Year ended December 31, 2017	1,104,675
Year ended December 31, 2018	1,104,675
Year ended December 31, 2019	1,121,246
Year ended December 31, 2020	1,143,670
Year ended December 31, 2021 and thereafter	6,387,969
Operating Leases, Future Minimum Payments Due, Total	$ 11,690,741

XML 75 R64.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Commitments and Contingencies [Line Items]
Loss Contingency, Damages Sought, Value		$ 118,000
Lease expense		$ 2,360,986
Lease expiration date		Dec. 31, 2026
Rental revenue from third party tenants of Marina Towers	$ 268,513
Minimum [Member]
Commitments and Contingencies [Line Items]
Lease Rent Expense Per Month		$ 4,200
Maximum [Member]
Commitments and Contingencies [Line Items]
Lease Rent Expense Per Month		$ 200,000

XML 76 R65.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details Textual)	3 Months Ended
INCOME TAXES (Details Textual)	Mar. 31, 2016 USD ($)
Income Tax Disclosure [Abstract]
Gain on sale of the property	$ 9,188,968
Tax basis gain	9,051,430
Alternative Minimum Tax liability	$ 181,089
Effective tax rate	38.60%

XML 77 R66.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details Textual) - USD ($)					3 Months Ended
SUBSEQUENT EVENTS (Details Textual) - USD ($)	Apr. 15, 2016	Apr. 02, 2016	Dec. 14, 2015	Jun. 09, 2015	Mar. 31, 2016
Subsequent Event [Line Items]
Maturity date			Jul. 30, 2017	Jul. 30, 2017	Apr. 01, 2016
Interest rate					12.00%
Cash advances from non related party					$ 133,796
MedTRX [Member] \| Two Promissory Notes [Member]
Subsequent Event [Line Items]
Balance due					$ 450,000
Subsequent Event [Member] \| MedTRX [Member] \| Two Promissory Notes [Member]
Subsequent Event [Line Items]
Maturity date		Apr. 02, 2016
Non-interest bearing promissory notes		$ 650,000
Subsequent Event [Member] \| B.A.C.K. Center [Member]
Subsequent Event [Line Items]
Purchase price	$ 560,000
Ownership percentage	40.00%
Cash Consideration	$ 140,000
Maturity date	Apr. 15, 2016
Non-interest bearing promissory notes	$ 420,000
Interest rate	8.00%

EXCEL 78 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 79 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 80 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 82 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 164 299 1 false 62 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://firstchoicehealthcaresolutions.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://firstchoicehealthcaresolutions.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://firstchoicehealthcaresolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://firstchoicehealthcaresolutions.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) Sheet http://firstchoicehealthcaresolutions.com/role/StatementOfStockholdersEquity STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://firstchoicehealthcaresolutions.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - BASIS OF PRESENTATION Sheet http://firstchoicehealthcaresolutions.com/role/BasisOfPresentation BASIS OF PRESENTATION Notes 7 false false R8.htm 00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://firstchoicehealthcaresolutions.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - LIQUIDITY Sheet http://firstchoicehealthcaresolutions.com/role/Liquidity LIQUIDITY Notes 9 false false R10.htm 00000010 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT Sheet http://firstchoicehealthcaresolutions.com/role/PropertyPlantAndEquipment PROPERTY, PLANT, AND EQUIPMENT Notes 10 false false R11.htm 00000011 - Disclosure - ADVANCES Sheet http://firstchoicehealthcaresolutions.com/role/Advances ADVANCES Notes 11 false false R12.htm 00000012 - Disclosure - LINES OF CREDIT Sheet http://firstchoicehealthcaresolutions.com/role/LinesOfCredit LINES OF CREDIT Notes 12 false false R13.htm 00000013 - Disclosure - SETTLEMENT PAYABLE Sheet http://firstchoicehealthcaresolutions.com/role/SettlementPayable SETTLEMENT PAYABLE Notes 13 false false R14.htm 00000014 - Disclosure - NOTE PAYABLE, RELATED PARTY Sheet http://firstchoicehealthcaresolutions.com/role/NotePayableRelatedParty NOTE PAYABLE, RELATED PARTY Notes 14 false false R15.htm 00000015 - Disclosure - NOTES PAYABLE Notes http://firstchoicehealthcaresolutions.com/role/NotesPayable NOTES PAYABLE Notes 15 false false R16.htm 00000016 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://firstchoicehealthcaresolutions.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 16 false false R17.htm 00000017 - Disclosure - CAPITAL STOCK Sheet http://firstchoicehealthcaresolutions.com/role/CapitalStock CAPITAL STOCK Notes 17 false false R18.htm 00000018 - Disclosure - STOCK OPTIONS AND WARRANTS Sheet http://firstchoicehealthcaresolutions.com/role/StockOptionsAndWarrants STOCK OPTIONS AND WARRANTS Notes 18 false false R19.htm 00000019 - Disclosure - VARIABLE INTEREST ENTITY Sheet http://firstchoicehealthcaresolutions.com/role/VariableInterestEntity VARIABLE INTEREST ENTITY Notes 19 false false R20.htm 00000020 - Disclosure - NON-CONTROLLING INTEREST Sheet http://firstchoicehealthcaresolutions.com/role/Non-controllingInterest NON-CONTROLLING INTEREST Notes 20 false false R21.htm 00000021 - Disclosure - SEGMENT REPORTING Sheet http://firstchoicehealthcaresolutions.com/role/SegmentReporting SEGMENT REPORTING Notes 21 false false R22.htm 00000022 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://firstchoicehealthcaresolutions.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 22 false false R23.htm 00000023 - Disclosure - INCOME TAXES Sheet http://firstchoicehealthcaresolutions.com/role/IncomeTaxes INCOME TAXES Notes 23 false false R24.htm 00000024 - Disclosure - SUBSEQUENT EVENTS Sheet http://firstchoicehealthcaresolutions.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 24 false false R25.htm 00000025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://firstchoicehealthcaresolutions.com/role/SignificantAccountingPoliciesPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 25 false false R26.htm 00000026 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://firstchoicehealthcaresolutions.com/role/SignificantAccountingPoliciesTables SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://firstchoicehealthcaresolutions.com/role/SignificantAccountingPolicies 26 false false R27.htm 00000027 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Tables) Sheet http://firstchoicehealthcaresolutions.com/role/PropertyPlantAndEquipmentTables PROPERTY, PLANT, AND EQUIPMENT (Tables) Tables http://firstchoicehealthcaresolutions.com/role/PropertyPlantAndEquipment 27 false false R28.htm 00000028 - Disclosure - NOTES PAYABLE (Tables) Notes http://firstchoicehealthcaresolutions.com/role/NotesPayableTables NOTES PAYABLE (Tables) Tables http://firstchoicehealthcaresolutions.com/role/NotesPayable 28 false false R29.htm 00000029 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables) Sheet http://firstchoicehealthcaresolutions.com/role/StockOptionsAndWarrantsTables STOCK OPTIONS AND WARRANTS (Tables) Tables http://firstchoicehealthcaresolutions.com/role/StockOptionsAndWarrants 29 false false R30.htm 00000030 - Disclosure - VARIABLE INTEREST ENTITY (Tables) Sheet http://firstchoicehealthcaresolutions.com/role/VariableInterestEntityTables VARIABLE INTEREST ENTITY (Tables) Tables http://firstchoicehealthcaresolutions.com/role/VariableInterestEntity 30 false false R31.htm 00000031 - Disclosure - NON-CONTROLLING INTEREST (Tables) Sheet http://firstchoicehealthcaresolutions.com/role/Non-controllingInterestTables NON-CONTROLLING INTEREST (Tables) Tables http://firstchoicehealthcaresolutions.com/role/Non-controllingInterest 31 false false R32.htm 00000032 - Disclosure - SEGMENT REPORTING (Tables) Sheet http://firstchoicehealthcaresolutions.com/role/SegmentReportingTables SEGMENT REPORTING (Tables) Tables http://firstchoicehealthcaresolutions.com/role/SegmentReporting 32 false false R33.htm 00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://firstchoicehealthcaresolutions.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://firstchoicehealthcaresolutions.com/role/CommitmentsAndContingencies 33 false false R34.htm 00000034 - Disclosure - BASIS OF PRESENTATION (Details Textual) Sheet http://firstchoicehealthcaresolutions.com/role/BasisOfPresentationDetailsTextual BASIS OF PRESENTATION (Details Textual) Details http://firstchoicehealthcaresolutions.com/role/BasisOfPresentation 34 false false R35.htm 00000035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://firstchoicehealthcaresolutions.com/role/SignificantAccountingPoliciesDetails SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://firstchoicehealthcaresolutions.com/role/SignificantAccountingPoliciesTables 35 false false R36.htm 00000036 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Textual) Sheet http://firstchoicehealthcaresolutions.com/role/SignificantAccountingPoliciesDetailsTextual SIGNIFICANT ACCOUNTING POLICIES (Details Textual) Details http://firstchoicehealthcaresolutions.com/role/SignificantAccountingPoliciesTables 36 false false R37.htm 00000037 - Disclosure - LIQUIDITY (Details Textual) Sheet http://firstchoicehealthcaresolutions.com/role/LiquidityDetailsTextual LIQUIDITY (Details Textual) Details http://firstchoicehealthcaresolutions.com/role/Liquidity 37 false false R38.htm 00000038 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Details) Sheet http://firstchoicehealthcaresolutions.com/role/PropertyPlantAndEquipmentDetails PROPERTY, PLANT, AND EQUIPMENT (Details) Details http://firstchoicehealthcaresolutions.com/role/PropertyPlantAndEquipmentTables 38 false false R39.htm 00000039 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Details 1) Sheet http://firstchoicehealthcaresolutions.com/role/PropertyPlantAndEquipmentDetails1 PROPERTY, PLANT, AND EQUIPMENT (Details 1) Details http://firstchoicehealthcaresolutions.com/role/PropertyPlantAndEquipmentTables 39 false false R40.htm 00000040 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Details Textual) Sheet http://firstchoicehealthcaresolutions.com/role/PropertyPlantAndEquipmentDetailsTextual PROPERTY, PLANT, AND EQUIPMENT (Details Textual) Details http://firstchoicehealthcaresolutions.com/role/PropertyPlantAndEquipmentTables 40 false false R41.htm 00000041 - Disclosure - ADVANCES (Details Textual) Sheet http://firstchoicehealthcaresolutions.com/role/AdvancesDetailsTextual ADVANCES (Details Textual) Details http://firstchoicehealthcaresolutions.com/role/Advances 41 false false R42.htm 00000042 - Disclosure - LINES OF CREDIT (Details Textual) Sheet http://firstchoicehealthcaresolutions.com/role/LinesOfCreditDetailsTextual LINES OF CREDIT (Details Textual) Details http://firstchoicehealthcaresolutions.com/role/LinesOfCredit 42 false false R43.htm 00000043 - Disclosure - SETTLEMENT PAYABLE (Details Textual) Sheet http://firstchoicehealthcaresolutions.com/role/SettlementPayableDetailsTextual SETTLEMENT PAYABLE (Details Textual) Details http://firstchoicehealthcaresolutions.com/role/SettlementPayable 43 false false R44.htm 00000044 - Disclosure - NOTE PAYABLE, RELATED PARTY (Details Textual) Sheet http://firstchoicehealthcaresolutions.com/role/NotePayableRelatedPartyDetailsTextual NOTE PAYABLE, RELATED PARTY (Details Textual) Details http://firstchoicehealthcaresolutions.com/role/NotePayableRelatedParty 44 false false R45.htm 00000045 - Disclosure - NOTES PAYABLE (Details) Notes http://firstchoicehealthcaresolutions.com/role/NotesPayableDetails NOTES PAYABLE (Details) Details http://firstchoicehealthcaresolutions.com/role/NotesPayableTables 45 false false R46.htm 00000046 - Disclosure - NOTES PAYABLE (Details 1) Notes http://firstchoicehealthcaresolutions.com/role/NotesPayableDetails1 NOTES PAYABLE (Details 1) Details http://firstchoicehealthcaresolutions.com/role/NotesPayableTables 46 false false R47.htm 00000047 - Disclosure - NOTES PAYABLE (Details Textual) Notes http://firstchoicehealthcaresolutions.com/role/NotesPayableDetailsTextual NOTES PAYABLE (Details Textual) Details http://firstchoicehealthcaresolutions.com/role/NotesPayableTables 47 false false R48.htm 00000048 - Disclosure - RELATED PARTY TRANSACTIONS (Details Textual) Sheet http://firstchoicehealthcaresolutions.com/role/RelatedPartyTransactionsDetailsTextual RELATED PARTY TRANSACTIONS (Details Textual) Details http://firstchoicehealthcaresolutions.com/role/RelatedPartyTransactions 48 false false R49.htm 00000049 - Disclosure - CAPITAL STOCK (Details Textual) Sheet http://firstchoicehealthcaresolutions.com/role/CapitalStockDetailsTextual CAPITAL STOCK (Details Textual) Details http://firstchoicehealthcaresolutions.com/role/CapitalStock 49 false false R50.htm 00000050 - Disclosure - STOCK OPTIONS AND WARRANTS (Details) Sheet http://firstchoicehealthcaresolutions.com/role/StockOptionsAndWarrantsDetails STOCK OPTIONS AND WARRANTS (Details) Details http://firstchoicehealthcaresolutions.com/role/StockOptionsAndWarrantsTables 50 false false R51.htm 00000051 - Disclosure - STOCK OPTIONS AND WARRANTS (Details 1) Sheet http://firstchoicehealthcaresolutions.com/role/StockOptionsAndWarrantsDetails1 STOCK OPTIONS AND WARRANTS (Details 1) Details http://firstchoicehealthcaresolutions.com/role/StockOptionsAndWarrantsTables 51 false false R52.htm 00000052 - Disclosure - STOCK OPTIONS AND WARRANTS (Details 2) Sheet http://firstchoicehealthcaresolutions.com/role/StockOptionsAndWarrantsDetails2 STOCK OPTIONS AND WARRANTS (Details 2) Details http://firstchoicehealthcaresolutions.com/role/StockOptionsAndWarrantsTables 52 false false R53.htm 00000053 - Disclosure - STOCK OPTIONS AND WARRANTS (Details 3) Sheet http://firstchoicehealthcaresolutions.com/role/StockOptionsAndWarrantsDetails3 STOCK OPTIONS AND WARRANTS (Details 3) Details http://firstchoicehealthcaresolutions.com/role/StockOptionsAndWarrantsTables 53 false false R54.htm 00000054 - Disclosure - STOCK OPTIONS AND WARRANTS (Details Textual) Sheet http://firstchoicehealthcaresolutions.com/role/StockOptionsAndWarrantsDetailsTextual STOCK OPTIONS AND WARRANTS (Details Textual) Details http://firstchoicehealthcaresolutions.com/role/StockOptionsAndWarrantsTables 54 false false R55.htm 00000055 - Disclosure - VARIABLE INTEREST ENTITY (Details) Sheet http://firstchoicehealthcaresolutions.com/role/VariableInterestEntityDetails VARIABLE INTEREST ENTITY (Details) Details http://firstchoicehealthcaresolutions.com/role/VariableInterestEntityTables 55 false false R56.htm 00000056 - Disclosure - VARIABLE INTEREST ENTITY (Details 1) Sheet http://firstchoicehealthcaresolutions.com/role/VariableInterestEntityDetails1 VARIABLE INTEREST ENTITY (Details 1) Details http://firstchoicehealthcaresolutions.com/role/VariableInterestEntityTables 56 false false R57.htm 00000057 - Disclosure - VARIABLE INTEREST ENTITY (Details Textual) Sheet http://firstchoicehealthcaresolutions.com/role/VariableInterestEntityDetailsTextual VARIABLE INTEREST ENTITY (Details Textual) Details http://firstchoicehealthcaresolutions.com/role/VariableInterestEntityTables 57 false false R58.htm 00000058 - Disclosure - NON-CONTROLLING INTEREST (Details) Sheet http://firstchoicehealthcaresolutions.com/role/Non-controllingInterestDetails NON-CONTROLLING INTEREST (Details) Details http://firstchoicehealthcaresolutions.com/role/Non-controllingInterestTables 58 false false R59.htm 00000059 - Disclosure - NON-CONTROLLING INTEREST (Details 1) Sheet http://firstchoicehealthcaresolutions.com/role/Non-controllingInterestDetails1 NON-CONTROLLING INTEREST (Details 1) Details http://firstchoicehealthcaresolutions.com/role/Non-controllingInterestTables 59 false false R60.htm 00000060 - Disclosure - NON-CONTROLLING INTEREST (Details Textual) Sheet http://firstchoicehealthcaresolutions.com/role/Non-controllingInterestDetailsTextual NON-CONTROLLING INTEREST (Details Textual) Details http://firstchoicehealthcaresolutions.com/role/Non-controllingInterestTables 60 false false R61.htm 00000061 - Disclosure - SEGMENT REPORTING (Details) Sheet http://firstchoicehealthcaresolutions.com/role/SegmentReportingDetails SEGMENT REPORTING (Details) Details http://firstchoicehealthcaresolutions.com/role/SegmentReportingTables 61 false false R62.htm 00000062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://firstchoicehealthcaresolutions.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://firstchoicehealthcaresolutions.com/role/CommitmentsAndContingenciesTables 62 false false R63.htm 00000063 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1) Sheet http://firstchoicehealthcaresolutions.com/role/CommitmentsAndContingenciesDetails1 COMMITMENTS AND CONTINGENCIES (Details 1) Details http://firstchoicehealthcaresolutions.com/role/CommitmentsAndContingenciesTables 63 false false R64.htm 00000064 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Textual) Sheet http://firstchoicehealthcaresolutions.com/role/CommitmentsAndContingenciesDetailsTextual COMMITMENTS AND CONTINGENCIES (Details Textual) Details http://firstchoicehealthcaresolutions.com/role/CommitmentsAndContingenciesTables 64 false false R65.htm 00000065 - Disclosure - INCOME TAXES (Details Textual) Sheet http://firstchoicehealthcaresolutions.com/role/IncomeTaxesDetailsTextual INCOME TAXES (Details Textual) Details http://firstchoicehealthcaresolutions.com/role/IncomeTaxes 65 false false R66.htm 00000066 - Disclosure - SUBSEQUENT EVENTS (Details Textual) Sheet http://firstchoicehealthcaresolutions.com/role/SubsequentEventsDetailsTextual SUBSEQUENT EVENTS (Details Textual) Details http://firstchoicehealthcaresolutions.com/role/SubsequentEvents 66 false false All Reports Book All Reports fchs-20160331.xml fchs-20160331.xsd fchs-20160331_cal.xml fchs-20160331_def.xml fchs-20160331_lab.xml fchs-20160331_pre.xml true true ZIP 84 0001575705-16-000130-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001575705-16-000130-xbrl.zip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�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end